The In Vivo and In Vitro Pharmacology of Selective D-Opioid Receptor Ligands. by Crook, Tracy J.
THE IN VIVO AND IN VITRO PHARMACOLOGY OF SELECTIVE 
6-OPIOID RECEPTOR LIGANDS
by
Tracy J. CROOK BSc. (Hons)
A thesis submitted in accordance with the requirements of the University of Surrey for
the Degree of Doctor of Philosophy.
Receptors and Cellular Regulation Research Group, October 1993
School of Biological Sciences,
University of Surrey,
Guildford,
Surrey, GU2 5XH.
ProQuest Number: 27558126
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27558126
Published by ProQuest LLO (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
ACKNOWLEDGEMENTS
I would like to thank the S.E.R.C. and Merck Sharp and Dohme for their financial 
support, also Professor L. King for the opportunity to work in his laboratories. I 
would like to say a big thank you to my supervisors Dr I Kitchen for all his help, 
advice and constant encouragement, and Dr R.G. Hill for his guidance and endless 
useful discussions throughout my PhD studies. Thank you also to Dr J. Kemp for the 
opportunity to work in his laboratory and to George Marshall for his tireless patience 
whilst teaching me the electrophysiology. Thanks also to Mrs Rosemary Jenkins for 
proof reading this thesis.
A big thanks to my parents for their constant support and the computer which made this 
thesis possible.
Thanks also to Julie, David, Lara and Steve for listening when I shouted and especially 
when I didn't.
And finally to Simon for being my strength when I needed it, keeping a sense of 
humour and for phoning once a week!
SUMMARY.
1. The effects of selective 5-opioid agonists and antagonists have been studied using 
both in vivo and in vitro models of 5-opioid receptor function to further investigate the 
physiology of this receptor. In addition, studies were aimed to explore the possibility 
that 5-receptors represent a heterogeneous population of receptor sites.
2. Using the warm water tail immersion test three highly selective 5-opioid receptor 
agonists DSLET, DPDPE and DELTI induced a dose-related antinociception in 25 day 
old rats following i.p. administration. This antinociception had peak tail immersion 
latencies of 7.5, 6.5 and 6.0 sec for DSLET, DPDPE and DELT I respectively. 
Calculation of EDys’s for the 5-agonists gave values of 0.65,0.66 and 0.032mg/kg for 
DSLET, DPDPE and DELT I respectively. The antinociception induced by the 
administration of the ED75 of the 5-agonists was fully antagonised by prior injection of 
the highly selective 5-opioid antagonist naltrindole (NTI) at a dose of 1 mg/kg. 
Administration of O.lmg/kg NTI fully reversed the effect of DSLET, partially reversed 
the effect of DPDPE but had no effect on the response to DELT I. Further O.Olmg/kg 
NTI had no effect on the response to DELT I but partially antagonised the responses to 
DSLET and DPDPE. The differential antagonism by NTI of the effects of the three 
selective 5-agonists suggests 5-receptor heterogeneity. Further, the lower sensitivity of 
the response to DELT I suggests that this agent may exert its antinociceptive effects at a 
different 5-receptor subtype from DPDPE or DSLET. Img/kg NTI had no effect on the 
antinociception induced by administration of the |i-agonist alfentanil demonstrating that 
the doses of NTI used are selective for 5-opioid receptors.
3. Administration of the highly selective 5-opioid antagonist naltriben (NTB) 
(50|ig/kg) fully reversed the antinociception induced by injection of the ED75 of each of 
the 5-agonists. However administration of 5pg/kg had no effect on the responses to 
DPDPE or DELT I but fully antagonised the antinociception induced by DSLET.
Similarly, 0.5|ig/kg NTB partially reversed the effect of DSLET with no effect on the 
responses to DPDPE and DELT I. The differential antagonism by NTB of the 
antinociceptive effects of three selective 5-agonists provides further support for 5- 
receptor heterogeneity confirrning the results obtained with NTI. Further the profile of 
antagonism of the 5-agonists by NTB is dissimilar to the profile of antagonism by NTI 
suggesting that these two antagonists have differential affinities for the putative
5-receptor subtypes. Administration of 50|Xg/kg NTB had no effect on the 
antinociception induced by a submaximal dose of alfentanil indicating that the doses of 
NTB used were selective for the 5-opioid receptors. The relative sensitivity to 
antagonism by NTT and NTB has been used to classify 5-mediated responses into 5i 
(NTB insensitive) and 5% (NTB sensitive) subtypes. In accordance with this 
nomenclature responses to DELT I and DSLET in the 25 day old rat can be designated 
as 5i and 5 2  respectively.
4. The antinociception induced by the ED75  of the three 5-agonists was also 
antagonised by ICI 174,864, at a dose (2mg/kg) which had no effect on the 
antinociception induced by a submaximal dose of alfentanil. A lower dose of 
ICI 174,864 (Img/kg) also significantly antagonised the effects of the three 5-agonists 
with a differential degree of attenuation, and being significantly less effective at 
antagonising the effects of DELT I. Thus, in addition to NTI and NTB the peptide 5- 
antagonist ICI 174,864 also shows a differential antagonism of the antinociceptive 
effects of the three 5-agonists. In addition, administration of the non-selective opioid 
antagonist naloxone (Img/kg) reversed the effects of all three 5-agonists to a similar 
degree indicating that the antinociception induced by these three agonists is opioid 
mediated and that naloxone does not distinguish between the putative 5-subtypes.
5. To study whether weaning stimulates the development of a subtype of the 5-opioid 
receptor the antinociceptive activity of putative 5i (DELT I) and 5 2  (DSLET) agonists in 
weaned and non-weaned rats was investigated. The antinociceptive effects of DSLET
and DELT I were investigated in 25 day old weaned and non-weaned rats. 
Administration of DSLET induced a dose-related antinociception in weaned rats but 
was without effect in non-weaned animals. In contrast DELT I induced a dose-related 
antinociception in both weaned and non-weaned animals. The effect of DSLET in 
weaned rats was antagonised by 5|Xg/kg NTB whereas the antinociception induced by 
DELT I in both weaned and non-weaned groups was unaffected by administration of 
this dose of NTB. The results suggest that the 6 i and Ô2 receptors develop 
differentially and the expression of Ô1 responses is independent of weaning whereas 
expression of 62  responses is weaning dependent.
6 . The potency of selective 6 -agonists and their reversal by the selective 6 -antagonists 
NTT and NTB were studied in the mouse vas deferens of two strains of mice (SCH and 
TO) and in the hamster vas deferens. DSLET, DPDPE and DELT I all produced an 
inhibition of the field stimulated contractions of the mouse vas deferens. The inhibition 
was dose-related and gave IC50 values of 1.98 and 1.12nM for DSLET in the SCH and 
TO mouse respectively, 3.32 and 4.20nM for DPDPE in the SCH and TO mouse 
respectively and 0.75 and 0.84nM for DELT I in the SCH and TO mouse respectively. 
Addition of NTI to the bath induced a parallel rightward shift in the agonist dose- 
response curves, indicating that NTI acts as a competitive antagonist in this tissue. 
Following Schild analysis significant differences in the pA2  values for NTI were seen 
and the slopes of the Schild plots for NTI versus DELT I (SCH) and DSLET (TO) 
were significantly different from unity raising the possibility that the agonists were 
exerting their effects via multiple 6 -sites. The pA2 values obtained following 
administration of NTB in the SCH mouse vas deferens were similar, but the slope of 
the Schild plot for NTB versus DSLET was significantly different from unity.
7. All three 6 -agonists inhibited the field stimulated contractions of the hamster vas 
deferens in a dose-related manner. Calculation of IC50 values yielded figures of 658, 
346 and 8 6 nM respectively for DSLET, DPDPE and DELT I. Addition of NTI or NTB
induced a parallel rightward shift in the agonist dose-response curves, indicating that 
these compounds act as competitive antagonists in this tissue. Ke values for NTI 
versus the 6 -agonists were not significantly different, however Ke values for NTB 
versus DPDPE and DELT I were significantly different with NTB being more effective 
at antagonising the response to DELT I, again raising the possibility that the effects of 
these compounds are mediated via a heterogeneous receptor population.
8 . In order to investigate if functional 6 -receptors were present in the VMH the action 
of 6 -selective agonists and antagonist were studied, by recording extracellularly the 
effects on neuronal firing from single neurones in the rat VMH in vitro. Perfusion of 
rat VMH in vitro with DSLET, DPDPE and DELT I led to a dose-related inhibition of 
neuronal firing. ED75 values of 65, 177 and 35nM were calculated for DSLET, 
DPDPE and DELT I respectively. The inhibition induced by DSLET and DPDPE was 
antagonised by perfusing the slice with lOnM NTI. This dose of NTI had no effect on 
the inhibition induced by the p-agonist DAGO nor the non-opioid depressant G ABA. 
The reversibility of the NTI antagonism was also investigated, and a full recovery of 
the DSLET response was achieved 120min after reperfusion with NTI-free aCSF. 
These results show the presence of functional 6 -receptors in rat VMH.
CONTENTS
Page
ACKNOWLEDGEMENTS 1
SUMMARY 2
LIST OF PUBLICATIONS 9
LIST OF TABLES 10
LIST OF FIGURES 12
CHAPTER 1-INTRODUCTION 17
1.1 General Introduction 18
1. L 1 Opioid Peptides 18
1.1.2 Multiple Opioid Receptors 22
1.1.3 Signal Transduction Systems 24
1.2 Selective 0-Opioid Agonists 27
1.3 8 -Selective Antagonists 33
1.4 Distribution of 5-Receptors 37
1.5 /rt y/v£> Pharmacology of 0-Selective Ligands 40
1.5.1 Antinociception 40
1.5.2 Gastrointestinal Function 63
1.5.3 Cardiovascular Function 6 6
1.5.4 Respiration 6 8
1.5.5 Behavioural Responses 70
1.5.6 Seizures and EEG Effects 72
1.5.7 Other In Vivo Effects 7 3
1.6 Transmitter Release 75
1.7 Isolation, Purification and Cloning of 5-Receptors 77
1.8  Aims of this Thesis 78
CHAPTER 2 79
2.1 Introduction 80
2 . 2 Materials and Methods 82
2 .2 .1 Animals and Experimental Conditions 82
2 .2 . 2 Nociceptive Testing 82
2.2.3 Drugs and Statistical Procedures 83
2.3 Results 84
2.4 Discussion 98
CHAPTER 3 105
3.1 Introduction 106
3.2 Materials and Methods 108
3.2.1 Animals and Experimental Conditions 108
3.2.2 Nociceptive Testing 108
3.2.3 Drugs and Statistical Procedures 108
3.3 Results 1 1 0
3.4 Discussion 115
CHAPTER 4 117
4.1 Introduction 118
4.2 Materials and Methods 1 2 0
4.2.1 Animals 1 2 0
4.2.2 Tissue Preparation 1 2 0
4.2.3 Determination of Agonist Potency 1 2 1
4.2.4 Determination of Antagonist Potency 1 2 2
4.2.5 Validation of the Neurogenic Origin of the Stimulated 
Contractions and Identification of the Synaptic 
Location of the 0-Opioid Receptors
123
4.2.6 Drugs and Statistical Procedures 123
4.3  ^Results 125
4.3.1 Schneider Mouse Vas Deferens 125
4.3.2 TO Mouse Vas Deferens 137
4.3.3 Hamster Vas Deferens
7
152
4.3 Discussion 164
CHAPTER 5 170
5.1 Introduction 171
5.2 Materials and Methods 173
5.2.1 Animals 173
5.2.2 Brain Slice Preparation 173
5.2.3 Extracellular Recording 175
5.2.4 Drugs 176
5.3 Results 177
5.4 Discussion 187
CHAPTER 6 -GENERAL DISCUSSION 190
REFERENCES 196
PUBLICATIONS ARISING FROM THE WORK DESCRIBED IN THIS THESIS.
T.J. Crook, I. Kitchen and R.G. Hill, (1991), Differences in sensitivity of antinociceptive 
effects of selective 5-opioid agonists to antagonism by naltrindole in 25-day-old rats. B rJ  
Pharmac., 104, 326P.
T.J. Crook, I. Kitchen and R.G. Hill, (1992), Effects of the 5-opioid receptor antagonist 
naltrindole on antinociceptive responses to selective 5-agonists in post-weanling rats. B rJ  
Pharmac., 107, 573-576.
T.J. Crook, I. Kitchen and R.G. Hill, (1993), Evidence for 5-opioid receptor heterogeneity 
from antinociceptive studies with selective 5-agonists and antagonists in 25 day old rats. NIDA 
Res.Mono graph, in press.
T.J. Crook, I. Kitchen and R.G. Hill, (1993), Differential antagonism of the antinociceptive 
effects of selective 5-opioid receptor agonists by the 5-antagonist naltriben in post-weanling 
rats. Pharmacol.Comm. 3, 351-356.
T.J. Crook, I. Kitchen and R.G. Hill, (1993), Electrophysiological effects of selective 5- 
opioid receptor agonists in rat ventralmedial hypothalamus in vitro. B rJ  Pharmac., 109, 
103P.
I. Kitchen, T.J. Crook, B.Y. Muhammad and R.G. Hill, (1993), In vivo evidence for 
differential development of 5-opioid receptor subtypes. RegJeptides, in press.
T.J. Crook, I. Kitchen and R.G. Hill, (1993), 5-opioid receptor subtypes in the mouse vas 
deferens. B rJ  Pharmac., in press.
I. Kitchen, T.J. Crook, B.Y. Muhammad and R.G. Hill, (1993), Weaning activates the 
development of a 5-opioid receptor subtype in the rat. Dev. Brain Res., submitted.
LIST OF TABLES
Page
Table 1 ô-selectivity of agonists derived from isolated tissue studies 28
Table 2 5-selectivity of agonists derived from radioligand binding 29
studies
Table 3 Distribution of 5-receptors in rat brain by autoradiography 38
using pH]NTI to label 5-sites
Table 4 /n viv<9 pharmacology of 5-selective ligands 42
Table 5 ED^g's and peak antinociceptive latencies to DSLET, DPDPE 8 8  
and DELT I in 25 day old rats
Table 6  IC 5 0  values obtained on repeated determination of 127
concentration response curves for DSLET, DPDPE and 
DELT I iu the isolated SCH mouse vas deferens
Table 7 Antagonist potency of NTI versus 5-agonists in the SCH 132
mouse vas deferens
Table 8  Antagonist potency of NTB versus 5-agonists in the SCH 136
mouse vas deferens
Table 9 IC50  values in the presence and absence of peptidase 138
inhibitors in the SCH mouse vas deferens
Table 10 Effect of DSLET, DPDPE and DELT I on the response to 139
noradrenaline (mg) in the SCH mouse vas deferens
Table 1 1  IC 5 0  values obtained on repeated determination of 142
concentration response curves for DSLET, DPDPE and 
DELT I in the isolated vas deferens of TO mice
10
Table 12 Antagonist potency of NTI versus Ô-agonists in the TO mouse 148
vas deferens
Table 13 IC5 0  values in the presence and absence of peptidase 149
inhibitors in the TO mouse vas deferens
Table 14 Effect of DSLET, DPDPE and DELT I on the response to 150
noradrenaline (mg) in the TO mouse vas deferens
Table 15 IC 5 0  values obtained on repeated determination of 154 
concentration response curves for DSLET, DPDPE and 
DELT I in the isolated hamster vas deferens
Table 16 Antagonist potency of NTI and NTB versus 5-agonists in 159
hamster vas deferens
Table 17 IC 5 0  values in the presence and absence of peptidase 160
inhibitors in the hamster vas deferens
Table 18 Effect of DSLET, DPDPE and DELT I on the response to 162
noradrenaline (mg) in hamster vas deferens
Table 19 Responses to DSLET, DPDPE, DELT I, DAGO and GABA 181
in the rat VMH in vitro
11
LIST OF FIGURES
Figure 1 The opium gatherer
Figure 2 Structure of 6-selective antagonists
Page
19
34
Figure 3 Dose related antinociception induced by DSLET in 25 day old
rats
Figure 4 Dose related antinociception induced by DPDPE in 25 day old
rats
Figure 5 Dose related antinociception induced by DELT I in 25 day old 87
rats
Figure 6  Effect of increasing doses of NTI on the antinociceptive 89
response to ED75 of DSLET in 25 day old rats
Figure 7 Effect of increasing doses of NTI on the antinociceptive 90
response to ED75 of DPDPE in 25 day old rats
Figure 8  Effect of increasing doses of NTI on the antinociceptive 91
response to ED75 of DELT I in 25 day old rats
Figure 9 Effect of increasing doses of NTB on the antinociceptive 92
response to ED75 of DSLET in 25 day old rats
Figure 10 Effect of increasing doses of NTB on the antinociceptive 93 
response to ED75 of DPDPE in 25 day old rats
Figure 11 Effect of increasing doses of NTB on the antinociceptive 94
response to ED75 of DELT I in 25 day old rats
Figure 12 Effect of (a) naloxone and (b) ICI 174,864 on the peak 95
antinociceptive response (5 min) to an ED75 of DSLET, 
DPDPE and DELT I in 25 day old rats
12
Figure 13 Effect of (a) NTI, (b) NTB and (c) ICI 174,864 on the 97 
antinociceptive response to alfentanil in 25 day old rats
Figure 14 Antinociceptive effects of DSLET in 25 day old (a) weaned 111
and (b) non-weaned rats
Figure 15 Antinociceptive effects of DELT I in 25 day old (a) weaned 112
and (b) non-weaned rats
Figure 16 Effect of NTB (5p.g/kg) in the antinociceptive effect of 113 
DSLET in 25 day old weaned rats
Figure 17 Effect of NTB (5}ig/kg) in the antinociceptive effect of 114 
DELT I in 25 day old (a) weaned and (b) non-weaned rats
Figure 18 Representative trace showing the effects of DSLET, DPDPE 126
and DELT I on SCH mouse vas deferens
Figure 19 Repeated cumulative concentration response curves for the 128
6 -agonists in isolated SCH mouse vas deferens
Figure 20 Effect of NTI on concentration effect curve of DSLET (a) and 129
Schüd analysis of the effect of NTI on the concentration effect 
curves (b) in the SCH mouse vas deferens
Figure 21 Effect of NTI on concentration effect curve of DPDPE (a) and 130
Schild analysis of the effect of NTI on the concentration effect 
curves (b) in the SCH mouse vas deferens
Figure 22 Effect of NTI on concentration effect curve of DELT I (a) and 131
Schild analysis of the effect of NTI on the concentration effect 
curves (b) in the SCH mouse vas deferens
Figure 23 Effect of NTB on concentration effect curve of DSLET (a) 133
and Schild analysis of the effect of NTB on the concentration 
effect curves (b) in the SCH mouse vas deferens
13
Figure 24 Effect of NTB on concentration effect curve of DPDPE (a) 134
and Schild analysis of the effect of NTB on the concentration 
effect curves (b) in the SCH mouse vas deferens
Figure 25 Effect of NTB on concentration effect curve of DELT I (a) 135
and Schild analysis of the effect of NTB on the concentration 
effect curves (b) in the SCH mouse vas deferens
Figure 26 Effect of lOOnM TTX on the field stimulated contractions and 140
the response to exogenous noradrenaline (1.6|iM) in the 
isolated SCH mouse vas deferens
Figure 27 Representative trace showing the effect of DSLET, DPDPE 141
and DELT I on TO mouse vas deferens
Figure 28 Repeated cumulative concentration response curves for the 143
ô-agonists in isolated TO mouse vas deferens
Figure 29 Effect of NTI on concentration effect curve of DSLET (a) and 145
Schild analysis of the effect of NTI on the concentration effect 
curves (b) in the TO mouse vas deferens
Figure 30 Effect of NTT on concentration effect curve of DPDPE (a) and 146
Schild analysis of the effect of NTI on the concentration effect 
curves (b) in the TO mouse vas deferens
Figure 31 Effect of NTT on concentration effect curve of DELT I (a) and 147
Schild analysis of the effect of NTI on the concentration effect 
curves (b) in the TO mouse vas deferens
Figure 32 Effect of lOOnM TTX on the field stimulated contractions and 151
the response to exogenous noradrenaline (1.6|iM) in the 
isolated TO mouse vas deferens
Figure 33 Representative trace showing the effects of DSLET, DPDPE 153
and DELT I on hamster vas deferens
14
Figure 34 Repeated cumulative concentration response curves for the 155
ô-agonists in isolated hamster vas deferens
Figure 35 Effect of NTI (a) and NTB (b) on the concentration effect 156
curve of DSLET in isolated hamster vas deferens
Figure 36 Effect of NTI (a) and NTB (b) on the concentration effect 157
curve of DPDPE in isolated hamster vas deferens
Figure 37 Effect of NTI (a) and NTB (b) on the concentration effect 158
curve of DELT I in isolated hamster vas deferens
Figure 38 Effect of IpM TTX on the field stimulated contractions and 163
the response to exogenous noradrenaline (1.6pM) in the 
isolated hamster vas deferens
Figure 39 Representative trace showing the dose related inhibition of 178 
firing by DSLET in a single neurone from rat VMH in vitro
Figure 40 Representative trace showing the dose related inhibition of 179 
firing by DPDPE in a single neurone from rat VMH in vitro
Figure 41 Representative trace showing the dose related inhibition of 180
firing by DELT I in a single neurone from rat VMH in vitro
Figure 42 Inhibition of quisqualate-induced neuronal firing by DSLET, 182
DPDPE and DELT I in rat VMH in vitro
Figure 43 Effect of lOnM NTI on the inhibition of the firing of a single 183
VMH neurone by DSLET in vitro
Figure 44 Effect of lOnM NTI on the inhibition of the firing of a single 184
VMH neurone by DPDPE in vitro
Figure 45 Effect of lOnM NTI on the inhibition of the firing of a single 185
VMH neurone by DAGO and GABA in vitro
15
Figure 46 The reversibility of the antagonism of DSLET by NTI in rat 186 
VMH in vitro
16
CHAPTER 1
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INTRODUCTION
1.1 GENERAL INTRODUCTION
1.1.1 OPIOID PEPTIDES
Archaeological evidence suggests that extracts from the opium poppy (Papaver 
somniferum) were used in medicine more than 5000 years ago in Mesopotamia (Zacon, 
1988). Their use has been widely documented throughout history (Figure 1) and they 
are stül in current therapeutic use. Drugs isolated from the poppy and compounds 
based on their structure are known as opiates or narcotic analgesics since they have 
been most extensively used as sleep-inducing painkillers. When it was discovered that 
derivatives of the compounds extracted from the poppy bound to brain membranes in a 
stereospecific and saturable manner the question of a specific target receptor for the 
opiate drugs was raised (Simon et a i, 1973; Pert & Snyder 1973). If a specific 
receptor for the opiates was present in the nervous systems of several species then it is 
likely to follow that the body produces a substance with opiate-like activity which could 
interact with these receptors. This question was first addressed by Hughes (1975) who 
showed that a low molecular weight substance could be isolated from the brains of 
rabbits, guinea-pigs, rats and pigs which mediated inhibition of electrically evoked 
contractions of the mouse vas deferens and the guinea-pig myenteric plexus. This 
inhibition was reversed by the opioid antagonist naloxone. Both of these tissues had 
previously been shown to be sensitive to morphine and other narcotic analgesics 
(Henderson et al., 1972; Kosterlitz et al., 1972). Results from Hughes' study also 
showed that the 'morphine-like substance' was unevenly distributed in the brain as 
would be expected for a neurotransmitter (Hughes et al., 1975). The brain extract was 
subsequently characterised (Hughes et al., 1975) and shown not to be a single 
compound but a mixture of two pentapeptides given the name enkephalins. The two 
peptides differed only in their C-terminal amino acid, one having the structure
18
A I7th-ceutun' engraving depicts a  m an in Eastern dress collecting opium  ju ic e  
from  the buds o f poppy plants. O pium ’s painkilling, calm ing, a n d  sleep- 
inducing properties ivere probably recognized as early  as 3.S00 nc.
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H-Tyr-Gly-Gly-Phe-Met-OH, [Met]enkephalin, and the other H-Tyr-Gly-Gly-Phe- 
Leu-OH, [Leu]enkephalin. The authors give a [Met]: [Leu]enkephalin ratio in brain of 
approximately 3 or 4:1. The term opioid peptide was given to these endogenous 
substances and to subsequent peptides based on their structure.
Subsequently it was found that the C-fragment of P-lipotrophin (P-LPH) incorporated 
the [Met]enkephalin sequence and that an extended peptide, residues 61-91 of p-LPH 
had opioid activity (Li & Cheung, 1976). This peptide was found in pituitary and was 
named p-endorphin from ’endogenous morphine' (Li & Cheung, 1976). p-LPH 
contained other sequences with opioid activity, p-LPH^i.?^ &nd P-LPH^i-??, and these 
were named a  and y endorphin respectively (Ling et a i, 1976). Other extended 
[Met] enkephalin peptides have also been discovered in the pituitary, including 
[Met]enkephalin-Arg6-Phe^ and [Met]enkephalin-Arg6  (Huang et a l, 1979; Stem 
et a l, 1979). Small amounts of other extended [Met]enkephahn molecules were found 
in brain and adrenal medulla (Lewis et al., 1980; Kangawa et al., 1980; Kilpatrick 
et al., 1981) A group of extended [Leu]enkephalin molecules were isolated from 
pituitary glands. One of these peptides had potent opioid activity and was termed 
dynorphin (1-13), dyn- from the Greek dynamis, meaning powerful, and 1-13 
representing the 13 amino acid chain length (Goldstein et al., 1979). Over the next few 
years more extended [Leu]enkephalins were isolated including a-neo-endorphin 
(Kangawa & Matsuo, 1979), dynorphin 1-8 (Minamino et al., 1980) and 
p-neo-endorphin (Minamino et al., 1981). In 1982 a 32 amino acid dynorphin was 
described (Fischi et al., 1982) in which the amino terminal contained dynorphin 1-17; 
this peptide was renamed dynorphin A. At the carboxy terminal the related 
tridecapeptide was termed dynorphin B, and these two peptides are separated by the 
processing signal Lys-Arg.
Following the characterisation of these three classes of opioid peptides, the 
enkephalins, endorphins and dynorphins, the search for their precursors began. A
20
31KDa precursor for both ACTH and P-endorphin was shown to be present in the 
pituitary gland and was given the name pro-opio-cortin because of the common 
precursor relationship of this protein to the opioid peptides and corticotrophin 
(Rubenstein et al., 1978). The precursor was later renamed pro-opio-melanocortin 
(POMC) as the sequence incorporated not only ACTH and opioid products of p-LPH 
but also for the melanocyte stimulating hormones a  and p-MSH (Chretien et a l, 
1979). The presence of the [Metjenkephalin sequence in POMC led to the initial idea 
that [Met]enkephalin was derived through further processing of P-endoiphin, although 
the results of subsequent studies suggested that this was unlikely to be the case, since 
P-endorphin is present in the brain at only 5-10% of the concentration of the 
enkephalins (Rossier et al., 1977), and it also shows substantial differences to the 
enkephalins in its distribution (Rossier et a l, 1977; Bloom et a l, 1978). In addition to 
this evidence POMC does not contain a copy of [Leu]enkephalin within its structure 
thus it was necessary to look for a precursor which contained copies of both the 
enkephalins.
This common precursor was pre-proenkephahn which was first sequenced from bovine 
adrenal medulla in 1982 (Noda et al., 1982). Within its stmcture it contained four 
enkephalins, [Met]enkephalin, [Leu]enkephalin, [Met]enkephalin-Arg6-Gly7-Leu^ and 
[Met]enkephalin-Arg^Phe7. Pre-proenkephalin contains six copies of [Met]enkephalin 
and one copy of each of the other peptides, confirming the observation by Hughes et al.
(1975) that there was 3-4 times more [Met]enkephalin isolated than [Leu]enkephalin. 
No peptides with other biological activities have been identified firom pre-proenkephalin 
unlike POMC. Neither POMC nor pre-proenkephalin accounted for the dynorphins 
thus at least one more gene product was necessary to explain their existence. Later in 
1982 the precursor for the dynorphins was established by cDNA cloning (Kakidani 
et al., 1982). This molecule which contains sequences for the [Leu]enkephalin 
containing dynorphins does not have a copy of [Met]enkephalin anywhere in its 
structure (Kakidani et al., 1982). The authors named this molecule
21
pre-proenkephalin B, however, Rossier (1982) suggested pre-prodynorphin would be 
more appropriate. Thus from the above evidence it can be seen that the three opioid 
peptide famihes originate from distinct gene products.
1.1.2 MULTIPLE OPIOID RECEPTORS
Shortly after the characterisation of the enkephalins an extensive study by Martin et al.
(1976) compared the effects of administration of opiates in the chronic spinal dog. 
Administration of opiate agonists produced three distinctive syndromes, characterised 
by morphine, ketocyclazocine and SKF 10,047. The effects produced in these 
syndromes were antagonised by the opioid antagonist naltrexone, suggesting mediation 
via opioid receptors. The syndromes, however, were sufficiently different that Martin 
and colleagues postulated mediation via distinct receptors. The receptors were termed 
\L (morphine), k  (ketocyclazocine) and a  (SKF 10,047). Further support for this 
hypothesis came from the observation that morphine and ketocyclazocine could not 
substitute for each other in the alleviation of withdrawal symptoms in dependent 
animals (Martin etal., 1976).
During the characterisation of the enkephalins (Hughes et al., 1975) differences in the 
potency of the enkephalins and the narcotic analgesics were seen in the isolated tissue 
bioassays used. These observations were later extended by Lord et al. (1977) who 
showed that the smaller peptides, including the enkephalins, were more potent in the 
isolated mouse vas deferens compared to the isolated guinea-pig ileum. The reverse 
was tme for morphine and its congeners, while p-endorphin was found to be equally 
potent in both assays. Differences were also seen in radioligand binding studies using 
guinea-pig brain, [^H][Leujenkephalin apparently bound to two sites and inhibition 
with unlabelled [Leu]enkephalin gave an ID50 close to Kp of the lower affinity binding 
site (Lord et a l, 1977). The enkephalins were found to be more potent at inhibiting 
pH] [Leu]enkephalin binding compared to pH]naloxone binding, whilst the opposite
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was true for morphine, p-endorphin was again equipotent at competing with both 
ligands. Thus it can be summarised that activity in the guinea-pig ileum is better 
correlated to inhibition of [^HQnaloxone binding, whereas activity in the mouse vas 
deferens is similar to the inhibition of pH][Leu]enkephalin binding. From these results 
the authors postulated the existence of a receptor in guinea-pig brain and mouse vas 
deferens for which the enkephalins had high affinity, and this site was designated the Ô 
(deferens) receptor (Lord et al, 1977). Thus the mouse vas deferens contained 
predominantly 5-receptors, although some p-receptors were present since the effects of 
morphine in the mouse vas deferens could be inhibited by approximately a ten fold 
lower dose of naloxone than was required to antagonise the effects of the enkephalins 
(Lord et al., 1977). In contrast the guinea-pig ileum was thought to contain 
predominantly p-receptors due to the high potency of the opiate alkaloids and the low 
doses of naloxone required to antagonise their responses. Differences in the dose of 
antagonist needed to antagonise the effects of opiates had previously been reported 
(Martin et al., 1976), in this study thirty times more naltrexone was required to 
antagonise the effects of the prototypic K-agonist, ketocyclazocine than the prototypic 
p-agonist, morphine. As P-endorphin was equipotent in both isolated tissue 
preparations it was likely that this peptide had equal affinity for both p and 5 receptors.
There is now much evidence to confirm the existence of three primary opioid receptor 
subtypes p ,  5 and k . However, since the early characterisation of opioid receptors 
other subtypes have been suggested, for example p-endorphin was found to be 2-3 
orders of magnitude more potent in the rat vas deferens than many p, 5, and K ligands 
and this prompted the suggestion that a specific P-endorphin receptor (e) mediates the 
effects of this agonist in the rat vas deferens (Schulz et al., 1979; Schulz et al., 1981). 
The existence of the e receptor remains contentious but many people feel the effects of 
p-endorphin in the rat vas deferens can be explained by a small receptor reserve in this 
tissue (Miller et al., 1986). The preliminary characterisation of opioid receptors has 
also been questioned, for example Snyder & Goodman (1980) failed to show
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K-receptor binding in rat brain. Later studies showed that a portion of opioid binding 
still persisted under conditions of and 5-suppression (Kosterlitz & Paterson, 1981) 
and that this site, which accounted for only 1 2 % of the opioid binding of several 
ligands, represented the K-receptor (Gillan & Kosterlitz, 1982). In addition to this 
problem with K-sites the a  receptor is now thought not to be an opioid receptor as its 
effects are not antagonised by naloxone (Wood, 1982).
There is some limited correlation between the opioid peptide families and activation of 
the three opioid receptors; for example the dynorphins display some selectivity for the 
K-receptor (Chavkin & Goldstein, 1981) and the enkephalins are 5-preferring (Lord 
et aU, 1977).
1.1.3 SIGNAL TRANSDUCTION SYSTEMS
The signal transduction pathways following activation of |X, 5 and k  receptors appear to 
be similar. Much of the work investigating opioid second messenger systems has been 
carried out on the neuroblastoma cell line NG108-15 which contain high levels of 
opioid binding (Hamprecht, 1977). The pharmacology of the receptors present in these 
cells suggest they are 5-sites (Chang et a/., 1978). Several lines of evidence suggest 
that opioid receptors are coupled to G-proteins. Guanine nucleotides were able to 
decrease the binding of opioids to their receptors in both NG108-15 cells (Blume 
1978a) and brain membranes (Blume 1978b), with GTP and Gpp(NH)p being the most 
potent. As for other systems, the guanine nucleotides were able to discriminate agonist 
and antagonist binding in the presence of sodium (Appelmans et al., 1986). Opioid 
agonists stimulate GTPase activity in NG108-15 cells in a naloxone reversible manner 
(Goski & Klee 1981). One unusual mechanism of G-protein function has been 
reported for NG108-15 cells, some 5-antagonists instead of producing no change in 
GTPase activity inhibit the effect of this enzyme (Costa & Herz 1989), suggesting 
some antagonists have negative intrinsic activity when binding to G-proteins.
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Studies using antibodies directed at different subtypes of G-proteins suggest that, at 
least in NG108-15 cells, the G{2 subtype is coupled to 5-receptors (McKenzie & 
Milligan 1990), however other studies have suggested that Gq couples the 5-receptors 
to Ca2+ channels in these cells (Heschelar et al., 1987). Reconstitution experiments in 
rat brain membranes suggest |x-receptors are coupled to both Gi and G© (Ueda et al., 
1990a). Similar experiments in guinea-pig cerebellum, demonstrate K-receptors may be 
coupled to Gi but not Gq (Ueda et al., 1990b).
Negative coupling to adenylate cyclase has been shown both in cultured cells and in 
brain (Sharma et al., 1977; Yu et al., 1986; Attali et al., 1989). Evidence from 
NG108-15 cells suggests that opioid inhibition of adenylate cyclase occurs for PGEi- 
stimulated, adenosine-stimulated and cholera-toxin stimulated activity or basal adenylate 
cyclase activity and as for other systems GTP and sodium are required. The addition of 
pertussis toxin completely abolished the opioid inhibition of adenylate cyclase both in 
cultured cells (Hsia et al., 1984) and in brain membranes (Abood et al., 1985) 
suggesting the effect is G protein mediated via Gi or Gq.
In addition to inhibition of adenylate cyclase opioid receptors are also associated with 
ion channels. Opioids selective for both [l- and 5-receptors hyperpolarise cells from 
myenteric neurones in a concentration dependent manner, this hyperpolarisation is 
associated with a decrease in neuronal input resistance and is dependent on extracellular 
potassium concentration suggesting that the opioid-induced hyperpolarisation occurs 
via an increase in membrane permeability to potassium (Morita & North, 1982). 
Submucous neurones of the guinea-pig caecum show an increase in potassium 
conductance following the addition of 5- but not |X- or K-agonists (Mihara & North, 
1986). In these neurones the hyperpolarisation induced by the agonist was rapid in 
onset, reaching its peak within 1 0 -2 0  seconds, and the membrane potential reversed 
rapidly to its resting level when the control solution was reintroduced. When
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membrane current was recorded under voltage clamp, superfusion with 
[Leu]enkephalin evoked an outward current having the same time course as the 
hyperpolarisation (Mihara & North, 1986). The peak amplitude of the 
hyperpolarisation was dependent on the concentration of agonist applied but never 
exceeded 35mV (Mihara & North, 1986). On a given neurone the increase in 
potassium conductance may be identical to the one activated by stimulation of many 
other neurotransmitter receptors including dopamine D2 , adenosine A% and somatostatin 
(North, 1986; North et al, 1987). By making intracellular recordings from myenteric 
neurones taken from guinea-pig ileum Cherubini et al. (1984) showed that evoked 
action potentials were followed by after hyperpolarisations which resulted from an 
increase in potassium conductance. Morphine applied by superfusion, increased the 
duration of the after hyperpolarisation and the underlying potassium conductance 
without changing the peak amplitude of the after hyperpolarisation. Stimulation of both 
|i- and 6 -receptors in dorsal root ganglion neurones causes a decrease in somatic 
calcium-dependent action potentials (Werz & MacDonald, 1983), similar to this 
stimulation of K-receptors, depresses calcium entry through voltage-sensitive channels, 
thus shortening the calcium action potential. This occurs without any change in the 
resting membrane potential and interferes with depolarisation-secretion coupling 
(Cherubini et al., 1985). Unlike |i- and 6 -receptors however stimulation of K-receptors 
has no effect of potassium conductance.
Thus opioid receptors appear to be coupled to G-proteins which are in turn negatively 
coupled to both adenylate cyclase and to potassium and/or calcium channels.
The 6  site is the least well studied of the opioid receptors, largely due, until recently, to 
a lack of highly selective agonists and especially selective and stable antagonists. Its 
physiology/pharmacology is therefore not well understood and its clinical potential 
unexplored. The remainder of this chapter will concentrate on what is currently known 
about the 6 -receptor from both in vitro and in vivo studies using selective 6 -ligands.
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1.2 SELECTIVE Ô-OPIOID AGONISTS
The 6 -selectivity of a ligand is usually investigated using in vitro techniques such as 
isolated tissue bioassay or by radioligand binding studies. Tables 1 and 2 summarise 
comparative data derived from several laboratories on the relative potencies of agonist 
ligands at the 6  site on the basis of in vitro data. Estimates of selectivity in isolated 
tissue studies (Table 1) have mostly been derived from IC50 ratios in the guinea-pig 
ileum and mouse vas deferens. Studies should be carried out in the presence of a 
cocktail of peptidase inhibitors since they have been shown to markedly increase the 
potency of some peptide agonists (McKnight et aL, 1983). Estimates of selectivity 
from binding studies (Table 2) have been mostly derived from displacement studies that 
have used [^H][D-Ala^, MePhe^, Gly-ol^jenkephalin (DAGO) to label \i sites. DAGO 
has a selectivity for |i-receptors over 6 -receptors of > 400 using [3H]DADLE to label 
6 -sites (Kosterlitz & Paterson, 1981).
The first '6 -selective' agonist to be described was the [Leu]enkephalin analogue 
[D-Ala^, D-Leu^]enkephalin (DADLE) (Miller et al., 1977), however this compound 
exhibits less than 10-fold selectivity for the 6 -site over the |X-receptor.
The most widely used selective agonists for the study of 6 -receptor function are the 
constrained cyclic penicillamine containing enkephalin analogues [D-Pen^, 
D-Pen5]enkephalin (DPDPE), [D-Pen^, L-Pen^]enkephalin (DPLPE), and [D-Pen^, 
L-Cys5]enkephalin (DPLCE) (for structures see Table 1) (Mosberg et al, 1983). 
These compounds have up to 3000-fold selectivity for the 6 -site. Structure activity 
relationships for compounds of this type have been described and originally it was 
proposed that the constrained structure of DPDPE and its analogues gave them their 
6 -selectivity since it was thought that the flexibility of the enkephalin molecule enabled 
it to bind to |X and 6  receptors (Mosberg et al., 1983). Subsequent investigations have
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shown that for DPDPE adverse steric interactions between the D-Pen^ group and the 
ji-receptor lead to the low |i receptor binding affinity observed for this compound 
(Mosberg et al., 1988a). If the ring size is increased 6 -affinity decreases while 
|i-affinity stays the same leading to more p-selective compounds (Mosberg et at., 
1988b) suggesting that the compact structure of DPDPE does play a role in its
6 -selectivity. Although selective for the 6 -site DPDPE has a low affinity for this 
receptor and much work has been carried out to find compounds of similar selectivity 
but increased affinity at the 6 -opioid receptor. The Phe^ residue of DPDPE has been 
shown to be extremely important for the selectivity of DPDPE (Toth et a i, 1990), and 
substitution of a parachloro group at this position leads to a compound pCl-DPDPE 
which is approximately 7 times more potent in the mouse vas deferens than DPDPE. In 
isolated tissue studies it shows 5400-fold selectivity for the 6 -site and 574-fold 
selectivity in binding assays (Toth et al., 1990). Modifications to the Tyr moiety at 
position one usually lead to decreases in receptor affinity, however, some changes can 
be made without disturbing the 'bioactive' conformation of DPDPE (Toth et al., 1992). 
Addition of the unnatural amino acid 2 ,6 -dimethyltyrosine (DMT) results in a 10-fold 
increase in affinity at the 6 -site accompanied by a 35-fold increase in potency at the 
ji-receptor but still retaining substantial 6 -selectivity (Hansen et al., 1992). 
DMT-DPDPE represents a major advance in peptide drugs as it is active following 
subcutaneous administration in the mouse writhing test (Hansen et at., 1992). Even 
with this degree of selectivity, it has been reported that at doses that have previously 
been shown to be selective for the 6 -receptor (for example see Dray et al., 1985), 
DPDPE can induce |i-mediated behaviours (Murray & Cowan, 1990).
The two [Leujenkephalin analogues [D-Ser^, Leu^]enkephalyl-Thr^ (DSLET) (Gacel 
et a l, 1980) and [D-Thr^, Leu^Jenkephalyl-Thi^ (DTLET) (for structures see Table 1) 
(Zajac et al., 1983) also have appreciable selectivity for the 6 -site, showing 3000-fold 
selectivity in isolated tissue studies, and 179-fold in binding assays (Zajac et al., 1983). 
However these two compounds are markedly sensitive to peptidase degradation
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* It should be stressed however, that pi activity is only seen at high doses and the 
antinociceptive tests used show litttle sensitivity to d-mediated effects.
(McKnight et al., 1985). In order to try and increase the selectivity of these 
compounds Gacel et al. (1988) increased the steric size of the residues in position 2 
and/or 6  of DTLET or DSLET, in order to reinforce the stmctural analogy with DPDPE 
and it was hoped would increase the affinity at the 6 -site. Two highly selective and 
high affinity compounds were synthesised DSTBULET and BUBU (for structures see 
Table 2). These hexapeptides were relatively resistant to peptidase degradation but their 
activity in antinociceptive tests could be correlated to their inhibition of pH] DAGO 
binding, suggesting possible mediation via )i-receptors (Gacel et al., 1988).* This has 
subsequently been confirmed for BUBU (Delay-Goyet et a i, 1991), showing that in 
vitro selectivity is not necessarily a good indication of in vivo selectivity. Further 
studies led to the synthesis of BUBUC which differs from BUBU only by a Cys(StBu) 
at position 2 (Gacel et al., 1990). This compound is 6 -selective both in vitro and in 
vivo and show such resistance to peptidase enzyme that it is systemically active.
The [Metjenkephalin analogue Metkephamid also shows some 6 -selectivity, as it shows 
a greater inhibition of DADLE binding over |Lt-agonists and requires a higher 
concentration of naloxone to inhibit its effects in the mouse vas deferens. It has a major 
advantage over most of the peptide analogues in that it is active after systemic 
administration but these effects are most likely to be mediated by both \x and 6 -receptors 
(Frederickson ef û/., 1981).
In 1981 a novel peptide was isolated from the skin of an arboreal frog belonging to the 
subfamily Phyllomedusinae (Montecucchi et al., 1981). This peptide named 
dermorphin, which shows no structural homology with the mammalian opioids (see 
below), was shown to have remarkable affinity for the |i-receptor (Montecucchi et al., 
1981). Dermoiphin is now established as the most potent morphine-like agonist 
currently known (Broccardo et al., 1981). Dermorphin is a heptapeptide with the 
structure Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 , later studies have shown that the D 
amino acid at position two is present in the precursor for dermorphin suggesting that
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the L to D transformation must occur at an early stage of biosynthesis (Mor et aL, 
1991). In 1989 two groups simultaneously published evidence for a new highly 
6 -selective peptide isolated from the skin of Phyllomedusa sauvagei . This 
heptapeptide was termed dermenkephalin (Mor et a i, 1989) or, the now more widely 
accepted deltorphin (Kreü et ai, 1989) and had the following structure Tyr-D-Met-Phe- 
His-Leu-Met-Asp-NH2 . Deltorphin was the most potent 6 -agonist thus far reported 
with an IC50 in the mouse vas deferens of less than InM (Kreil et ai, 1989), with a |X/6  
ratio of close to 3000. Subsequently two more deltorphin peptides were isolated from 
frog skin (Erspamer et aL, 1989), which contained a D-Ala residue at position 2. Their 
amino acid sequence was different to that of the parent deltorphin, [D-Ala^jdeltorphin I 
(DELT I) having the structure Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 . The second 
peptide [D-Ala^jdeltoiphin II (DELT II) differs only by a Glu at position 4. Isolation 
of the cDNAs coding for DELT I and DELT II indicated that the D-Ala residue was 
coded for by a normal GCG codon for L-alanine, (Richter et aL, 1990), which would 
suggest that the insertion of a D-amino acid at position 2 is a post-translational event. 
The presence of a D-amino acid in the structure of the deltoiphins renders them resistant 
to degradation by rat plasma and relatively resistant to rat brain membranes (Marastoni 
et al., 1991). Structure-activity relationships for the deltorphins suggest the C-terminal 
end of the peptide is crucial for 6 -selectivity. Further amidation of the C-terminal is 
critical for the 6 -affinity of these compounds (Lazarus et al., 1991). The location of 
charged groups relative to the hydrophobic domains are important in allowing the 
folded confirmation seen in the deltorphins (Salvadori et al, 1991). If this folding is 
prevented such as in dermorphin, jx-selectivity is indirectly favoured. Changes to the 
hydrophobic region associated with the Val^ residue of DELT II can lead to marked 
effects on 6 -selectivity, an increase in the hydrophobicity at this residue results in an 
increase in both affinity and selectivity (Sasaki etal., 1991). The introduction of amino 
acids with charged side-chains to the C-terminal increases 6 -selectivity by causing a 
marked decrease in p-receptor affinity (Melchiorri et al., 1991), which confirms the 
earlier work of Temussi et al. (1989). Temussi et al. (1989) showed that the
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N-terminal of deltorphin and dermorphin were the same thus the presence or absence of 
charged residues at the C-terminal determines the 6 - or p-selectivity of these 
compounds respectively.
A major advance in 5-opioid receptor selective compounds has come with the synthesis 
of the first 6 -selective non-peptide agonist BW 373U86. In both isolated tissue and 
binding assays it shows good 6 -selectivity (Lee et al., 1993) although preliminary 
studies are showing that it has an atypical 6 -agonist profile (Dykstra et a i, 1993). This 
wiU be discussed later in section 1.5.1.
1.3 6 -SELECTIVE ANTAGONISTS
The most widely used opioid receptor antagonist is the prototypic opioid antagonist 
naloxone. Naloxone has affinity for all three opioid receptor subtypes showing 
approximately 1 0 -fold and 1 0 0 -fold selectivity for p sites in comparison with 6 -and 
K-sites respectively (Hill 1981). The first 6 -selective antagonist, ICI 154,129 was 
described in 1982 (Shaw et a l, 1982). ICI 154,129 is a peptide based on the sequence 
of [Leujenkephalin (Figure 2) where structural changes were introduced to improve the 
metabolic stability of the molecule. ICI 154,129 was found to 30-fold selective for 
6 -sites over p-sites in isolated tissue studies, with a relatively poor affinity (Ke 250nM) 
and was only slowly inactivated by tissue homogenates (Shaw et al., 1982). A second 
peptide antagonist, ICI 174,864, was found to have equal affinity with naloxone at the 
6 -receptor (Ke 30nM) but this was coupled with a greater than 150 fold selectivity for 
6 - over p-sites (Cotton et al., 1984). One possible problem with the use of 
ICI 174,864 in vivo is that its postulated carboxypeptidase breakdown product 
(LY281217) is an agonist at the p-receptor (Cohen et al., 1986). One effect that has 
limited the use of this compound is that after intrathecal and injection it causes motor 
dysfunction, neuronal degeneration and widespread cell death by an unknown
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Figure 2. Structure of 6 -selective antagonists
ICI 154,129
N,N diallyl-Tyr-Gly-Gly-\}r-(CH2 S)-Phe-Leu-0 Hl
ICI 174,864
N.N diallyl-Tyr-Aib-Phe-Leu-OH^
N n  and related compounds
OH
HO O '
X R
NTI NH H
NTB 0 H
5'NTII NH N=C=S
signifies replacement of the amide CO-NH bond by CH2 S 
2 Aib = a-aminoisobutyric acid
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mechanism (Long et al.  ^ 1988). In spite of these problems ICI 174,864 has provided 
some useful information on 6 -receptor function.
A major advance in the study of 6 -opioid receptors came with the synthesis of the first 
selective, stable non-peptide antagonist naltrindole (NTI) (Portoghese et aL, 1988). 
NTI is the indole analogue of the non-selective opioid antagonist naltrexone (Figure 2), 
it shows high affinity for the 6 -receptor (pA2 9.7) and is about 100-fold selective for 
the 6 -site on the basis of isolated tissue and binding studies (Portoghese et a l, 1988; 
Rogers et a i, 1990). NTI was designed using the message-address concept 
(Schwyzer, 1977), which suggests that peptide hormones are sychnologically 
organised to contain a message sequence and address sequence of amino acids each 
being proximal to one another in the peptide chain. The message component is 
involved in signal transduction at the receptor, while the address provides additional 
binding affinity and is not essential to the transduction process. For a group of 
peptides associated with more than one receptor type, such as the enkephalins, the 
message component is similar or the same, while the address segment is variable and a 
determinant of selectivity for a particular type of receptor. One interpretation of this 
concept applied to opioid peptides is that the Tyrl residue forms the message 
component, and the sequence starting with the Phe4 constitutes the address; in this 
context Gly2-Gly3 serves as a spacer (Portoghese et a l, 1990a). This view is 
consistent with the structure-activity relationships of non-peptide opioid ligands that 
contain only one aromatic ring which presumably mimics the Tyr^ residue. NTT was 
designed with the naltrexone message unit joined to a benzene moiety which was 
envisaged to be the key 6 -address component that simulates the Phe4 residue of 
enkephalin. A spacer molecule was also included to restrict the benzene molecule to a 
single confirmation (Portoghese et a/., 1990a). Conformational rigidity was an 
important consideration, because a rigid address moiety might confer greater 
6 -selectivity by precluding possible conformational adaption of the ligand in the binding 
to other opioid receptor types.
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Other analogues of NTI show greater potency and selectivity for the 5-receptor 
(Takemori et a i, 1990; Larson et a/., 1990). These include the benzofuran analogue of 
NTI, naltriben (NTB). NTB was synthesised while the authors were exploring the 
effects of the spacer and address molecules in the basic NTI structure (Portoghese 
et a i, 1991). NTB shows good affinity at the 6 -site (Ke 0.27nM) and shows 100-fold 
selectivity for 6 - over ji-sites and 178-fold selectivity for 6 - over K-sites in isolated 
tissue studies. Unusually NTB shows even greater selectivity for 6 -sites in binding 
assays, 1446-fold ji/ô and 11723-fold k /6  (Portoghese et al, 1991). The apparent lack 
of correlation between the antagonist potency in the mouse vas deferens and in the 
binding assays raises the possibility that some of the sites bound by the radioligand are 
not in common with those involved in 6 -antagonism in the functional model. Both NTI 
and NTB have been shown to exhibit K-agonist effects in mice (Takemori et aL, 1992) 
and these effects, although quite potent, require higher doses than are needed for 
6 -antagonism (Sofuoglu et a/., 1991). One recent report has suggested that NTI has 
agonist effects at 6 -receptors and causes behavioural toxicity similar to that seen with 
ICI 174,864 (Stapelfield et al., 1992). It must be stressed that these effects are seen at 
doses 1 0 0 0 -fold greater than is required for 6 -receptor antagonism.
Other antagonists that have been employed as 6 -antagonists for in vivo studies these 
include C700 and J7747 (Curtis & Lefer, 1983), although the only evidence for the 
'6 -selectivity' of these compounds is their ability to block the effects of 
[Leu]enkephalin in the mouse vas deferens. 16-Methyl cyprenorphine (M8008) shows 
a 2-fold selectivity for 6 - over |i-sites (Smith, 1987).
Efforts to develop opioid receptor affinity labels (non-equilibrium ligands) have been 
pursued as biochemical and pharmacological tools to address the problem of receptor 
multiplicity and receptor isolation. The fentanyl derivatives FIT (Rice et al., 1983) and 
SUPERFIT (Burke et al., 1986) both show good selectivity for the 6 -site but are not
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active in vivo. The peptide [D-Ala^, Leu^, Cys^]enkephalin (DALCE) has been 
reported to bind covalently to 8 -receptors by a thiol-disulphide exchange mechanism 
(Bowen et al., 1987), and it also appears to possess a pharmacological profile in vivo 
consistent with a non-equilibrium 8 -receptor antagonist after short term agonist effects 
(Calcagnetti et al., 1989). The first non-peptide, non-equilibrium 8 -receptor antagonist 
which showed activity in vivo was the isothiocyanate derivative of NTI (5’NTII) 
(Portoghese et al., 1990b). Its in vivo effect peak 24 hours after central administration 
indicating that its antagonist effect may take place through a covalent binding 
mechanism.
1.4 DISTRIBUTION OF 8 -RECEPTORS
A detailed knowledge of the discrete regional distribution of 8 -receptors would be 
invaluable in correlating these sites with specific functional roles. This has been partly 
answered by the use of in vitro autoradiographic methods. The presence of 8 -receptors 
by autoradiography have been shown in rat (McLean et al., 1986; Blackburn et al., 
1988; Delay-Goyet etal., 1990), mouse (Moskowitz & Goodman, 1984), guinea-pig 
(Sharif and Hughes, 1989), dog (Sharif etal., 1990), monkey (Lewis etal., 1985) and 
human brain (Delay-Goyet et al., 1987; Blackburn et al., 1988). These studies have 
shown that the distribution of sites is extremely well conserved across species.
Early studies were performed using [^H]DADLE and so large cross-reactivity with 
|X-sites was likely (Duka et al., 1981), some authors added |X-selective compounds in 
order to reduce this cross-reactivity (Moskowitz & Goodman, 1984; McLean et al., 
1986; Blackburn et al., 1988). The following description summarises the results 
obtained by McLean et al. (1986) as these are representative of the results obtained with 
[3H]DADLE. 8 -sites were found in all layers of the neocortex but showed an overall 
bilaminar pattern of relatively higher density in the supragranular layers (I-III) and in 
the deep portion of layer V extending into layer VI. In the olfactory bulb [^H]DADLE
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Table 3. Distribution of 6 -receptors in rat brain by autoradigraphy using [^HJNTI to 
label 5-sites.
BRAIN AREA DENSITY
Hippocampus *
Dentate gyrus *
Rostral caudate ***
Globus paUidus *
Thalamus
Dorsal medial *
Ventral medial ***
Hypothalamus *
Cortex
Laminae 1-3 ***
Laminae 4 **
Laminae 5-6 ***
Nucleus accumbens ***
Claustrum **
Olfactory bulb
External plexiform layer ***
Internal plexiform layer ***
Anterior olfactory nucleus **
Frontal cortex **
Entorhinal cortex *
Spinal Cord
Substantia gelatinosa *
*** represents a density of >2 0 fmol/tissue equivalent, ** 1 0 -2 0 fmol/tissue equivalent 
and * <10fmol/tissue equivalent The values were taken from Drower et al. (1993).
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binding was found only in the external plexiform layer. 6 -sites were visualised in the 
hippocampus with the most dense binding in the pyramidal and granular cell layers and 
over the molecular layers of the dentate gyrus and CA fields. The subcortical limbic 
structures were sparsely labelled. In the basal ganglia dense 6 -binding was seen in the 
striatum, some binding was seen the nucleus accumbens, but very little in the globus 
pallidus. Moderate to high densities were seen in the amygdaloid nuclei with higher 
binding caudally. [^HJDADLE binding in the hypothalamus was sparse and barely 
detectable in the magnocellular nuclei, similarly the thalamus showed very little 
6 -binding. In contrast the corpus callosum was densely labelled by pH]DADLE.
Later studies performed using more selective 6 -ligands such as [^HJDPDPE Sharif & 
Hughes, 1989), [^HJDSTBULET (Delay-Goyet e ta l,  1990) or [3H]NTI (Drower et 
al, 1993) found a similar distribution to that seen with DADLE, however, they were 
able to visualise sites in several thalamic nuclei and also scarce, but significant binding 
in the ventromedial hypothalamus, ventral tegmental area and periaqueductal grey 
(Delay-Goyet et a l, 1990). It should be noted that injection of 6 -opioid receptor 
agonists into these areas causes marked behavioural effects (Jenson & Yaksh, 1985; 
Calenco-Choukram et a l, 1991, discussed further in section 1.6), thus indicating that 
the density of receptors may not reflect the importance of their effects. 6 -binding is 
also found in all levels of the spinal cord, but it appears to be mainly restricted to the 
substantia gelatinosa (Delay-Goyet et al, 1990; Drower et a l, 1993). Table 3 shows 
the distribution of 6 -sites in rat brain using pH]NTI to label 6 -sites. The distribution 
of 6 -sites in the spinal cord has been shown to be associated with the dorsal root, one 
study has shown that binding sites originating from the C7 root are distributed over at 
least four segments, two rostral and one caudal to the segment of entry (Besse et a l, 
1991). Using selective lesion techniques the authors showed these receptors are 
associated with fine-diameter primary afferents.
39
Thus it appears that 5-opioid receptors are highly concentrated in the more recently 
developed areas of the brain (cortex, neostriatum) where they could be involved in 
modulation of integrational processes. This could be via dopaminergic pathways as
5-sites are associated with the nucleus accumbens, striatum and medial preffontal cortex 
regions known to receive dopaminergic afferents emanating from the mesencepalic 
tegmentum (Dilts & Kalivas, 1990). The presence of 5-sites in the corpus callosum 
may signify a role in interhemisphere transfer and their location on primary afferents in 
the spinal cord lends to a role in modulation of sensory input.
1.5 IN VIVO PHARMACOLOGY OF 5-SELECnVE LIGANDS 
1.5.1 ANTINOCICEPTION
There is clear evidence from several laboratories that 5-selective agonists are 
antinociceptive (Table 4). Several nociceptive tests have been employed to gain this 
information. Thermal tests include the warm-water tail-immersion test (Janssen et a l, 
1963) where the tail is placed in warm water, usually at 50°C, and the time taken to 
remove the tip of the tail from the water, the immersion latency, is recorded as a 
measure of antinociception. The greater the immersion latency the more antinociceptive 
the drug. The radiant heat tail-flick (D Amour & Smith, 1941) has a similar principle, 
where the tail is placed in a high intensity light beam and the time taken to remove the 
tail is measured. The hot plate test (Eddy & Leimbach, 1953) requires the animal to be 
placed on a plate usually at 55°C. In rats the latency to lick a rear paw is recorded, 
while in mice the latency to lick the front paws or to jump is recorded. The paw 
pressure or paw withdrawal test (Randal & Selitto 1957) has been used to measure 
mechanical nociceptive threshold. The mechanical stimulus is applied using an 
analgesymeter which generates a linearly increasing mechanical force, applied by a 
dome-shaped plastic tip, to the dorsal surface of the rats hind paw. The nociceptive 
threshold is defined as the force in grams at which the animal withdraws its paw.
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Nociceptive thresholds to chemical stimuli may be measured using either the formalin 
test or the acetic acid writhing test. Foimalin ( 5%) is injected subcutaneously into the 
dorsal surface of one of the rear paws, lifting and licking of the paw are scored and 
used to quantify the nociceptive response. The mouse writhing response is defined as a 
contraction of the abdominal musculature followed by the extension of the hind limbs 
(Collier et al, 1968). Writhing has been commonly induced by an intraperitoneal (i.p.) 
injection of 0 .6 % acetic acid.
The antinociception induced by 6 -agonists is likely to be mediated at two levels, 
supraspinally and spinally. Supraspinal antinociception is usually measured after 
intracerebroventricular (i.c.v.) injection or after injection into discrete brain regions, 
spinal antinociception is measured following intrathecal (i.t.) injection and possibly 
after peripheral administration. However, if the compound being studied is able to 
easily cross the blood brain barrier, supraspinal antinociception can be induced 
following i.t. or peripheral administration and some spinally mediated effects may be 
seen after central administration. In the following section for ease of description these 
sites will be considered separately.
Most studies have employed thermal stimuli to elicit a nociceptive response since these 
tests have been shown to be the most sensitive to 6 -modulation (Schmauss & Yaksh, 
1984). The most extensively studied 6 -agonist, DPDPE, is antinociceptive following 
i.c.v. injection in both rats and mice (Galligan et a l, 1984; Porreca et al., 1987), 
however, this is both species and test dependent. DPDPE is only active in the mouse in 
the warm water tail immersion test, but is antinociceptive in both species in the hot plate 
test (Heyman et a i, 1987a). Due to this species difference following i.c.v. injection, 
most of the studies investigating supraspinal antinociception, using thermal tests, have 
been performed in the mouse. 6 -mediated antinociception has been shown for various
6 -selective agonists in addition to DPDPE, including DPLPE (Galligan et al., 1984), 
DSLET (Jenson & Yaksh, 1985; Belknap & Laursen, 1986; Jiang et al., 1991),
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DTLET (Sanchez-Blanques & Garzon, 1989), DELT II (Jiang et al., 1991; Mattia 
et al., I99I) and DALCE (Calcagnetti et al., 1989). This antinociception is dose- 
related and peaks approximately I0-I5mins after agonist administration. The effects 
are opioid mediated shown by their sensitivity to naloxone (Galligan et al., 1984; 
Heyman et al., 1987b; Kovacs et al., 1988) and also ô-mediated since reversal by the 
selective antagonists ICI 174,864 (Porreca etal., 1987; Sanchez-Blanques & Garzon, 
1989; Jiang et al., 1990a; Suh & Tseng, 1990c) and NTI (Ayres et al., 1990; 
Calcagnetti & Holtzman 1991) has been shown. It has also been noted that 
subantinociceptive doses of DPDPE significantly potentiate morphine antinociception 
via an ICI 174,864 reversible mechanism (Porreca et al., 1987; Heyman & Porreca, 
1988) and this effect was seen in both morphine tolerant and naive mice (Jiang et al., 
1990a). The mechanism by which this potentiation occurs is unknown, but the 
possibility of a complex consisting a |i- and 5-site has been proposed and this is 
discussed further in section 2.4. 5-antinociception has also been shown in Jimpy mice 
(Mathiason & Vaught, 1987) and in CXBX mice (Raffa et al., 1992) which are 
genetically deficient in functional |X-receptors.
Antinociceptive studies in the rat have utilised mechanical and chemical stimuli in 
addition to thermal tests. DPDPE is antinociceptive in the paw-pressure test (Frank 
et al., 1991) and this effect shows synergy with ^.-agonists (Miaskowski et a l, 1991). 
Antinociception is also seen in the formalin test (Fanselow et al., 1989) as well as in its 
mouse equivalent, the writhing test (Hong & Takemori, 1989). Antinociception is also 
seen following injection of 5-agonists into discrete brain regions, such as the 
periaqueductal grey (Jenson & Yaksh, 1985), even though this area shows only sparse
5-binding (Delay-Goyet et al., 1990), and also following injection into the area 
tempestas, a small region found in the prefrontal cortex (D’Amore et al., 1990).
Mediation of antinociception via spinal 5-receptors has been implicated since studies in 
both rats and mice have shown potent 5-mediated, antagonist reversible antinociception
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* However, similar to the results obtained by Gacel et al., (1988), the test used appears to be 
relatively insensitive to d-mediated effects.
following i.t. administration of 5-agonists (Table 4). These studies have been 
performed using thermal tests in both rats and mice (Porreca et al., 1987; Heyman 
et al., 1987a; Drower et a l, 1991; Sofuoglu et al., 1990; Kalso et al., 1992) and 
mechanical tests (Rodriquez et al., 1986) in rats. This effect is dose-related and peaks 
around lOmin after agonist administration. The antinociception shown in the radiant 
heat tail-flick test was shown to be additive with the effects of ji-agonists (Roerig & 
Fujimoto, 1989), while in the paw pressure test the effect of DPDPE proved to be 
synergistic with K-agonists (Miaskowski et al., 1990). The relatively non-selective 
agonists DADLE and Metkephamid are also antinociceptive following i.t. 
administration in primates (Yaksh, 1983), but these effects are at least partially 
mediated via 5-sites since the effect of DADLE is not cross-tolerant with morphine. 
The relatively non-selective agonist DADLE has been given to a single patient showing 
tolerance to morphine where it provided potent pain relief for up to 48 hours after a 
single i.t dose of DADLE (Onofrio & Yaksh, 1983). Subsequently DADLE was given 
with morphine and the dose of morphine was able to be reduced from 64mg to lOmg a 
day (Onofrio & Yaksh, 1983).
Intrathecal administration of two enkephalinase inhibitors (SCH 34826 and SCH 
32615) leads to antinociception in rats which is partially reversed by ICI 174,864 and 
NTI indicating that physiological antinociception mediated by the enkephalins is in part 
due to activation of 5-sites (Cowan et al., 1990; Oshito et al., 1990). Others have 
argued that enkephalin antinociception is mediated exclusively via |i-receptors since the 
pA2 values for naloxone verses the enkephalins correlated better with ji-antagonism 
(Chaillet et al., 1984), also the naloxone pA2 for the antagonism of the antinociception
mediated by the enkephalinase inhibitor RB101 is not significantly different to that for
*
DAGO (Noble et al., 1992). However, Noble et al. (1992) also showed that the 
increase in tail-flick latency and motor responses to tail stimulation are reversed by
5-selective doses of NTI. There is much evidence that substance P is the 
neurotransmitter released by nociceptive primary afferent fibres. When administered
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i.t substance P produces a syndrome indicative of peripheral irritation, and this effect 
is reversed by DADLE by a mechanism refractory to ^-antagonists (Hylden & Wilcox, 
1983).
The non-peptide 6 -agonist BW373U86 is ineffective in the rat tail-flick assay when 
administered by the i.c.v., i.p. or oral routes, however, it produces a time and dose- 
dependent antinociception when administered i.t. (Wild et ai, 1993), in addition to this 
its antinociceptive effects are antagonised by naloxone and ICI 174,864. It is also 
active in the acetic acid writhing test when administered i.c.v. and i.t. (Wild et al., 
1993). In contrast to the previous results BW373U86 is not antinociceptive when 
administered intramuscularly to primates, however, it markedly potentiates the effects 
of methadone in a NTI reversible manner (Dykstra et al., 1993).
In models of peripheral inflammation both DPDPE and the inhibition of enkephalinase 
by a combination of thioiphan and bestatin produce antinociception in the inflamed paw 
using mechanical tests after local administration to the paw (Stein et al., 1989; Parsons 
& Herz, 1990), the effect was not seen in the contralateral paw. The potency of i.t.
6 -agonists increases during inflammation using the paw pressure test on the inflamed 
paw (Hylden et al., 1991), and this antinociception is blocked by the tt2 antagonist 
idazoxan indicating a role for descending noradrenergic mechanisms in opioid 
antinociception during inflammation (Hylden et al., 1991). The increase in paw- 
withdrawal latency following administration of DPDPE can be antagonised by both 
NTI and NTB, however, in this model the same doses of NTI and NTB antagonised 
the effects of DAGO suggesting that in the carrageenan-inflamed paw withdrawal test, 
either these antagonists lose their selectivity or DAGO acts via 6 -sites in this test 
(Stewart & Hammond, 1993). The sensitivity to ICI 174,864 confirms the 6 -mediation 
of this effect (Stein et al., 1989). Intradermal administration of bradykinin also causes 
a marked hyperalgesia which is reversed by DPDPE, and this effect is thought to be 
mediated by action on sympathetic postganglionic neurone terminals (Taiwo & Levine,
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1991). 6 -receptors are not thought to play a role in models of tonic pain as DPDPE is 
inactive in the ’refined mouse formalin' paradigm used to assess this type of 
nociception (Murray & Cowan, 1991).
In addition to behavioural antinociceptive tests, electrophysiological studies show
6 -mediated dose-related inhibition of dorsal horn neurones in spinal cord evoked by 
stimulation of unmyelinated C-fibres, while no effect was seen on neurones stimulated 
by stimulation of A-fibres (Dickenson et al., 1987). Application of DSTBULET 
together with the enkephalinase inhibitor, kelatorphan, topically onto lumbar spinal 
cord in anaesthetised rats produces a maximal inhibition of dorsal horn neurones in 
spinal cord neurone responses to C-fibre stimulation equivalent to that observed with 
either DSTBULET or kelatorphan alone suggesting that the endogenous enkephalins 
and the 6 -agonist have a common site of action in the spinal cord (Dickenson et al.,
1988). The effects of DSTBULET were also tested on the response of dorsal horn 
neurones in spinal cord neurones to a more prolonged chemical stimulus by giving 
subcutaneous injection of 5% formalin. The formalin produced a biphasic pattern of 
activity with an initial peak at lOmin followed by a prolonged response over the next 
50min. DSTBULET completely abolished the second phase response and markedly 
reduced the first (Sullivan et al, 1989). ICI 174,864 was able to antagonise the effects 
of DSTBULET in both of the above models (Sullivan et al., 1989). The influence of 
DSLET on different spinal reflex pathways in decapitated, high spinal cats has been 
investigated (Schmidt et al., 1991). Monosynaptic reflexes were tested to analyse 
excitatory and inhibitory flexor reflex afferent pathways from nociceptive and non­
nociceptive afferents, as well as an excitatory nociceptive non-flexor reflex afferent 
pathway. DSLET when superfused over the spinal cord caused a concentration- 
dependent depression of transmission in nociceptive and non-nociceptive flexor reflex 
afferent pathways, with the excitatory pathways being more sensitive than the 
inhibitory ones. Similar effects were seen following intravenous (i.v.) DSLET 
administration, and in addition all of these effects were inhibited by naloxone (Schmidt
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et al., 1991). ô-agonists are also able to inhibit the responses of wide dynamic range 
neurones (based on a neurone's response profile to increasing intensities of receptive 
field stimulation) to thermal noxious stimuli in the cat. The effect was reversed by ICI
174,864 and synergistic with |i-agonists (Omote et al., 1990).
5-opioid receptors have also been implicated in the antinociception induced by non­
opioid compounds. ICI 174,864 is able to partially block nitric oxide antinociception, 
although the main effect appears to be at ^.-receptors (Quock et ah, 1990). The 
antinociception induced by i.c.v. injection of cholecystokinin octapeptide (CCK-8) can 
be antagonised by naloxone with a pA2 not significantly different to that for antagonism 
of DPDPE, and the effect of CCK-8  is significantly antagonised by ICI 154,129 but 
not by the |i-antagonist p-funaltrexamine (p-FNA) nor the K-antagonist nor- 
binaltorphamine (nor-BNI) (Hong & Takemori, 1989). CCK- 8  is also able to 
antagonise ji-agonist inhibition of dorsal horn neurone activity evoked by C-fibre
stimulation, although it has no effect on the response to DSTBULET (Magnuson et al., 
I  antinociceptive
1990). Thesexeffects of nitric oxide and CCK-8  are likely to be mediated by the release 
of enkephalins. Dopamine D2 agonists are able to potentiate the effects of 6 -agonists in 
the warm water tail-immersion test (Rooney & Sewell, 1989), as do a 2 adrenergic 
agonists using the substance P behavioural test (Roerig et al., 1992). The 
antinociception induced by i.c.v. injection of P-endorphin to mice is mediated by the 
release of [Metjenkephalin in the spinal cord (Suh & Tseng, 1990a). Tolerance to 6 - 
but not ii-agonists administered i.t. prevents this P-endorphin-induced antinociception 
(Suh & Tseng, 1990a) and pretreatment with P-endorphin markedly reduces the 
potency of DPDPE but not DAGO (Suh & Tseng, 1990b).
The development of analgesic peptide drugs selective for the 6 -receptor could yield 
several major advantages over the ^-selective narcotic analgesics used in medicine 
today (Rapaka & Porreca, 1991). Peptides will be metabolised to their constituent 
amino acids and the metabolic end products, unlike the opiates, are polar and easily
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eliminated from the body. Peptide agonists at the 5-receptor do not demonstrate 
marked cross-tolerance to opiates, thus they are likely to be useful analgesics in patients 
undergoing chronic therapy with p-opiates. They are also likely to have a decreased 
dependence/abuse liability (see section 1.5.7), and are also less likely to cross the 
placenta, in addition to which 5-sites have not been found in human foetal tissue 
making these drugs safer to use during pregnancy.
5-receptors have been suggested to mediate stress-induced antinociception (SIA) in rats 
and mice following warm-water swimming (Hart et al., 1983), cold-water swimming 
(Parsons & Herz, 1990) and restraint-stress (Calcagnetti et al., 1990). The SIA 
induced by warm-water swimming in rats and mice can be antagonised by ICI 
154,129, ICI 174,864, and NTI (Hart et al., 1983; 1985; Jackson et al., 1989a; 
Jackson & Kitchen, 1989; Jackson & Nutt, 1990). p-receptors are also involved in 
SIA in neonatal rats and a transition between p- and 5-receptor control of this behaviour 
occurs around the time of weaning (Kitchen & Pinker, 1990). Associated stress- 
induced elevations in plasma corticosterone are unaltered by ICI 174,864 (Kitchen & 
Rowan, 1984) or NTI (Kitchen & Kennedy, 1990), suggesting this mechanism is 
independent of the antinociception.
1.5.2 GASTROINTESTINAL FUNCTION
The available evidence suggests that 5-opioid receptors are involved in several aspects 
of gastrointestinal (GI) function (Table 4). DPDPE is able to inhibit castor oil induced 
diarrhoea in mice after both i.c.v. and s.c. administration in a naltrexone reversible 
manner (Shook et al., 1989). These observations were confirmed and extended by 
Lemcke et al. (1991) who showed, using the prostaglandin E2 induced diarrhoea model 
in the mouse, that DPDPE was also able to inhibit the induced diarrhoea after i.t. 
administration. The potency of DPDPE was dependent on route of administration with 
i.c.v. being the most potent and s.c. being the least potent. DELT II is also able to
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inhibit experimental diarrhoea following i.c.v. and i.t. injection and this effect is 
antagonised by NTI (Broccardo & Improta, 1992a). Intrathecal administration of 
ô-agonists causes an inhibition of GI transit as measured by the movement of a Na^^Cr
meal (Porreca et a i, 1984), however both DPDPE and DPLPE were found to be 
inactive after i.c.v. injection indicating that 0-receptors do not appear to affect GI transit 
following central administration in the mouse (Porreca et al., 1984). The results 
described above confirm the observations of Ward & Takemori (1982) who showed 
that DADLE causes a p-mediated inhibition of GI transit following i.c.v. 
administration. The effects of Ô-agonists on GI transit in the rat appear to be 
inconsistent since DPDPE is ineffective following i.p. injection, DSLET appears to 
inhibit transit but its effect is not linearly related to dose and DADLE produces a dose- 
related inhibition of transit which is insensitive to p-antagonists but is antagonised by 
ICI 174,864 (Tavani et al., 1990). ô-opioid control of colonic transport appears to be 
more consistent, in the mouse DPLPE induced an inhibition of colonic transport after 
i.c.v. administration (Raffa et al., 1987), and a similar effect was seen following s.c. 
injection of Metkephamid (Cowan & Gmerek, 1982). In the rat DELT II caused a 
dose-related, NTI reversible inhibition of colonic transport with no effect on small 
intestinal transit (Broccardo & Improta, 1992). Inhibition of colonic transport is also 
seen following i.m. injection of DPDPE in the cat (Krevsky et al., 1991). All of these 
observations are in contrast to the study in dogs which showed that i.v. Metkephamid 
causes an increase in intestinal contractility (Vaught et a l, 1985) and in this species 
DPDPE is also able to inhibit the neuronally evoked relaxation of the dog lower 
oesophageal sphincter (Barnette et al., 1990).
Ô-opioid effects on fluid secretion are unclear as although in the mouse an increase in 
intestinal fluid absorption is seen (Jiang et a/., 1990b), this is not reversed by ICI 
174,864. Ô-receptors associated with submucosal neurones may inhibit the release of 
an undefined non-adrenergic, non-cholinergic transmitter which tonically reduces 
chloride absorption in the pig (Quito & Brown, 1990). The role of Ô-receptors in the
64
control of gastric acid secretion is equivocal, since DPDPE has no apparent effect after 
both i.v. and i.c.v. administration in the rat (Fox & Burks, 1988), and DADLE appears 
to be without effect in the dog (Bartolini et a i, 1985). However, Metkephamid was 
able to decrease basal acid secretion after i.p. administration (Glavin et al., 1990) and 
Metkephamid also led to a decrease in ethanol-induced ulcers (Glavin et a i, 1990) 
which accords with the association of S-mediated responses under conditions of stress.
The specific involvement of 5-receptors in controlling food intake is unproven. In the 
rat there is evidence that central administration of DPDPE causes an acute increase in 
feeding (Majeed et al., 1986), as do DSLET (Gosnell et al., 1986a) and DADLE 
(Jackson & Sewell, 1985). DALCE has also been shown to potentiate 2-deoxy-D- 
glucose (2DG) induced feeding for up to 6  hours after administration. However, if the 
rats are pretreated with DALCE 24 hours prior to testing , (a pretreatment schedule 
which produces irreversible 5-antagonism), a high dose leads to a decrease in 2DG 
induced feeding whereas a low dose induces an increase in feeding. DALCE 
pretreatment also induces a significant increase in free-feeding for 4-6 hours (Aijune et 
al., 1991). The above results indicate that both the agonist and antagonist effects of 
DALCE may be able to increase feeding. The agonist effects, however, are reversed by 
the selective K-antagonist nor-BNI, but not by pretreatment with DALCE itself, thus 
indicating involvement of K-receptors (Aijune et al., 1991). Benton et al. (1984a) 
showed that ICI 154,129 had no effect on feeding induced by a 23 hour deprivation, 
suggesting 5-receptors may not be involved in the regulation of food intake following 
deprivation. There is, however, a possible tonic role of 5-receptors in free feeding 
since both ICI 154,129 and ICI 174,864 cause a decrease in feeding when given i.c.v. 
(Jackson & Sewell, 1985). DPDPE, after i.c.v. injection, has been shown to have no 
overall effect on response rates for food reward in operant trained rats during a 1 hour 
session, although it was noted that high doses of DPDPE caused a marked decrease in 
responses in the first 24 minutes of the session, with response rates subsequently 
increasing so that at the end of the session no difference was seen compared to predrug
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levels (Adams & Holtzman, 1991). Similar results were obtained in morphine-tolerant 
rats indicating that the apparently opposite effects were not due to the high doses of 
DPDPE acting at the ^.-receptor (Adams & Holtzman, 1991).
The effect of ô-receptors in the control of water intake appears to be dependent on the 
site of administration, since i.c.v. injection of ICI 154,129 and ICI 174,864 causes a 
marked decrease in water intake, while administration of DADLE increased water intake 
(Jackson & Sewell, 1985). In contrast intrahypothalamic injection of DPDPE to rats 
had no effect on spontaneous, deprived or saline-induced water intake (Ukai et al.,
1988). The poorly selective 5-antagonist M8008 was able to reduce intake of a 
saccharin/glucose solution over a 30 minute period although the effect appears not to be 
linearly related to dose (Calcagnetti et al., 1990b). The evidence for a role of 5- 
receptors in control of food and water intake is contradictory, as both agonists and 
antagonists may increase, decrease or have no effect on these behaviours.
1.5.3 CARDIOVASCULAR FUNCTION
The effect of 5-agonists on the cardiovascular system appears to be dependent on 
whether the animal is anaesthetised or not. [Leu]enkephalin administered i.v. to 
conscious dogs causes an increase in both heart rate and mean arterial blood pressure, 
which can be inhibited by vagal interruption suggesting [Leujenkephalin stimulates 
afferent pathways within the vagosympathetic trunk to reflexly increase heart rate and 
blood pressure (Giles & Sander, 1983). Similar effects are seen following i.c.v. 
injection of DPDPE to conscious rabbits and these effects are fully reversed by 
naloxone (May et al., 1989). In conscious rats a similar hypertensive response to 
DPDPE is observed which is partially reversed by ICI 174,864 (Kiritsy-Roy et al., 
1986; 1989).
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Experiments in anaesthetised animals have yielded opposite results, DADLE injected 
i.c.v. into rats produces a decrease in arterial blood pressure by decreasing sympathetic 
outflow (Holaday, 1982). Similarly an injection of DADLE into the nucleus tractus 
solitaris of anaesthetised cats induces a decrease in both heart rate and blood pressure 
(Hassen et a l, 1982). Following administration into the rostroventrolateral meduUa of 
anaesthetised rabbits ICI 174,864 causes a marked increase in blood pressure while 
blockade of \l- and K-sites was without effect (Morilak et a i, 1990a). ICI 174,864 
also reverses the hypotensive effect of DADLE in this model, however, administration 
of NTI has no effect when administered alone nor does it reverse the effects of DADLE 
(Morilak et aL, 1990b). In a subsequent report the authors claimed that the same dose 
of nor-BNI which was inactive previously (Morilak et a i, 1990a) was able to reduce 
blood pressure and heart rate indicating a role for K-receptors in this response (Drolet 
et al., 1991). The reasons for the differences in results between conscious and 
anaesthetised animals may be due to anaesthesia suppressing reflex responses. DPDPE 
has no effect on heart rate or blood pressure in the foetal lamb (Szeto et al., 1990).
ô-receptors have been implicated in certain pathophysiological cardiovascular 
conditions such as hypertension. Chronic administration of ICI 154,129 to 
spontaneously hypertensive rats causes a marked decrease in blood pressure compared 
to saline treated controls (Kraft et al, 1991). Spontaneously hypertensive rats showed 
increased immunoreactive [Leujenkephalin in the heart, compared to normotensive 
controls, with no concomitant change in lung tissue (Dumont & Lemaire, 1988). 
Binding studies performed in the same experiment showed pHjDPDPE bound to two 
sites in membrane preparations from the hearts of normotensive rats but only to a high 
affinity site in spontaneously hypertensive rats. From this data it was postulated that 
the hypertensive state in spontaneously hypertensive rats is manifested through a rise in 
cardiac [Leujenkephalin and selective down regulation of a low affinity binding site.
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The involvement of endogenous opioids in the cardiovascular response to shock was 
raised by the observation that large doses of the non-selective opioid antagonist 
naloxone given after the induction of endotoxic (Holaday et al., 1978), haemorrhagic 
(Curtis & Lefer, 1980) and anaphylactic shock (Amir, 1982) reverses the precipitous 
fall in blood pressure to preshock levels. This effect is mediated by increased central 
sympathetic outflow to both sympathetic nerves and adrenal medulla (Amir, 1983). 
The 5-receptor was implicated in this response as the two antagonists J-7747 and 
C-7000 were also able to reverse the fall in blood pressure after haemorrhagic shock 
(Curtis & Lefer, 1983) and ICI 154,129 was effective after endotoxic shock at doses 
which had no effect on morphine antinociception (Holaday et al., 1982). There may be 
some interaction with |x-receptors in the mediation of this response since the irreversible 
^-antagonist p-FNA prevents the restorative effects of ICI 174,864 (Holaday & 
D'Amato, 1983).
1.5.4 RESPIRATION
Opioid-induced respiratory depression is a serious clinical side-effect and much 
attention has therefore been given to assessing the role of the 5 -receptor in this 
phenomenon. Preliminary studies in the rat showed that DADLE was more potent than 
morphine at inducing respiration and that its effects were not reversed by P-FNA (Ward 
& Takemori, 1983). DSLET administered both centrally (Pazos & Florez, 1983) and 
peripherally (Morin-Surun et al., 1984a) was able to decrease respiratory frequency. 
Further, the doses of DADLE and DSLET required to cause an inhibition of respiration 
were smaller than those required to elicit antinociception (Pazos & Florez, 1984). 
DPDPE is also able to reduce respiratory frequency and tidal volume after i.c.v. 
injection in rats and its effects are fully naloxone reversible (Yeadon & Kitchen, 1990). 
The action of the selective antagonist ICI 174,864 could not be investigated since this 
compound alone caused fatal respiratory depression when administered centrally 
(Yeadon & Kitchen, 1990). Application of DSLET to the bulbar respiratory neurones
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of the cat produces a prolonged inhibition with rapid onset of spontaneous and evoked 
activity (Morin-Surun et ai, 1984b). However there is also evidence that both DPDPE 
and DELT I are able to stimulate respiration in the foetal lamb. DPDPE increases the 
number of breaths per hour in a NTI insensitive manner, however, it also produces a 
more continuous regular breathing pattern, an effect which is readily antagonised by 
NTI (Cheng et al., 1992a). DELT I increases the breathing movements of the lamb via 
a NTI-sensitive mechanism (Cheng et al., 1992b, c).
There is also evidence that 6 -receptor activation is involved in the respiratory 
depression seen following administration of |X-agonists. ICI 154,129 (Ward & 
Holaday, 1982), ICI 174,864 (Freye etal., 1988,1991), NTI (Freye etal., 1990), 
M8008 (Freye et al., 1990) and NTB (Freye et al., 1992) are all able to reverse the 
respiratory depressant effects of |i-agonists in rats and dogs at doses which have no 
effect on p-mediated antinociception. It has been postulated that this effect could be 
mediated via a p/ 6  complexed receptor rather than being a p-receptor mediated action of 
these selective 6 -antagonists (Freye etal., 1988,1991).
Thus there is some evidence that 6 -receptor activation is involved in the respiratory 
depression induced by both 6 - and p-agonists. Some authors (Morin-Surun et al., 
1984a) have proposed that p-receptor activation mediates tidal volume depression and
6 -receptor activation frequency depression, but because of the internal physiological 
links between frequency and volume such simplistic conclusions should be treated with 
caution. In support of this hypothesis it has been shown that i.c.v. DPDPE in rats 
depresses minute ventilation predominantly by a reduction in respiratory frequency 
(Yeadon, 1988).
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1.5.5 BEHAVIOURAL RESPONSES
I.C.V. administration of DADLE, Metkephamid (Locke & Holtzman, 1986), DPDPE 
(Cowan et aL, 1985) and DELT II (Negri et aL, 1991a) all produce a dose-dependent 
increase in locomotor activity in rats (Table 4). High doses of DELT n  induced barrel 
rolling and circling by a naloxone insensitive mechanism (Negri et a i, 1991a). The 
stimulation of locomotor activity persisted in morphine tolerant rats (Locke & 
Holtzman, 1986) supporting 6 -mediation of this effect. Behavioural arousal by 
stimulation of 6 -receptors is likely to be mediated via the mesolimbic/nigrostriatal 
dopamine system as intemigral injection as well as direct administration into the nucleus 
accumbens and nucleus caudatus all induce hyperactivity (MoreUi et al., 1989; Longoni 
et al., 1991). Coadministration of DPLPE and the Di agonist, SKF 38393, induce a 
marked increase in linear locomotion (Toyoshi et al., 1992). This effect is reversed by 
NTI and both Di and D2 antagonists indicating that the selective activation of Di 
dopamine receptors by 6 -opioid systems results in a marked behavioural potentiation 
mediated by dopamine D2 receptors. Administration of DTLET produces a marked 
hyperactivity which is antagonised by ICI 174,864 (Dauge et a l, 1988), and peripheral 
administration of a non-selective dopamine antagonist reverses the effect of DTLET in 
the nucleus caudatus but not the nucleus accumbens (Dauge et a l, 1989). This is in 
good agreement with the ability of 6 -agonists to enhance the release of newly 
synthesised dopamine from rat striatal slices (Petit et a l, 1986). Administration of 
DPDPE into the ventral pallidum of rats also induces an increase of locomotor activity 
(Austin & Kalivas, 1990; Hoffman e ta l,  1991) as does administration of DTLET, 
DSTBULET and BUBU into the ventral tegmental area (Calenco-Choukroun, 1991). 
Similar to the results obtained with rats, administration of DADLE, DPLPE (Ukai et 
a l, 1989), DPDPE (Micheal-Titus et a l, 1989; Mickley et a l, 1990) to mice, all 
induced an increase m locomotor activity, the agonists increased both the horizontal and 
vertical components of locomotion (Micheal-Titus eta l, 1989).
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It is unlikely that Ô-receptors play a tonic role in the control of locomotion as chronic 
treatment with ICI 154,129 had no effect on locomotor activity (Volterra et al., 1984). 
ô-receptors may play a role in regulation of social activity, since ICI 154,864 causes a 
decrease in social investigation in mice (Benton et al., 1984b) and DPDPE administered 
into the stria terminalis of cats causes a decrease in defensive behaviour (Shaikh et al., 
1990).
ô-opioid receptors may play a role in the maintenance of high alcohol consumption. In 
rats genetically selected for their high voluntary ethanol consumption ICI 174,864 is 
able to suppress ethanol intake, while administration of an enkephalinase inhibitor 
increases alcohol intake (Froelich et al., 1991). Further chronic administration of 
ethanol increases affinity of [^HJDPDPE for 5-sites without changing the number of 
receptors (Przewlocka & Lason, 1990) and DADLE is also able to inhibit the 
audiogenic seizures associated with ethanol withdrawal in rats (Kotlinska & 
Langwinski, 1986).
There is some evidence for the involvement of ô-receptors in motivation as i.c.v. 
administration of DPDPE causes a marked place preference for the drug associated 
place (Shippenburg et al., 1987; Bals-Kubik et al, 1990). This place preference can be 
abolished by pretreatment with pertussis toxin, suggesting G-protein coupling of the 
receptor (Suzuki et al., 1991).
Stimulation of the 5-receptor has been shown to impair both acquisition and retention of 
active avoidance in mice (Schlteis et al., 1988), rats (Weinburger et al., 1989) and 
chicks (Patterson et ai, 1989) after both central and peripheral administration (Table 4). 
This impairment was antagonised by both ICI 154,129 (Schlteis et al., 1988) and ICI
174,864 (Patterson et al., 1989; Schlteis & Martinez, 1990). Using the same active 
avoidance paradigm it was shown that ICI 154,129 alone could significantly enhance
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acquisition (Schlteis & Martinez, 1988). No effect was seen with ICI 174,864 in 
chicks but this could be because the training procedure assured a high level of 
avoidance in control animals (Patterson et ai, 1989). In all of the above studies control 
experiments showed responses were not due to changes in antinociceptive responses, 
locomotor changes or motivational effects, all of which are affected by activation of 
5-receptors. One study has shown centrally administered DELT I is able to 
significantly improve acquisition of passive avoidance, with no effect on retention. The 
improvement could be reversed by a large dose of NTI and was not due to changes in 
antinociceptive or locomotor responses (Pavone et ai, 1990). Differential effects of 
5-agonists could be dependent on the test used since DADLE has been shown to impair 
acquisition in an active avoidance paradigm, but facilitates acquisition in an inhibitory 
avoidance task (Rigter, 1980).
1.5.6 SEIZURES AND EEG EFFECTS
Central administration of both DADLE and Metkephamid raises the seizure threshold in 
rats exposed to the volatile convulsant flurothyl (Tortella et a/., 1983) and this effect 
was reversed by ICI 154,129. At high doses, however, ICI 154,129 was also able to 
show antiepileptogenic activity (Tortella et a l, 1984), and agonist actions of this 
compound have been reported elsewhere (Leander et al., 1986). The effect of DADLE 
may be mediated via the proposed p/5 complexed receptor since the irreversible 
p-antagonist p-FNA prevented the antagonism of the increase in seizure threshold by 
ICI 154,129 (Tortella et at., 1985). The seizure protection afforded by administration 
of morphine is reduced if 5-receptors are blocked using ICI 154,129 (Pinsky et a i, 
1986). DPDPE also exhibits antiepileptogenic activity following i.c.v. injection to rats 
in the maximal electroshock model and this effect can be reversed by ICI 154,129 and 
ICI 174,864 (Tortella et al., 1988). Evidence for the involvement of endogenous 
enkephalins in seizure protection come from data showing that NTI increases the 
severity of seizures induced by maximal electroshock (Jackson & Nutt, 1991a).
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However 5-receptors do not appear to be involved in the antinociception and catalepsy 
associated with seizures as these effects are not reversed by NTI (Jackson & Nutt, 
1991b).
The above results indicate an antiepileptogenic activity of 5-agonists, and thus it is 
possible that these compounds could be used in the treatment of epilepsy. However, 
caution is needed as DSLET is able to kindle convulsions when injected into the 
amygdala (Cain et aL, 1990), while DTLET, after peripheral injection, produces EEG 
recordings similar to those seen during 'petit-mal' seizures (Stutzman et a i, 1986).
1.5.7 OTHER//VV7FG EFFECTS
The role of 5-receptors in the control of body temperature remains equivocal. An early 
report suggested that central administration of DPDPE led to a decrease in body 
temperature and the animals given the choice of two ambient temperatures chose the 
lower temperature as the body temperature falls (Spencer & Burks, 1986). Later 
studies showed that this response was found in both restrained and unrestrained 
animals but was not reversed by ICI 174,864 (Spencer et aL, 1988). The response 
was potentiated by naloxone. The effects of DPDPE were not mediated via |i-or 
K-receptors as stimulation of p- or K-receptors induces an increase or decrease in body 
temperature respectively which is naloxone reversible (Spencer et al., 1988). Central 
administration of DELT II caused a significant hypothermia in rats placed in a cold 
environment (4°C) (Broccardo & hnprota, 1992b). This agonist was less effective in a 
normal environment (22°C) and ineffective in a warm environment (34°C). The effects 
of DELT n  on body temperature were reversed by NTI indicating a role for central 
5-receptors in adjusting rat body temperature via modulation of the process governing 
heat conservation and production (Broccardo & Improta, 1992b).
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Volume-induced spontaneous bladder contractions in the anaesthetised rat have been 
established as a model for opioid function in the CNS (Table 4). DADLE induces an 
inhibition of the contraction which is reversed by naloxone (Dray & Metsch, 1984). 
Both DPDPE and DPLPE inhibit the contractions after i.c.v. injection and this effect is 
reversed by ICI 174,864 (Dray et a i, 1985). DPLPE is also active after i.t. 
administration (Dray et aL, 1985). This response is likely to be mediated by a 
descending serotonergic pathway, as the response to i.c.v. DPLPE can be inhibited by 
i.t. administration of the serotonergic antagonist methysergide but not the adrenergic 
antagonist phentolamine (Dray et aL, 1986). p-agonists are also able to inhibit 
contractions in this test and sub-effective doses of DPDPE are able to potentiate the 
effects of morphine, normorphine and etorphine but not other p-agonists such as 
DAGO and sufentanil (Sheldon et ai, 1989). Although there was no indication that the 
doses of p-agonists were equally effective, it is possible that these effects are at the 
proposed complexed receptors for morphine and non-complexed receptors for DAGO.
There is much evidence that the endogenous enkephalins are potent immunomodulators 
but there is no conclusive evidence that their effects are mediated via the 5 -receptor 
(Carr & Klimpel, 1986; Jankovic & Marie, 1986; Marie & Jankovic, 1990; Jankovic & 
Marie, 1990). However, 5-opioid receptors have been found on lymphocytes (Carr 
et al., 1988) and stimulation by DPDPE or DSLET stimulates proliferation of 
peripheral lymphocytes. The similar effects of [Met]enkephalin on these cells is 
reversed by ICI 174,864 (Hucklebridge et a i, 1990). 5-selective agonists are also able 
to inhibit phagocytosis by peritoneal macrophages (Casellas et a l, 1991). DELT II 
induces a potent proliferation of lymphocytes in response to mitogen, and the addition 
of this agonist to human granulocytes resulted in cellular adherence and conformational 
changes indicative of cellular activation at doses as low as lOpM (Stefano et al., 1992). 
A role of the endogenous enkephalins in immune function acting via 5-receptors is 
likely, as addition of NTI to lymphocytes suppresses stimulated production of 
immunoglobulins (Carr et al., 1990). NTI has been shown to have a potent
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immunosuppressive effect powerfully inhibiting the xenogenic mixed lymphocyte 
reaction without affecting cell viability (Arakawa et a l, 1992). NTI also increases the 
survival time of rats given a renal allograft, indicating a possible use of NTI following 
organ transplant (Nagase et a l, 1992).
One other in vivo effect of 5-opioid agonists is the phenomenon of tolerance and 
dependence. Tolerance to the antinociceptive effects of DPDPE develop very quickly 
(Kovacs et at., 1988) and this is associated with a decrease in binding in the cortex, 
midbrain and striatum (Tao et aL, 1991). However only a very slight degree of 
dependence is seen after chronic treatment (Maldonado et at., 1990). Recent evidence 
has suggested a role for the 5-receptor in the development of tolerance and dependence 
to n-receptor agonists. Prior administration of NTI or 5'NTH leads to an inhibition of 
the development of tolerance and dependence to morphine (Abelmid et at., 1991), and 
animals made tolerant to morphine show a long term sensitisation to the locomotor 
effects induced by DELT II (Melchiorri et at., 1992). This involvement of 5-sites in 
H-receptor dependence is further supported by studies showing the non-peptide agonist 
BW 373U86 is able to inhibit morphine withdrawal symptoms but causes no 
dependence when chronically administered alone (Dykstra et at., 1993). Thus, if
5-antagonists were administered clinically with |x-agonists, analgesia could possibly be 
maintained with reduced risk of tolerance and dependence.
1.6 TRANSMITTER RELEASE
There is much evidence that 5-opioid receptors are involved in the modulation of the 
release of neurotransmitters both in the central and peripheral nervous systems. 
DTLET is able to enhance the spontaneous and evoked release of newly synthesised 
dopamine from striatal slices (Petit et a i, 1986). Administration of p-endorphin to the 
nucleus accumbens of rats results in an increase of dopamine and its metabolites, and 
this effect can be antagonised by ICI 174,864 indicating a role for the 5-receptor in
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mediating the effects of P-endorphin (Spanagel et a l, 1990). DPDPE (Schoffelmeer et 
a i, 1988), DSLET, DTLET (Mulder et a l, 1989) and DSTBULET (DeVries et aL,
1989) have all been shown to inhibit the release of acetyl choline (ACh) from rat striatal 
slices. Using rat globus pallidus slices DPDPE has been shown to dose-dependently 
inhibit potassium evoked ACh release in a calcium dependent manner, an effect 
reversed by ICI 174,864 (Ruzicka & Jhamandas, 1991). This inhibitory effect of the 
0 -agonists could be antagonised by stimulation of presynaptic muscarinic receptors 
with oxotremorime or in the presence of the acetyl choline-esterase inhibitors 
physostigmine and neostigmine (Ruzicka & Jhamandas, 1988). The inhibition of 
glutamate stimulated ACh release by 5-agonists could be completely antagonised by 
administration of the GABA antagonists bicuculline or phaclofen, but these compounds 
were ineffective against potassium evoked release (Arenas et a l, 1990). DPDPE was 
unable to inhibit the potassium evoked ACh release in animals lesioned with
6 -hydroxydopamine (to destroy dopamine neurones), suggesting that 5-agonists act on 
dopaminergic terminals to inhibit ACh release (Arenas et a l, 1991). DPDPE has also 
been shown to inhibit the potassium evoked release of serotonin from rat hippocampus 
and this effect is antagonised by ICI 174,864 (Passarelli & Costa, 1989).
The effects of 5-agonists on the release of CCK-like material from rat spinal cord 
appear to be complex, with low doses causing an inhibition and higher doses a 
stimulation of release (Benoliel et ai, 1991). The increase in CCK release by DTLET 
was unlikely to have been mediated via the [i-receptor since stimulation of this receptor 
led to an inhibition of the release of CCK-like material from the spinal cord (Benoliel 
e ta i ,  1991).
The release of in the substance P-like material has also been shown to be inhibited by 
DTLET and DELT, and this effect is reversed by NTI (Collin et a i, 1991). In addition 
a role for the endogenous enkephalins in the control of substance P release is indicated
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as the addition of NTI alone caused a marked increase in the outflow of 
substance P-like material from anaesthetised rat spinal cord (Collin et ai, 1991).
Opioid neurones are also thought to possess presynaptic autoreceptors since the 
addition of DTLET and |i-agonists results in a decrease in the release of 
[Met]enkephalin-like material from the spinal cord. The inhibition caused by DTLET 
was antagonised by NTI (Bourgoin et a l, 1991). Further discussion of the 
electrophysiology of 5-ligands can be found in section 5.4.
1.7 ISOLATION, PURIFICATION AND CLONING OF 5-RECEPTORS
The opioid receptors have proved to be extremely difficult targets for isolation and 
subsequent characterisation. The 5-site was first isolated using p-endorphin, this 
ligand labelled both |i- and 5-sites in brain homogenates (Howard et a i, 1985) and 
subsequent gel electrophoresis showed two distinct bands of 65K and 53K, the ratio of 
the two bands varied with the p/5 ratio in various tissues and in NG108-15 cells only 
the 53K band was present indicating that this was likely to be the 5-receptor (Howard 
et aL, 1986). Competition studies with selective ligands showed that the 53K band 
virtually disappeared in the presence of DPDPE with no effect on the 65K band 
(Howard et aL, 1986). However although these results indicated the presence of 
5-sites in several species they yielded no information about the molecular structure of 
the receptor, for this purified or cloned receptors would be necessary. The 5-receptor 
from NG108-15 cells was purified to apparent homogeny using the irreversible ligand 
SUPERFIT (Simonds et al., 1985), the protein was glycosylated with a molecular 
weight of 58,000 and had a tendency to dimerise under reducing conditions (Simonds 
et a i, 1985). Unfortunately the amino acid sequence of this pure receptor protein was 
not investigated.
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Recently two independent laboratories have reported the cloning of a 5-receptor from 
NG108-15 cells (Evans et a i, 1992; Kieffer et a l, 1992). Both groups prepared RNA 
from NG108-15 cells and constructed a cDNA library. The plasmid DNA was 
transfected into COS-1 cells, these were then screened using either [125i] DADLE 
(Evans et a i, 1992) or pHJDTLET (Kieffer et aL, 1992) for positive cells, after further 
rounds of purification and retransfection an individual cDNA was isolated. The nature 
of the protein coded for by this cDNA was determined using competition studies, both 
of the proteins coded for by the isolated cDNAs resembled the 5-site in both ligand 
selectivity and stereospeciricity. They also showed similar affinity for 5-agonists to the 
native NG108-15 cells. The cloned receptor showed sequence homology to members 
of the seven transmembrane spanning/G-protein coupled receptors, showing a 37% 
homology to the somatostatin receptor and 31% homology to the angiotensin receptor. 
Evans et a l  (1992) also showed that the cDNA coded for a functional receptor as the 
binding of DPDPE to it reduced the forskolin induced c AMP increase by approximately 
40%. PCR of the non-coding region of the isolated cDNA, a region thought not to be 
conserved across species showed a 100% homology with mouse DNA, indicating that 
the cloned receptor is the mouse receptor (Kieffer et al., 1992). Northern blots of the 
RNA from NG108-15 cells showed multiple hybridising transcripts indicating that the 
probe might recognise related receptors (Evans et al., 1992). However, Southern blot 
analysis of the cDNA reveals only a single strongly hybridising species. Therefore, the 
heterogeneity of hybridising species may not reflect multiple genes but may derive from 
alternative RNA splicing, giving a route to possible subtypes of the 5-receptor (Evans 
etal. (1992).
1.8 AIMS OF THIS THESIS
The aim of this thesis was to further investigate and characterise the pharmacology of 
the 5-opioid receptor employing the most selective agonists and antagonists currently 
available and utilising several in vivo and in vitro techniques.
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CHAPTER 2
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2.1 INTRODUCTION
From the studies described in section 1.5.1 it can be seen that administration of 
5-agonists led to a marked antinociception in the rat. The aim of the work described in 
this chapter was to further investigate the nature of the antinociception mediated via 
5-sites in the rat. To do this three selective 5-agonists were chosen, [D-Ser^, Leu^, 
Thr^]enkephalin (DSLET), [D-Pen^, D-Pen^]enkephalin (DPDPE) and 
[D-Ala^Jdeltorphin I (DELT I). These agonists show a 5-selectivity of 621, 3164 and 
9375 respectively in isolated tissue studies (see Table 1). The agonists were chosen not 
only for their selectivity but also because they represent three different classes of 
5-agonists. DSLET is a stabilised derivative of [Leu]enkephalin, it is a linear molecule 
and is likely to have a flexible structure (Gacel et aL, 1980). DPDPE is also based on 
the structure of [Leujenkephalin, however it is a constrained cyclic peptide with a more 
rigid structure (Mosberg et a i, 1983). DELT I represents a completely novel peptide 
structure (see section 1.2), it is a heptapeptide isolated from frog skin (Erspamer et al.,
1989). It is synthesised with a normal L-alanine moiety in position 2 but this is 
converted to D-alanine by post-translational modification (Richter et al., 1990).
Several antagonists were employed to characterise the agonist antinociception, 
naltrindole (NTI) and naltriben (NTB) were chosen as they are the most stable and 
selective 5-antagonists currently available and evidence indicates they are both active 
after peripheral administration (Portoghese et al., 1988; Takemori et al., 1990). Until 
the introduction of NTI, the peptide antagonist ICI 174,864 was the drug of choice for 
studying 5-receptor antagonism thus it was included as the classical peptide 
5-antagonist. The non-selective opioid antagonist naloxone was included to exclude 
any possible effects at non-opioid sites.
The 50°C warm-water tail immersion test (Janssen et al., 1963) was chosen for the 
quantification of nociceptive responses as previous studies have shown this test is
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sensitive to 6 -responses during stress-induced antinociception (SIA) in the rat (Jackson 
& Kitchen, 1989a). 25 day old rats were selected as 5-responses to SIA are seen at this 
age (Kitchen & Pinker, 1990) and in these animals a reproducible antinociception can 
be induced. Also younger animals should allow better penetration to the 5-receptors as 
in the rat the blood brain barrier is not fully developed until postnatal day 30 (Keep 
et al., 1986). Ontogenetic studies have also shown that most 5-sites have developed 
by this age (Spain et al, 1985).
For ease of administration all compounds were injected via the intraperitoneal (i.p.) 
route. Previous studies have shown that naloxone, ICI 174,864 and NTI are all active 
following i.p. administration in 25 day old rats (Jackson & Kitchen, 1989a; Kitchen & 
Pinker, 1990) and NTB is active following subcutaneous (s.c.) administration to adult 
mice (Takemori et al., 1990).
During the course of this study results from two laboratories suggested that in the 
mouse the antinociception mediated via 5-sites may not be due to activation of a single 
site but by multiple subtypes of the 5-receptor. Sofuoglu et al. (1991a) found that the 
antinociceptive effect of centrally administered DSLET, using the radiant-heat tail-flick 
test, was more sensitive to antagonism by NTT and NTB than that of DPDPE. This 
effect was even more pronounced if the agonists were injected intrathecally (i.t.) 
(Sofuoglu et a l  1991a). Using the warm-water tail immersion test Jiang et al. (1991) 
showed that the antinociceptive effects of DPDPE could be antagonised by the 
irreversible peptide antagonist [D-Ala^, Leu^, Cys^Jenkephalin (DALCE) but not by the 
non-equilibrium 5-antagonist 5'naltrindole isothiocyanate (5'NTII). In contrast the 
effects of DSLET and DELT II were unaffected by DALCE but completely antagonised 
by 5'NTII (Jiang et al. 1991). Subsequently it was shown that no cross-tolerance 
developed between the effects of DPDPE, DELT II or |x-agonists lending further 
support that the effects of these two agonists are mediated via distinct 5-sites (Mattia 
e ta l,  1991).
81
2.2 MATERIALS AND METHODS
2.2.1 ANIMALS AND EXPERIMENTAL CONDITIONS
25 day old male Wistar albino rats (University of Surrey strain) weighing 60-90g were 
used in all studies. All rats were weaned at day 21 and subsequently housed in groups 
of 8-10 and maintained at 22±1°C in a constant 12 hour light-dark cycle (lights on at 
07hr OOmin). Water and standard laboratory chow were available ad libitum. 
Experimental procedures were carried out in a quiet, windowless, air-conditioned 
laboratory between 14hr OOmin and 18hr OOmin to minimise diurnal variation. Animals 
were allowed to acclimatise for at least 2  hours before experimentation.
2.2.2 NOCICEPTIVE TESTING
Animals were divided into treatment groups so that nociceptive tests took place for 
saline- and drug-treated animals on at least three separate days to minimise interday and 
interlitter variation. Drugs (in 0.9% w/v saline) were administered i.p. in a dose 
volume no greater than 0.1ml. Nociceptive responses were measured using the 50°C 
warm water tail immersion test (Janssen et al., 1963) modified for use in young rats 
(Kitchen et al., 1984). Rats were hand held and the terminal 3cm of the tail placed in a 
50°C water bath. Nociceptive responses were defined as withdrawal of the tip of the 
tail from the surface of the water. The time taken to withdraw the tail was termed the 
tail immersion latency and was measured using a hand held stopwatch. A maximum 
1 0 s cut-off time was employed to prevent tissue damage, animals whose responses 
reached this maximum had their tails withdrawn from the water and were assigned a tail 
immersion latency of 10s. Response latencies were measured 15 min before 
administration of the 6 -agonists DPDPE, DSLET, DELT I, Cl-DPDPE or the |X-agonist 
alfentanil. Tail immersion latencies were then redetermined 2,5,10 and 15 min after 
agonist administration.
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When studied, antagonists (naloxone, NTI, NTB or ICI 174,864) were injected 10 min 
before agonist administration. The BD75 of each of the 5-agonists was chosen for 
antagonism studies and was calculated as the 75% of maximum effect from linear 
regression of full dose response curves at peak antinociception, with saline control 
values defined as 0 %.
2.2.3 DRUGS AND STATISTICAL PROCEDURES
Drugs used were [D-Pen^, D-Pen^]enkephalin (DPDPE), [D-Ser^, Leu^, 
Thr6 ]enkephalin (DSLET), ICI 174,864 (Allyla-Tyr-Aib-Aib-Phe-Leu-OH) 
(Cambridge Research Biochemicals), D-Ala^ deltorphin I (DELT I), naloxone 
(Dupont), NTI (Research Biochemicals Incorporated), alfentanil was a gift firom 
Janssen Pharmaceuticals and NTB a gift from Dr P.S. Portoghese (University of 
Minnesota).
Antagonism of the antinociceptive responses to the 5-agonists was analysed at each 
time point by a one way analysis of variance followed by post-hoc analysis with 
Duncans multiple range test using the SuperANOVA package for the Macintosh.
Stock solutions of drugs were made at Img/ml (except where higher concentrations were 
required) in 0.9% saline and 0.5ml aliquots were frozen for further use. Stocks solutions were 
subjected to freeze-thawing only once.
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2.3 RESULTS
Administration of increasing doses of DSLET induced a dose-related antinociception 
which peaked around Img/kg and had an ED75  of 0.65mg/kg (Figure 3). 
Administration of DPDPE and DELT I also produced a dose-related antinociception but 
in the case of these two agonists the curve was bell-shaped (Figures 4 and 5). ED75’s 
of 0.66mg/kg and 0.032mg/kg were obtained for DPDPE and DELT I respectively. 
The responses to these three agonists were qualitatively similar with peak 
antinociception being observed 5 minutes after administration (Figures 3-5, Table 5).
Figures 6 -8  show the effect of NTI (0.01-lmg/kg) on the antinociceptive responses to 
the ED7 5  of DSLET, DPDPE and DELT I respectively. NTI (O.Olmg/kg) significantly 
attenuated the peak response to DSLET and DPDPE, while higher doses (0.1 and 
1 mg/kg) completely antagonised the effect of DSLET. NTI (O.lmg/kg) markedly 
reduced the response to DPDPE and the response following 1 mg/kg NTI did not 
significantly differ from saline control values. In contrast NTI (0.01 and O.lmg/kg) 
did not alter antinociception induced by DELT I, and only the highest dose of NTI 
(Img/kg) significantly antagonised the antinociception induced by this agonist.
Figures 9-11 show the effect of NTB (0.5-50pg/kg) on the antinociceptive responses to 
the ED7 5  of DSLET, DPDPE and DELT I. The lowest dose of NTB (0.5|ig/kg) 
significantly antagonised the antinociceptive response to DSLET but had no effect on 
responses to DPDPE and DELT I. A higher dose (5jig/kg) completely antagonised the 
response to DSLET but was completely ineffective against DPDPE and DELT I. The 
highest dose of NTB used (50fxg/kg) completely antagonised the antinociceptive effect 
of all three agonists.
Naloxone (Img/kg) significantly antagonised the response to DSLET, DPDPE and 
DELT I producing a similar degree of attenuation of the antinociceptive effects of all
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Figure 3. Dose related antinociception induced by DSLET in 25 day old rats.
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(a) shows the time course of the antinociception. Values are the mean of at least 
six determinations. Error bars have been omitted for clarity but varied from 3-12% 
of the mean. (O) represents saline control values, ( • )  O.lmg/kg, (□) 0.2mg/kg, 
(■) 0.25mg/kg, (A) 0.5mg/kg, (A) 0.75mg/kg, (V) Img^g, (T) 2mg/kg and (O) 
4mg/kg DSLET. (b) shows the dose response relationship for DSLET (# ) at peak 
antinociception (5 min). Values aremeans±s.e.means of at least six determinations.
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Figure 4. Dose related antinociception induced by DPDPE in 25 day old rats. 
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(a) shows the time course of the antinociceptive. Values are the mean of at least 
six determinations. Error bars have been omitted for clarity but varied from 3-14% 
of the mean. (O) represents saline control values, (#) 0.25mg/kg, (□) 0.5mg/kg, 
(■) Img/kg, (A) 2mg/kg, (À) 4mg/kg and (V) 8mg/kg DPDPE. (b) shows the dose 
response relationship for DPDPE (#) at peak antinociception (5 min). Values are 
means ± s.e.mean of at least six determinations.
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Figure 5. Dose related antinociception induced by DELT I in 25 day old rats.
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(a) shows the time course of the antonociception. Values are the mean of at least six 
determinations. Error bars have been omitted for clarity but varied from 2-10% of 
the mean. (O) represents saline control values, ( • )  O.Olmg/kg, (□) 0.02mg/kg, (■)
0.05mg/kg, (A) O.lmg/kg, (A) 0.15m ^g, (T) 0.3mg/kg and (V) O.bmg^g DELT I.
(b) shows the dose response relationship for DELT I (#) at peak antinociception 
(5 min). Values are the means±s.^.yieans of at least six determinations.
Table 5. EDjg's and peak antinociceptive response latencies to DSLET, DPDPE and
DELT I in 25 day old rats.
Ligand ED75 (mg/kg) Peak response latency (sec)
DSLET 0.65 7.3210.29
DPDPE 0 .6 6 6.5410.67
DELT I 0.032 6.0410.17
Response latencies are means ± s.e.mean of 6-10 observations, EDvs's were 
calculated from linear regression of full dose response curves at peak antinociception 
(5 min) with saline control values defined as 0%.
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Figure 6 . Effect of increasing doses of NTI on the antinociceptive response to
BD7 5  of DSLET in 25 day old rats.
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Values are means ± s.e.mean of at least six observations. (O) represents 
saline control values, ( • )  0.65mg/kg DSLET, (□) DSLET + Img/kg NTI, 
(■) DSLET+ O.lmg/kg NTI and (A) DSLET + O.Olmg/kg NTI. Significant 
differences following one way ANOVA and Duncans New Multiple range 
test, ** p < 0.01 vs agonist alone, ++ p < 0.01, + p < 0.05 vs saline control. 
Responses to antagonist alone were not significantly different from saline 
controls (data not shown).
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Figure 7. Effect of increasing doses of NTI on the antinociceptive leponse to
ED7 5  of DPDPE in 25 day old rats.
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Values are means ± s.e.mean of at least six observations. (O) represents saline 
control values, (#) 0.66mg/kg DPDPE, (□) DPDPE + Img/kg NTT, (■) DPDPE 
+ O.lmg/kg NTI and (A) DPDPE + O.Olm ^g NTI. Significant differences 
following one way ANOVA and Duncans New Multiple range test, ** p < 0.01 
vs agonist alone,++ p < 0.01 vs saline control. Responses to antagonist alone 
were not significantly different firom saline controls (data not shown).
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Figure 8 . Effect of increasing doses of NTI on the antinociceptive response to
ED7 5  of DELT I in 25 day old rats.
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Values are the means ± s.e.mean of at least six observations. (O) represents 
saline control values, ( • )  0.032mg/kg DELT I, (□) DELT 14 Img/kg NTI, 
(■) DELT 14 O.lmg/kg NTI, (A) DELT 14 O.Olmg/kg NTI. Si^ificant 
differences following one way ANOVA and Duncans New Multiple range 
test ** p < 0.01 vs agonist alone, 44 p < 0.01 vs saline control. Responses 
to antagonist alone were not significantly different firom saline conttols (data 
not shown).
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Figure 9. Effect of increasing doses of NTB on the antinociceptive response to
ED7 5  of DSLET in 25 day old rats.
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Values are the means ± s.e.mean of at least six observations. (O) represents
saline control values, ( • )  0.65mg/kg DSLET, (□) DSLET + 50[Xg/kg NTB,
(■) DSLET + S ji^ g  NTB and (A) DSLET + O.Sjig/kg NTB. Significant 
differences following one way ANOVA and Duncans New Multiple range 
test ** p < 0.01 vs agonist alone, ++ p < 0.01, + p < 0.05 vs saline control. 
Responses to antagonist alone were not significantly different from saline 
controls (data not shown).
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Figure 10. Effect of increasing doses of NTB antinociceptive response to ED7 5  of
DPDPE in 25 day old rats.
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Values are means ± s.e.mean of at least six observations. (O) represents
saline control values, ( • )  0.66mg/kg DPDPE, (□) DPDPE + 50}ig/kgNTB,
(■) DPDPE + 5 p ,^ g  NTB and (A) DPDPE + 0.5|Xg/kg NTB. Significant 
differences following one way ANOVA and Duncans New Multiple range 
test **p<0.01 ,*p< 0.05 vs agonist alone, ++ p < 0.01 vs saline control. 
Responses to antagonist alone were not significantly different from saline 
controls (data not shown).
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Figure 11. Effect of increasing doses of NTB on the antinociceptive response to
ED7 5  of DELT I in 25 day old rats.
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Values are the means ± s.e.mean of at least six observations. (O) represents
saline control values, ( • )  0.032mg/kg DELT I, (□) DELT I +50|Xg/kg NTB,
(■) DELT I + 5 |i # g  NTB and (A) DELT I + O.Sp-g/kg NTB. Significant 
differences following one way ANOVA and Duncans New Multiple range 
test ** p < 0.01 vs agonist alone, ++ p < 0.01 vs saline control. Responses 
to antagonist alone were not significantly different from saline controls (data 
not shown).
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Figure 12. Effect of (a) naloxone and (b) ICI 174,864 on the peak antinociceptive
response (5 min) to an ED7 5  of DSLET, DPDPE and DELT I in 25 day old rats.
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Values are means ± s.e.mean (vertical bars) of at least six observations. Sal = 
saline; Nal = naloxone Img/kg; ICI = ICI 174,864 Img/kg; DSLET 0.65mg/kg; 
DPDPE 0.66mg/kg; DELT 10.032mg/kg. Significant differences following 
one way ANOVA and Duncans New Multiple range test, ** p < 0.01, * p < 0.05 
versus agonist alone and ++ p < 0 .0 1  versus saline control.
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three agonists (Figure 12). ICI 174,864 (Img/kg) also significantly antagonised the 
antinociceptive effects of these agonists with a differential degree of attenuation 
(DSLET> DPDPE> DELT I) (Figure 12). Further, ICI 174,864 (2mg/kg) completely 
blocked antinociceptive responses to all the ô-agonists but at this dose in some animals 
this antagonist caused behavioural toxicity, including hindlimb stretching, flaccidity and 
barrel rolling. NTI, NTB and naloxone showed no overt behavioural toxicity at the 
highest doses used. None of the antagonists had any effect on the tail-immersion 
latencies when administered alone.
NTI (Img/kg), NTB (50p,g/kg) and ICI 174,864 (2mg/kg) had no effect on the 
antinociceptive response induced by a submaximal dose (60|ig/kg) (Kitchen & Pinker, 
1990) of the |i-agonist alfentanil (Figure 13).
96
Figure 13. Effect of (a) NTI, (b) NTB and (c) ICI 174,864 on the antinociceptive 
response to alfentanil in 25 day old rats.
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Values are means ± s.e.mean of at least six observations. (O) represents
saline control values, (#) Img/kg NTI, 50|ig/kg NTB, 2mg/kg ICI 174,864,
(□) 60|ig/kg alfentanil, (■) alfentanil + NTI, NTB or ICI 174,864. Alfentanil 
vs alfentanil + antagonist; not significant one way ANOVA.
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2.4 DISCUSSION
The determination of the importance of the 6 -opioid receptor in mediating 
antinociception has been difficult because of the lack of suitable brain-penetrating 
selective agonists and antagonists. Studies with DPDPE implicate 6 -sites in both spinal 
(Rodriquez et al., 1986) and supraspinal (Heyman et ai, 1987b) antinociception. Most 
studies have employed i.t. or i.c.v. routes for administration of these agonists (see 
Table 4 Chapter 1) and administration by parental routes in the rat has generally been 
unsuccessful in inducing antinociception (Tavani et al., 1990). The success in 
obtaining dose-related antinociceptive responses to DPDPE, DSLET and DELTI after
i.p. injection most probably reflects the age of the animals, since in the rat, the blood 
brain barrier is not fuUy mature until postnatal day 30 (Keep et al., 1986). Distribution 
studies in adult mice using [^H] DPDPE have shown that small but significant amounts 
of this peptide can be found in the brain five minutes after i.v. administration (Weber 
et al., 1991), and the amount reaching the brain is likely to be increased in less mature 
animals.
NTI shows 100-fold selectivity for 6 -receptors over other opioid receptors in isolated 
tissue preparations (Portoghese et al., 1988) and in radioligand binding studies (Rogers 
et al., 1991). Confirmation of the 6 -receptor selectivity of NTI at doses used in this 
study was provided by the lack of antagonism of the highly selective |i-agonist 
alfentanil, and agrees with the previous assessment of this antagonist by others 
(Kitchen & Pinker, 1990; Calcagnetti & Holtzman, 1991). Similarly, NTB has a 
1,500-fold selectivity for 6 - over ji-opioid sites in binding studies (Takemori et al., 
1990) and the lack of antagonism of alfentanil in this test again confirms the
6 -selectivity of the doses employed in this study. The observation that responses to 
DPDPE, DSLET and DELT I were antagonised to an equivalent degree by naloxone 
shows that opioid receptors mediate the antinociception induced by all three of these 
agonists. The differential sensitivity to antagonism by NTI and NTB points to the
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possibility that these 5-agonists do not mediate their effects via a common site. The 
results suggest that DSLET and DELT I mediate their effects via different d-sites since 
these compounds show a greater than 10-fold difference in sensitivity to antagonism by 
5-selective doses of NTI and NTB. DPDPE would appear to have affinity for both 
sites, as when NTI was used as the antagonist DPDPE had a similar, but not identical, 
profile to DSLET but following administration of NTB, DPDPE had a similar profile 
to DELT I.
The possibility that the differential antagonist effects of NTI and NTB might, in part, 
reflect pharmacokinetic differences in the distribution of the three d-agonists cannot be 
excluded. The differences in sensitivity to the antagonists are unlikely to be explained 
by m-activity of DELT I since this peptide shows over 3000-fold selectivity for d-sites 
in isolated tissue studies (Erspamer et a l, 1989). Metabolism of DELT I to a non- 
selective m/d compound is also unlikely as its antinociceptive effects are fully reversed 
by all of the 5-antagonists used at doses which had no effect on the antinociception 
induced by the highly selective p-agonist alfentanil.
Others have found differential antagonism of DPDPE and DSLET by NTI and NTB 
after i.t. injection in mice (Sofuoglu et ai, 1991a) and have suggested that these 
differences might be explained by the existence of 5-receptor subtypes. The apparent 
differences between this work and that of Sofuoglu et al. (1991a) could reflect species 
differences, although route of administration may be important as very little difference 
in the antagonism of DPDPE and DSLET were seen after i.c.v. administration. Similar 
to this study however, a greater difference of the antagonism of these two compounds 
was seen with NTB.
Subsequently Jiang et al. (1991) using two non-equilibrium antagonists, DALCE 
(Bowen et al., 1987) and 5'NTII (Portoghese et al., 1990b) showed that these two 
compounds had selectivity for the 'DPDPE site' and the 'DSLET site' respectively in
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the mouse, each reversing the effects of its own agonist with no effect on the other. 
Interestingly Jiang et al. (1991) found that DELT II, which differs from DELT I only 
by a single amino acid at position 4 had a profile similar to that of DSLET, which is in 
contrast to the results of this study where the deltorphin analogue had the opposite 
selectivity to DSLET. Whether this reflects a species difference or a difference bought 
about by the single difference in the amino acid sequence is not known and can only be 
resolved if both agonists are used in both paradigms. Further evidence for d-receptor 
subtypes has come from work, again in the mouse, showing that the antinociceptive 
effects of i.c.v. DPDPE and those of DELT II do not show cross-tolerance (Mattia 
et al.y 1991). In addition to this no cross-tolerance is seen between DPDPE and 
DSLET following i.t. injection (Sofuoglu et al., 1991b). These subtypes were 
classified as ôi 'DALCE-sensitive' and 6 2  '5'NTII-sensitive' by Mattia et al. (1992) 
who showed that the antinociception induced by i.t. administration of d-agonists in the 
mouse, measured using the warm-water tail immersion test, appears to be exclusively 
mediated by the proposed 62-site. Based on this nomenclature the responses to DSLET 
in 25 day old rats would appear to be mediated by a 6 2  subtype and thus DELT I acts 
via a Ô1 site.
Recently evidence for 6 -subtypes in the rat spinal cord has been published. Tiseo & 
Yaksh (1993) showed that the antinociceptive effects of DPDPE, in the hot-plate test, 
were reversed by a low dose NTI while those of DADLE were unaffected even at much 
higher doses. As DADLE showed only partial cross-tolerance with q-agonists DPDPE 
and DADLE were claimed to be acting via different 6 -sites. Again this profile of 
agonist activity is different to that seen in the mouse where DPDPE and DADLE have a 
similar agonist profile (Sofuoglu et al., 1991b). One other piece of in vivo evidence for 
the existence of d-subtypes has come from work which has shown differential 
functional antagonism of DPDPE and DELT II responses by tetraethylammomia and 
glibenclamide respectively (Wild et al., 1991). The characterisation of 6 -subtypes 
should be further aided by the recent introduction of the first non-peptide 6 1 -selective
1 0 0
antagonist 7-benzlylidenenaltrexone (BNTX) (Portoghese et al., 1992a). This 
compound is active after peripheral administration in the mouse and completely 
antagonises the antinociceptive effect of DPDPE with no effect on DSLET or |Li- and 
K-agonists. In radioligand binding studies it shows approximately 100-fold selectivity 
for 5i over 6 % sites (Portoghese et al., 1992a).
As mentioned above there are differences between the results of this study and those 
performed in the mouse and one explanation for these observations is a species 
difference. The mouse has a greater number of d-sites compared to the rat and this has 
been proposed to explain the differences in potency of 5-ligands in these two species 
(Yoburn et a l, 1991). In addition to this, Shimohigashi et al. (1987) described a 
compound containing E-cyclopropylphenylalanine (T^Phe), [D-Ala^,(2S,3R)- 
TLphe^,Leu5]enkephalin which showed a very high affinity for the 5-receptors in rat 
brain (comparable with DPDPE) but was completely inactive in the mouse vas deferens 
preparation.
In addition to the accumulating in vivo data pointing to subtypes of the 5-receptor there 
has recently been reports of evidence for multiple d-sites from ligand binding 
experiments. DPDPE shows a biphasic inhibition of [^H]DELT I binding to rat brain 
membranes (Negri et al, 1991b). The resulting Hill plot has a slope significantly less 
than one and is best fitted to a two-site model. It is possible however, that this data 
could represent binding to two affinity states of the same receptor. Under condition of 
m-suppression the binding, to mouse brain membranes, of [^HJDSLET, DPDPE 
and [3R]DADLE are all best fitted to a single site model (Sofuoglu et a l, 1992). NTB 
and DSLET were equipotent at competing for the sites labelled by all three compounds 
while DPDPE and DADLE were more potent at inhibiting [^H]DPDPE and 
[3H]DADLE binding compared to the sites labelled by pH]DSLET (Sofuoglu et a l,
1992). In addition to the above evidence Sofuoglu et al. (1992) also found that 
[3R]DSLET labels significantly more sites than either [^RJDPDPE or pR]DADLE
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which may also indicate that these ligands are binding to different sites. DPDPE, 
DELT I and DELT II all inhibit [^HJDADLE binding with a Hill slope significantly less 
than one (Xu et al., 1991), and this effect persists in the presence of the stable GTP 
analogue GppNHp suggesting the effect is not due to binding to multiple affinity states 
of the same receptor. The binding was performed in the presence of the acylating agent 
BIT (Rothman et a l, 1988) to block binding to ji-sites, and it is possible that the 
acylation agent is 'creating' two sites. 5'NTII has different effects on the binding of 
DPDPE and [3H]DSLET to guinea pig brain membranes (Portoghese et al., 
1992b) 5'NTn causes a significant decrease in the Bmax value of pH]DPDPE without 
affecting the K<j. However, its effects on [^HjDSLET binding were very different, in 
that large increases in the B^ax &nd values were observed in the presence of 5'NTII 
(Portoghese et ai, 1992b).
In addition to their independent antinociceptive actions, agonists at the 5-receptor are 
also able to modulate the potency of p-agonists at subeffective doses. This effect was 
first described for [Leu] and [Met]enkephalin which increase and decrease the potency 
of morphine respectively (Vaught & Takemori, 1978). Subsequent studies with more 
5-selective ligands have shown that both DPDPE (Heyman et a i, 1989a) and DSLET 
(Barrett & Vaught, 1982) and more recently DELT II (Horan et al., 1992) are able to 
potentiate the effects of morphine at sub-antinociceptive doses, while [D-Ala^, 
Met^]enkephalinamide (DAMA) significantly decreased the potency of morphine 
(Heyman et al., 1989b) as did [D-Ala^,(2S,3R)-T^Phe^,Leu^]enkephalin 
(Shimohigashi et al., 1988). The effects of DPDPE and DAMA can be antagonised by 
the 5-antagonist ICI 174,864 but not directly by m-antagonists such as naloxonazine 
(Heyman et al., 1989b). However, the irreversible p-antagonist P-FNA prevented the 
antagonism by ICI 174,864 without affecting the agonist action suggesting a common 
antagonist binding site (Heyman et al., 1986). The modulation of morphine 
antinociception by [Leu]enkephalin has been shown to be a synergistic interaction 
(Porreca et al., 1990) which adds support to the hypothesis that this modulation occurs
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at a receptor distinct from the p-receptor on which morphine is acting, since if this was 
the case, a simple additive interaction would be expected. One further piece of evidence 
which suggests that this modulation occurs via a 5-site is that it persists under 
conditions of morphine (p) tolerance (Jiang et al., 1990a). The above results suggest 
that d-receptors could exist in two forms, either as an independent entities or physically 
associated with p-receptors. This idea became known as the p/5 complexed receptor 
and the 5-receptors associated with it 5-complexed or 5cx receptors, while the 
independent 5-sites were termed 5-noncomplexed or 5ncx- At first it was believed that 
the 5-receptors in and out of the complex were the same, but certain stimuli caused 
them to associate with neighbouring p-sites probably via a common GTP binding 
protein (Schoffelmeer ef a/., 1987).
In addition to the in vivo evidence for the association of m-and d-sites evidence also 
exists from in vitro techniques. Radioligand binding studies have suggested an 
allosteric coupling between morphine and enkephalin sites in rat brain as morphine non- 
competitively inhibits pH][Leu]enkephalin binding (Rothman & Westfall, 1982a) and 
the enkephalins are non-competitive inhibitors of [^HJetoiphine binding (Rothman & 
Westfall, 1982b). [125i]p_endorphin labels an 80KDa protein in rat striatal 
membranes, the binding can be partially inhibited by naloxone and the p-agonist DAGO 
as weU as by the 5-agonist DSTBULET (Schoffelmeer et al., 1990). It is interesting to 
note that 80KDa represents the combined weights of the p- and 5-receptors. The 
evidence for a complexed receptor in brain has led to the development of ligands such 
as 6-desoxy-6|3-fluoronaltrexone (cycloFOXY) (Rothman et al., 1991a) and 
SUPERFIT (Rothman et a i, 1991b) which reportedly label the p-and 5-receptor in the 
complex respectively.
The existence of multiple 5-sites may explain some of the anomalies seen in the 
literature when using 5-selective ligands, for example, the marked hypotensive effect of 
DADLE when given to rabbits is readily reversed by ICI 174,864 (Morilak et al..
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1990a) but is unaffected to NTI (Morilak et al., 1990b). The presence of a DADLE 
sensitive, NTI insensitive ô-site has been described in the rat (Tiseo & Yaksh, 1993) 
and thus it is possible that such a site exists in the rabbit.
It is not yet known if the d-receptor subtypes suggested by this and other studies 
represent the dcx and dncx receptors of further subtypes of the Ôncx site, but so far a 
body of evidence exists to suggest heterogeneity of 5-opioid receptors in several 
species. In fact the recent cloning of the 5-receptor also indicates the possibility of 
multiple 5-sites by the presence of multiple RNA transcripts (Evans et al., 1992).
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CHAPTER 3
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3.1 INTRODUCTION
The ontogeny of the 5-opioid receptor has been widely studied in rats and appears to 
show a different pattern of development to both p- and K-receptors. Both p- and 
K-sites appear very early in development, after birth the density of p-sites declines for 
several days and then rises sharply over the next two weeks (Spain et al., 1985). 
Levels of K-sites are relatively low at bhth and increase slowly over the posmatal period 
(Spain et al., 1985). In contrast no evidence of 5-sites can be seen until the end of the 
first postnatal week in the brainstem (Xia & Haddad, 1991) when a 100-300% increase 
in [3H]DADLE binding is seen between postnatal day 5 and postnatal day 10. These 
experiments were performed in the presence of IpM PL017 to suppress binding to 
p-sites. Throughout the rest of the brain 5-sites do not seem to appear until the second 
postnatal week (Spain et al., 1985) after which they show a rapid increase over the next 
two weeks. Indeed the concentration of 5-sites increases more rapidly than the increase 
in protein over this period (Petrillo et al., 1987). At postnatal day 21 the levels of 
5-sites present in rat brain are approximately 50-60% of adult levels (Petrillo et a l, 
1987). Studies with the more selective 5-ligand [^H]DPDPE have shown a similar 
profile of development with the levels at day 21 being approximately 75% of the adult 
(McDowell & Kitchen, 1986) and detection of sites using this ligand is not observed 
until postnatal day 1 0 .
The time around weaning (postnatal days 21-25) appears to be an active time for the 
development of the 5-receptor. The mediation of stress-induced antinociception (SIA) 
switches from an exclusively p-mediation to a predominantly 5-mediation between days 
20-25 in the rat (Kitchen & Pinker, 1990). It has recently been shown that if weaning 
is delayed this transition of p- to 5-mediation does not occur by day 25 (Muhammad & 
Kitchen, 1993). However, if the rats are not weaned the transition is apparent by 
postnatal day 30 suggesting the transition is delayed rather than permanently blocked 
(Muhammad & Kitchen, 1993). Evidence from mice suggests that the antinociception
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associated with cold water swim-stress is mediated via the 6 2  receptor subtype 
(Vanderah et al., 1992). If the same was true in the rat then it is possible that weaning 
(at day 21) could be the stimulus for the development of a 6 -receptor subtype, as 25% 
of 6 -sites do not develop until after weaning (McDowell & Kitchen, 1986), and 
weaning appears to influence the 6 -mediation of SIA (Muhammad & Kitchen, 1993).
The following experiments were designed to investigate this theory from an in vivo 
(antinociceptive) prospective. Based on the profile of activity of DSLET and DELT I 
described in chapter 2.3 the effects of a 51-selective (DELT I) and a 6 2 -selective 
(DSLET) agonists were investigated in 25 day old weaned and non-weaned rats. In 
addition the effects of a 6 2 -selective dose of NTB was investigated on the effects of the 
two agonists.
I  This work was carried out in collaboration with Bala Y Muhammad.
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3.2. MATERIALS AND METHODS
3.2.1 ANIMALS AND EXPERIMENTAL CONDITIONS
25 day old Wistar albino rats of either sex were housed in groups of ten. In groups 
where animals were weaned this was carried out at day 2 1  by the removal of the mother 
from the cage. For the non-weaned groups the pups remained with their mother at all 
times apart from drug administration and nociceptive testing. All other experimental 
conditions were as described in section 2 .2 .1.
3.2.2 NOCICEPTIVE TESTING
The 50°C warm water tail immersion test was used and carried out as described in 
section 2.2.2. Briefly the rats were hand-held and the terminal 3cm of the tail placed in 
a 50°C water bath. The time taken to remove the tip of the tail was recorded on a 
stopwatch. Tail immersion latencies were measured 15 min before i.p. administration 
of DSLET or DELT I and 2, 5, 10 and 15 min after agonist injection. Four doses of 
DSLET or DELT I were chosen which represented the full dose response relationship 
previously described in section 2.3. The agonists were then tested for their abililty to 
induce antinociception in 25 day old weaned and non-weaned rats. For this study the 
single dose of NTB was studied for its antagonism of all four doses of the agonists 
used in both weaned and non-weaned groups. NTB was injected i.p. 10 min prior to 
agonist administration.
3.2.3 DRUGS AND STATISTICAL PROCEDURES
The drugs used were DSLET, DELT I and NTB, their sources were as listed in 
section 2.2.3.
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Comparisons of the agonist dose-response curves in weaned and non-weaned rats and 
their antagonism by NTB were analysed by one way ANOVA and Duncans New 
Multiple range test using the SuperANOVA package for the Macintosh.
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3.3 RESULTS
In weaned rats DSLET (0.25-lmg/kg) produced significant dose-related antinociception 
(Figure 14a) with a peak latency of 4.7 seconds at 5 min. While in non-weaned 
animals DSLET had no effect (Figure 14b), at all time points the response to DSLET 
was not significantly different to saline control latencies. DELT I (0.01-0. Img/kg) 
produced significant dose-related responses in both weaned and non-weaned rats with 
peak response latencies of 5.7 and 4.7 seconds respectively (Figure 15a & 15b), 
similar to the results obtained with DSLET peak antinociception was seen 5 min after 
agonist administration. Also the effects of DELT I in the weaned and non-weaned 
groups were not significantly different at any time point (ANOVA and Duncans New 
Multiple range test). NTB (5pg/kg) abolished the antinociceptive responses to DSLET 
in weaned rats (Figure 16), but had no effect on responses to DELT I in either weaned 
or non-weaned groups (Figure 17).
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Figure 14. Antinociceptive effects of DSLET in 25 day old (a) weaned and
(b) non-weaned rats.
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Values are means ± s.e.mean of six observations. (O) represents saline 
controls, (#) 0.25mg/kg DSLET, (□) 0.5mg/kg DSLET,(0) 0.75mg/kg 
DSLET and (A) Img/kg DSLET. Significant differencesfrom saline 
controls at 5 min: DSLET (weaned, A  doses) p < 0.05; DSLET 
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Figure 15. Antinociceptive effects of DELT I in 25 day old (a) weaned and
(b) non-weaned rats.
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Figure 16. Effect of NTB (5pg/kg) on the antinociceptive effect of DSLET
in 25 day old weaned rats.
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control values, (#) 0.25mg/kg DSLET, (□) 0.5mg/kg DSLET, (■) 0.75 
mg^g DSLET and (A) Img/kg DSLET. Significant differences from 
equivalent groups in the absence of NTB, DSLET all doses p < 0.05, one 
way ANOVA and Duncans New Multiple range test
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Figure 17. Effect of NTB (5pg/kg) on the antinociceptive effect of DELT I 
in 25 day old (a) weaned and (b) non-weaned rats.
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3.4 DISCUSSION
The evidence for multiple 0-receptors has previously been discussed in section 2.4. 
The marked contrast between the profiles of DELT I and DSLET in the 25 day old 
weaned and non-weaned rats adds further support to the hypothesis that these two 
agonists exert their antinociceptive effects at different sites in these animals. Further 
support for this comes from the antagonism of the DSLET response by a low dose of 
NTB, and the lack of effect of this dose of antagonist on the responses to DELT I. 
This antagonist profile confirms the 5-subtype selectivity of these agonists, that is, 5i 
for DELT I and Ô2 for DSLET.
The complete lack of activity of DSLET in non-weaned animals is in sharp contrast to 
marked antinociception in weaned rats and points to weaning activating a system which 
is responsible for mediating the effects of this agonist In contrast, no distinction could 
be observed between weaned and non-weaned animals in their response to DELT I 
suggesting that the mediation of antinociception by this agonist differs from that for 
DSLET and is not activated by the weaning process. At the molecular level, it is most 
likely that weaning either initiates the global developmental expression of a 5-subtype 
for which DSLET has high affinity or activates a specific regional expression of
5-receptors which are essential for antinociception produced by DSLET but not that 
produced by DELT I. Alternatively, weaning could initiate coupling of 5-receptors to 
second messengers allowing specific 5-mediated responses at the cellular level. From 
the current evidence it is not possible to determine if weaning activates the receptor or 
the coupling system, but with the recent cloning of the 5-receptor (Evans^r al., 1992; 
Keiffer et al., 1992) showing that the necessary mechanism for alternative splicing as a 
route to receptor subtypes is present in the gene, it seems probable that weaning turns 
on expression of a 5-receptor subtype.
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Recent evidence from mice using the cold water swim-stress model has suggested that 
under these conditions the SIA observed is mediated via the 6 2 -receptor since it is 
antagonised by the selective 0 2 -antagonist 5'NTII and not by the 61-antagonist DALCE 
nor by selective |i- or K-antagonists (Vanderah et al., 1992). In addition to this the SIA 
showed a two-way cross-tolerance with the 6 2 -agonist DELT II but not with the 
51-agonist DPDPE (Vanderah et al., 1992). It has recently been demonstrated 
(Muhammad & Kitchen, 1993) that the stimulus of weaning is a crucial element in 
receptor transition from |i- to 6 -receptor operation of SIA, thus it is possible that it is 
the 6 2 -receptor which mediates this effect in the rat. Indirect evidence for this is 
provided by these results as the 6 2 -agonist, as defined in these animals, is inactive in 
non-weaned animals and 6 -mediation of SIA is also absent (Muhammad & Kitchen,
1993).
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CHAPTER 4
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4.1 INTRODUCTION
Electrical field stimulation of the isolated mouse vas deferens produces a contraction 
which is mediated by the presynaptic release of noradrenaline which stimulates the 
muscle to contract (Famebo & Malmfors, 1971). This contractile response was later 
shown to be inhibited by morphine in a naloxone-reversible manner (Henderson et al., 
1972). Thus, following the isolation of the enkephalins (Hughes, 1975) these 
compounds were tested for their ability to inhibit the evoked contractions of the mouse 
vas deferens, which they did in a dose-dependent manner (Hughes, 1975). In fact it 
was shown in a later study that the enkephalins were very potent at inhibiting 
contractions of the mouse vas deferens (Lord et al., 1977) and a specific target 
receptor, 5, was assigned to mediate their responses in this tissue (see section 1 .1 .2  for 
further detail).
Although the mouse vas deferens was thought to contain predominantly 6 -receptors, 
some p-receptors could also be demonstrated since the effect of morphine was 
antagonised by low doses of naloxone (Lord et al., 1977) and the effects of p- and
6 -ligands did not show cross-tolerance to each other (Schulz et al, 1980). The mouse 
vas deferens has also been shown to have a variety of tissue peptidases and the potency 
of the enkephalins is markedly increased in the presence of a cocktail of peptidase 
inhibitors (McKnight et al., 1983).
As the mouse vas deferens represents a simple in vitro method of assaying compounds 
it has become the standard method of assessing new opioid compounds especially those 
selective for the 6 -receptor (for example; Himing et al., 1985; Takemori et al., 1986; 
Rogers et al., 1991). Used in conjunction with the p-receptor enriched guinea pig 
ileum it can be used to give a p/6  ratio as an indication of selectivity.
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Some years after the discovery of the opioid receptors in the mouse vas deferens the 
vas deferens of the hamster was shown to contain a population of opioid receptors 
which appeared to be exclusively 5 (McKnight et al., 1984). In this tissue DPDPE, 
DSLET and DADLE were all full agonists while compounds selective for p- and 
K-receptors were without effect (McKnight et al., 1985; Sheehan et al., 1986). The 
hamster vas deferens was found to contain higher concentrations of peptidase enzymes 
than the mouse, as approximately three times more thiorphan was required to 
maximally inhibit the breakdown of [Met] or [Leu]enkephalin (McKnight et al., 1985).
The aim of the work presented in this chapter was two fold; firstly to characterise the 
agonists used for the in vivo studies in an in vitro assay using both the mouse and 
hamster vas deferens. Secondly, to investigate the possibility of 5-receptor subtypes in 
these isolated tissue systems. The concentration of agonist producing a 50% inhibition 
of the contraction (IC50) was used to measure agonist potency, and the pA2 from 
Schild analysis used as a measure of antagonist potency.
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4.2 MATERIALS AND METHODS
4.2.1 ANIMALS
Male Schnieder (University of Surrey) or TO (Bantin & Kingman) weighing 25-30g 
were used for the mouse vas deferens preparation and male Golden Syrian hamsters 
(Wrights) weighing 110-140g were used for the preparation of hamster vas deferens. 
Mice were housed in groups of 10-15 and maintained on a 12 hour light-dark cycle 
(lights on 7hr OOmin) with water and laboratory chow freely available. Hamsters were 
housed individually under the same conditions as the mice.
4.2.2. TISSUE PREPARATION
Animals were killed by cervical dislocation and the abdomen opened to expose the 
testes and vas deferens. The vas deferens were freed from the epididymis and cut as 
near to the junction with the urethra as possible. Tissues were then placed in a petri 
dish containing magnesium-free Krebs, (composition 118mM NaCl, 25mM NaHCOg, 
llm M  D-glucose, 1.2mM KH2PO4 , 4.8mM KCl and 2.5mM CaCl2 .2 H2 0 ), and the 
connective tissue and closely adhering blood vessels were gently removed. Any semen 
present was expelled by gently pressing the tissue with a finger.
A length of cotton was tied to the prostatic end of the vas deferens to allow connection 
to a tissue holder and the same was repeated at the epididymal end to allow connection 
to the transducer. Both threads were tied as close as possible to the end of vas deferens 
so a maximum length of tissue was available for stimulation. After attachment to the 
tissue holder the tissue was transferred to a 3.5ml organ bath containing magnesium- 
free Krebs at 35-36°C and aerated with 9 5 %0 2 /5 %C0 2  taking care not to pull or stretch 
the tissue in any way. The vas deferens was then attached to a Grass FT03 transducer
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connected to a Grass polygraph. Following a 30min incubation period with frequent 
washing the tissue was placed under 2 0 0 mg tension and allowed a further 30min 
equilibration time.
4.2.3. DETERMINATION OF AGONIST POTENCY
After the equilibration time the tissues were then incubated with a cocktail of peptidase 
inhibitors (McKnight et al., 1985) for 30min to allow the determination of agonist 
responses. The same cocktail was used in the mouse and hamster vas deferens 
consisting of lOpM thiorphan, 30pM bestatin, lOpM captopril and 2mM 
Leucyl-leucine. At the end of the 30min period the bath was emptied and refilled and 
the peptidase inhibitors rapidly readded, to ensure a fresh stock of inhibitors was 
present to protect the agonists. The vas deferens was then field stimulated via two 
linear platinum electrodes 0.5cm apart. Stimulation was achieved by using a Grass S48 
stimulator and the following parameters; Twin pulses of 70V, duration of 1ms with a 
frequency of O.lHz. The delay between the twin pulses was set at 75ms for the mouse 
vas deferens and 50ms for the hamster vas deferens.
Dose-response curves to each of the agonists (DSLET, DPDPE and DELT I) were 
determined by cumulative dosing, as pilot experiments with DPDPE showed no 
difference in the ICso's obtained by cumulative and intermittent dosing. Doses were 
added in half log units, each new dose was added when 3 or more contractions of the 
same height were achieved. Following the first determination of the agonist dose 
response curve the tissue was repeatedly washed for 2 0 min and then reincubated with 
the peptidase inhibitors for 30min. After this the agonist dose response curve was 
repeated. In the mouse vas deferens this was carried out twice more until 4 dose 
response curves were obtained, in the hamster only two curves were obtained, this was 
to ensure the reproducibility of the agonist response over the duration of the 
experiment. Only one agonist was tested on each tissue. The percentage inhibition of
1 2 1
stimulated contractions was plotted against final bath concentration of agonist and 
regression lines were fitted for responses between 10 and 90% for the mouse vas 
deferens and 20 and 80% for the hamster vas deferens. From these regression lines the 
concentration of agonist causing a 50% inhibition of contraction (IC5 0 ) was 
determined.
4.2.4. DETERMINATION OF ANTAGONIST POTENCY
When it had been established that no change in sensitivity occurred after repeating dose-
response curves the antagonist potency of NTI and NTB was investigated. In the
mouse vas deferens the agonist dose response curves were determined as described
above except after the first dose response curve the tissues were incubated with three
doses of the NTI or NTB. From the four dose response curves obtained the dose-ratio
for each dose of antagonist was obtained using the following formula;
dose-ratio = ICsp of the agonist in the presence of the antagonist.
IC50 of the agonist in the absence of the antagonist.
The results were then subjected to Schild analysis by plotting the log of the dose-ratio-1
against log of the concentration of antagonist. The intercept on the x axis of the
resulting graph gives an estimation of the antagonist pA% value. If the slope of the line
does not differ significantly from unity then it can be constrained to one and the
X intercept then represents the pKy, the inverse log of the antagonist affinity.
In the hamster vas deferens the antagonist potency was measured using Ke
determination. The first dose response curve was obtained but before determination of
the second curve the tissue was incubated with a single concentration of either NTI or
NTB. The Ke is the equilibrium dissociation constant and is determined by the
following formula;
Ka = Fantagonistl 
dose-ratio- 1
1 2 2
Due to a small tachyphylaxis on repeated dosing with DSLET in the TO mouse vas 
deferens the antagonist potency was determined using an unpaired experimental 
protocol. Separate tissues were used to determine ICgp's from a single dose-response 
curve in the absence or presence of NTT.
4.2.5 VALIDATION OF THE NEUROGENIC ORIGIN OF THE STIMULATED 
CONTRACTIONS AND IDENTIFICATION OF THE SYNAPTIC LOCATION OF 
THE 6 -OPIOID RECEPTORS
In order to check that the stimulation parameters used were initiating neurogenic 
contractions lOOnM (mouse) or IpM (hamster) teterodotoxin (TTX) was added to the 
bath while the tissues were being stimulated. TTX blocks sodium channels and thus 
nervous transmission, but at the doses used should have no effect on either direct 
muscle stimulation nor the effect of exogenously administered noradrenaline.
To investigate if the effects of the opioid agonists were due to the activation of pre or 
postsynaptic receptors and to see if the agonists had any effects on the muscle directly 
the effects of the agonists on a submaximal dose of noradrenaline was investigated.
The IC50 for each agonist was also determined in the absence of peptidase inhibitors. 
Determination of agonist potency was carried out as previously described except the 
peptidase inhibitors were omitted for the final 30min incubation.
4.2.6 DRUGS AND STATISTICAL PROCEDURES
The drugs used were DSLET, DPDPE, DELT I, NTI and NTB from the sources 
described in section 2.2.3. NaCl, NaHCOg, KCl, KH2PO4 , CaCl2 .2 H2 0  and D- 
glucose (Fisons) TTX and noradrenaline (Sigma).
123
Analysis of log ICso’s was carried out using a paired t-test (Statview for the 
Macintosh). Slopes of the Schild plots were t-tested against a population mean of unity 
(Kenakin, 1984) and the comparison of pA2 and Ke values by a one way analysis of 
variance and post hoc Duncans New Multiple range test (SuperANOVA for the 
Macintosh).
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4.3. RESULTS
4.3.1. SCHNEIDER MOUSE VAS DEFERENS
Field stimulation of the Schneider mouse vas deferens initiated a constant contraction 
typically of approximately 400mg tension (Figure 18). All three 6 -agonists employed 
gave an inhibition which was of rapid onset and dose related (Figure 18). The order of 
potency for the agonists was DELT I > DSLET > DPDPE, all of the agonists were very 
potent showing IC50 values in the low nanomolar range (Table 6 ). Repeated 
determination of the concentration response curves showed that the agonist responses 
were reproducible (Figure 19) and no significant differences were seen in the IC50 
values obtained over the duration of the experiment (Table 6 ).
Incubation with increasing doses of NTI caused a parallel, rightward shift of the 
agonist dose response curves with no depression in the maximum effect for all three 
agonists (Figures 20-22). Schild analysis of the individual NTI curves (Figures 20-22 
and Table 7) gave pA2 values for DSLET and DELT I which were significantly 
different (p < 0.05). The pA2 value obtained for NTI versus DPDPE fell between the 
values versus DSLET and DELT I and was not significantly different from either of 
them. The slopes of the Schild plots for NTI versus DSLET and DPDPE were not 
significantly different from unity, but the slope for NTI versus DELT I was 
significantly different from one (p < 0.05, t-test). For the compounds where the slopes 
of the Schild plots did not significantly differ from unity, their slopes were constrained 
to unity to allow an estimation of the pKy for NTI. When this procedure was carried 
out the pKb values obtained for DSLET and DPDPE were identical (Table 7).
Incubation with increasing doses of NTB caused a parallel, rightward shift of the 
agonist dose response curves with no depression in the maximum effect for all three 
agonists (Figures 23-25). Schild analysis of the individual NTB curves (Figures 23-25
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Table 6 . IC50 values obtained on repeated determination of concentration response 
curves for DSLET, DPDPE and DELT I in the isolated vas deferens of SCH mice.
Ligand ICsonM 2ndJC5onM 3:dlC50nM 4 Ü1 IC50 nM
DSLET 1.98±0.47 1.30±0.27 1.3210.32 1.3210.42
DPDPE 3.32±0.50 2.7410.28 2.8610.33 3.3710.59
DELT I 0.75+0.02 0.9710.18 0.7110.10 0.6510.13
Values are means ± s.e.mean of 4-7 determinations and there were no significant 
differences in ICso's determined for each of the agonists during the experiment 
(ANOVA).
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Figure 19. Repeated cumulative concentration-repsonse curves for the ô- 
agoinists in isolated SCH mouse vas deferens.
a
1 0 0
10.1 10 1 0 0
[DSLET] nM
1 0 0
1 0 01 100.1
1 0 0
t-H
1010.1
[DPDPE] nM [DELTI]nM
Values are means ± s.e.mean of 4-7 observations and are expressed as percentage 
inhibition of field stimulated contractions versus the final bath concentration of 
agonist in nM. (O) represents the initial determination, ( • )  second, (□) third and 
(■) fourth determination, each following a 30min incubation with a cocktail of 
peptidase inhibitors and 2 0 min washout period.
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Figure 20. Effect of NU on concentration effect curve of DSLET
(a) and Schild analysis of the effect of NTI on the concentration
effect curves (b) in the SCH mouse vas deferens.
1 0 0
10 100 1000 1000010.1
[DSLET] nM
3.5
2.5
0.5
10 -9.5 -9 -8.5 - 8  -7.5 -7 -6.5
Log [NTI]
Values are means ± s.e.mean of 3-6 observations. (O) represents DSLET 
alone, ( • )  + 3nM NTI, (□) + lOnM NTI, (■) +30nM NTI, (A) +lGOnM 
NTI and(A) + 300nM N ^ . (b) shows the Schild plot obtained following 
Schild analysis of the curves shown in (a), pA2 9.96, slope 0.70 andr = 0.998.
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Figure 21. Effect of NTI on concentration effect curve of DPDPE
(a) and Schild analysis of the effet of NTI on the concentration
effect curves (b) in the SCH mouse vas deferens.
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Values are means ± s.e.mean of 3-6 observations. (O) represents DPDPE 
alone, ( • )  +ICnM NTI, (□) +30nM NTI, (■) +lQ0nM NTI and (A) +300 
nM NTI. (b) shows the Schild plot obtained following Schild analysis of 
the curves shown in (a), pA2 9.49, slope 0.93 and r = 0.994.
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Figure 22. Effect of NTI on concentration effect curve of DELT I
(a) and Schild analysis of the effect of NTI on the concentration
effect curves (b) in the SCH mouse vas deferens.
I
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Values are means ± s.e.mean of 2"6 observations. (O) represents DELT I 
alone, ( • )  + lOnM NTI, (□) + 30nM NTI, (■) + lOOnM NTI and (A) + 
300nM NTI. (b) shows the Schild plot obtained following Schild analysis 
of the curves shown in (a), pA2 8.50, slope 1.64 and r = 0.992.
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Table 7. Antagonist potency of NTI versus 5-agonists in SCH mouse vas deferens.
Ligand NTIpA2 Slope NTTpKb
DSLET 9.91+0.37 0.86±0.09 9.31±0.12
DPDPE 9.39±0.44 1.15±0.21 9.31±0.16
DELT I 8.75+0.07 1.28+0.06 n.d.
Schild analysis of individual experiments with DSLET, DPDPE, DELT I and NTI. 
Values are means ± s.e.mean of 5-6 determinations. The slopes of the Schild plots for 
DSLET and DPDPE did not significantly differ fi*om unity thus their slopes were 
constrained to one to allow the determination of a pKb value. The slopes of the Schild 
plot for NTI versus DELT I were significantly different to one (t-test, p<0.01) thus the 
slope could not be constrained and a pKb was not determined, n.d. not determined.
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Figure 23. Effect of NTB on concentration effect curve of DSLET
(a) and Schild analysis of the effect of NTB on the concentration
effect curves (b) in the SCH mouse vas deferens.
1 0 0
g
3
1
10 100 1000 100000.1 1
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9 -8.5 - 8  -7.5 7-9.5
Log [NTB]
Values are means ± s.e.mean of 3-11 observations. (O) represents DSLET 
alone, ( • )  + 3nM NTB, (□) +lGnM NTB and (■) + 30nM NTB. (b) shows 
the Schild plot obtained following Schild analysis of the curves shown in (a), 
pA% 9.32, slope 0.84 and r = 0.998.
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Figure 24. Effect of NTB on concentration effect curve of DPDPE
(a) and Schild analysis of the effect of NTB on the concentration
effect curves (b) in the SCH mouse vas deferens.
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T—4
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Log [NTB]
Values are means ± s.e.mean of 4-8 observations. (O) represents DPDPE 
alone, ( • )  + lOnM NTB, (□) + 30nM NTB and (■) + lOOnM NTB. (b) 
shows the Schild plot obtained following Schild analysis of the curves shown 
in (a), pA2  9.57, slope 1.0 and r = 0.999.
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Figure 25. Effect of NTB on concentration effect curve of DELT I
(a) and Schild analysis of the effect of NTB on the concentration
effect curves (b) in the SCH mouse vas deferens.
1 0 0
gI
1 10 100 10000.1
[DELTI]nM
2.5-,
2 -
0 .5 -
9.5 "9 “8.5 “8  “7.5 ~7 “6.5 “6
[NTB] nM
Values are means ± s.e.mean of 4 observations. (O) represents DELT I 
alone, ( • )  + 3nM NTB, (□) + lOnM NTB and (■) + 30nM NTB. (b) 
shows the Schild plot obtained following Schild analysis of the curves 
shown in (a), pA2  9.27, slope 1.10 and r = 0.919.
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Table 8 . Antagonist potency of NTB versus 6 -agonists in the SCH mouse vas 
deferens.
Ligand NTBpAi Slope NTBpKb
DSLET 9.59±0.10 0.84±0.10 n.d.
DPDPE 9.58+0.20 1 .10±0 .1 0 9.64+0.17
DELT I 9.38+0.16 1.07±0.10 9.44±0.14
Schild analysis of individual experiments with DSLET, DPDPE, DELT I and NTB. 
Values are means ± s.e.mean of 4-11 determinations. The slopes of the Shild plots for 
DPDPE and DELT I did not significantly differ from unity thus their slopes were 
constrained to one to allow the determination of a pKy value. The slopes of the 
Schild plots for NTB versus DSLET were significantly different to one (t-test, 
p<0.05) thus the slope could not be constrained and a pKy was not determined. n.d. 
not determined.
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and Table 8 ) gave similar pA2 values for NTB versus all three ô-agonists. The slopes 
of the Schild plots for NTB versus DPDPE and DELT I were not significantly different 
from unity, but the slope for NTB versus DSLET was significantly different from one 
(p < 0.05, t-test). Thus the slopes of the Schild plots for NTB versus DPDPE and 
DELT I were constrained to unity to allow an estimation of the pKy for NTB. When 
this procedure was carried out the pKt, values for DPDPE and DELT I were not 
significantly different (Table 8 ).
In the absence of peptidase inhibitors the response to DPDPE was unchanged, but the 
responses to DSLET and DELT I showed a 2.9 and 3.9-fold increase in potency 
(Table 9). The qualitative responses to the agonists was unchanged,
A Imin preincubation of the unstimulated vas deferens with each of the 6 -agonists had 
no effect on the response to exogenously applied noradrenaline (Table 10).
Addition of lOOnM TTX rapidly and completely inhibited the stimulated contractions of 
the vas deferens (Figure 27). The muscle also showed a good response to exogenously 
applied noradrenaline in the presence of TTX (Figure 26).
4.3.2 TO MOUSE VAS DEFERENS
Field stimulation of the TO mouse vas deferens produced a constant contraction 
typically of 300-400mg tension (Figure 27). All three 6 -agonists employed gave an 
inhibition which was of rapid onset and dose related (Figure 27). All of the agonists 
were very potent showing IC50 values in the low nanomolar range, the rank order of 
potency for the agonists was DELT I > DSLET > DPDPE (Table 11). Repeated 
determination of the concentration response curves showed that for DPDPE and 
DELT I the agonist effects were reproducible (Figure 28) and no significant differences 
were seen in the IC50 values obtained over the duration of the experiment (Table 1 1).
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Table 9. IC50 values in the presence and absence of peptidase inhibitors in the SCH 
mouse vas deferens.
Ligand IC50 with P.I. IC50 no P.I. dr
DSLET 1.98±0.47nM 0.68±0.13nM 2.9
DPDPE 3.32±0.50nM 2.76±0.63nM 0
DELTI 0.75±0.02nM 0.19±0.04nM 3.9
Values are means ± s.e.mean of 4 determinations. P.I = peptidase inhibitors, lOjiM 
thiorphan, 30|iM bestatin, lOjiM captopril and 2mM Leucyl-leucine. dr = dose ratio 
defined as IC50 in the presence of peptidase inhibitors divided by IC50 in the absence of 
peptidase inhibitors.
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Table 10. Effect of DSLET, DPDPE and DELT I on the response to noradrenaline 
(mg) in the SCH mouse vas deferens.
Ligand + Dose (nM) Without 5-agonist With 6 -agonist
DSLET 3 535+170 472+151
DPDPE 30 446+88 468+90
DELTI 3 576+164 482+127
Values are means ± s.e.mean of 4 observations and represent the tension, in mg, 
generated upon the addition of a submaximal dose (1.6|iM) of noradrenaline to the 
unstimulated tissue.
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Table 1 1 . IC50 values obtained on repeated determination of concentration response 
curves for DSLET, DPDPE and DELT I in the isolated vas deferens of TO mice.
Ligand ICsonM 2 »dlC5onM SrdlCsonM 4 th IC50 nM
DSLET 1 .1 2 ±0 .1 0 1.69+0.17* 1.62±0.13* 2.34±0.34*
DPDPE 4.20±0.43 4.14±0.60 4.64±1.05 3.00±0.37
DELTI 0.84±0.24 1.18±0.48 0.94±0.33 0.97±0.35
Values are means ± s.e.mean of 5-7 determinations. * indicates significant difference 
(p < 0.05) from the first IC50 determination (ANOVA).
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Figure 28. Repeated cumulative concentration-response curves for the 
ô-agonists in isolated TO mouse vas deferens.
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Values are means ± s.e.mean of 5-7 observations and are expressed as percentage 
inhibition of field stimulated contractions versus the final bath concentration of 
agonist in nM. (O) represents the initial determination, ( • )  second, (□) third and 
(■) fourth determination, each following a 30min incubation with a cocktail of 
peptidase inhibitors and 2 0 min washout period.
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However DSLET showed a small but significant tachyphylaxis over the course of the 
experiment (Figure 28) and significant (p < 0.05) differences were seen in the IC50 
values obtained (Table 11).
Incubation with increasing doses of NTI caused a parallel, rightward shift of the 
agonist dose response curves with no depression in the maximal effect for all three 
agonists (Figures 29-31). Schild analysis of the individual NTI curves (Figures 29-31 
and Table 12) gave pA% values for DPDPE and DELT I which were significantly 
different (p < 0.05), however analysis showed that the slopes of the Schild plots did 
not significantly differ from unity and thus they were constrained to unity to allow pKb 
values to be determined. This procedure yielded values for NTI versus DPDPE and 
DELT I which were not significantly different from each other (Table 12). No 
statistical comparisons could be made for NTI versus DSLET as it represents a single 
value but similar to DPDPE in the Schneider mouse vas deferens it lies between the 
values obtained for the other agonists.
Determination of the agonist IC50 values in the absence of peptidase inhibitors showed 
that both DSLET and DPDPE showed only a very slight increase in potency but the 
values were not significantly different from the values in the presence of the peptidase 
inhibitors (Table 13). However DELT I showed a 3.2-fold increase in potency in the 
absence of the peptidase inhibitors similar to that seen in the Schneider mouse vas 
deferens.
A Imin preincubation of the unstimulated vas deferens with each of the ô-agonists had 
no effect on the response to exogenously appUed noradrenaline (Table 14).
Addition of lOOnM TTX rapidly and completely inhibited the stimulated contractions of 
the vas deferens (Figure 32). Increasing the pulse width to 40ms generated small
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Figure 29. Effect of NTI on concentration effect curve of DSLET
(a) and Schild analysis of the effect of NTI on the concentration
effect curves (b) in theTO mouse vas deferens.
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Values are mean ± s.e.mean of 4 observations. (O) represents DSLET alone, 
( • )  +3nM NTI, (□) + lOnM NTI and (■) + 30nM NTI. (b) shows the Schild 
plot obtained following Schild analysis of the curves shown in (a), pA2 9.14,
slope 1.38 and r = 0.992.
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Figure 30. Effect of NTI on concentration effect curve of DPDPE
(a) and Schild analysis of the effect of NTI on the concentration
effect curves (b) in the TO mouse vas deferens.
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Values are mean ± s.e.means of 4-8 observations. (O) represents DPDPE 
alone, ( • )  + 3 nM NTI, (□) + lOnM NTI and (■) + SOnM NTI. (b) shows 
the Schild plot obtained following Schild analysis of the curves shown in (a), 
pA2 9.78, slope 0.78 and r = 0.992.
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Figure 31. Effect of NTI on concentration effect curve of DELTI
(a) and Schild analysis of the effect of NTI on the concentration
effect curves (b) in the TO mouse vas deferens.
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Values are means ± s.e.mean of 4 observations. (O) represents DELT I 
alone, ( • )  + lOnM NTI, (□) + SOnM NTI and (■) + lOOnM NTI. (b) 
shows the Schild plot following Schild analysis of the curves shown in 
(a), pÀ2 8.72, slope 1.31 and r = 0.998.
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Table 12. Antagonist potency of NTI versus 6 -agonists in TO mouse vas deferens.
Ligand NTIpA2 Slope NTIpKb
DSLET 9.14* 1.38* n.d.
DPDPE 9.60±0.22 0.85±0.07 9.31±0.16
DELT I 8.78±0.12 1 .2 0 ±0 .1 2 9.01±0.41
Schild analysis of individual experiments with DSLET, DPDPE, DELT I and NTI. 
With the exception of DSLET values are means ± s.e.mean 6-7 determinations. 
* indicates data taken from non-paired experiments (n=4) due to tachyphylaxis. The 
slopes of the Schild plots for DPDPE and DELT I were not significantly different from 
unity (t-test) thus the slopes were constrained to one and estimates of the pKt, values 
determined. n.d. not determined.
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Table 13. IC50  values in the presence and absence of peptidase inhibitors in TO 
mouse vas deferens.
Ligand IC50 with P.I. IC50 no P.I. dr
DSLET 1.12±0.10nM 0.73±0.17nM 1.5
DPDPE 4.20±0.43nM 2.74±0.82nM 1.5
DELT I 0.84±0.24nM 0.26±0.04nM 3.2
Values are means ± s.e.mean of 4 determinations. P.I. = peptidase inhibitors, lOjxM 
thiorphan, SOjiM bestatin, lOpM captopril and 2mM Leucyl-leucine. dr = dose ratio 
defined as IC50 in the presence of peptidase inhibitors divided by IC50 in the absence of 
peptidase inhibitors.
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Table 14. Effect of DSLET, DPDPE and DELT I on the response to noradrenaline
(mg) in the TO mouse vas deferens.
Ligand + Dose (nM) Without ô-agonist With 5-agonist
DSLET 30 500±76 516191
DPDPE 30 357±33 346157
DELTI 3 5931201 5341152
Values are means ± s.e.mean of 4 observations and represent the tension, in mg, 
generated upon addition of a submaximal dose (1.6jiM) of noradrenaline to the 
unstimulated tissue.
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contraction bought about by direct muscle stimulation. The muscle also responded to 
exogenously applied noradrenaline in the presence of TTX (Figure 32).
4.3.3. HAMSTER VAS DEFERENS
Stimulation of the hamster vas deferens produced a constant contraction typically of 
300mg tension (Figure 33). All three 8 -agonists studied gave an inhibition which was 
of slower onset than that seen in the mouse but was still dose-related (Figure 33). The 
rank order of potency for the agonists was DELT I > DPDPE > DSLET, and the 
agonists were substantially less potent in the hamster than in the mouse with the IC50 
values being in the high of nanomolar range (Table 15). Repeated determination of the 
concentration response curves showed that the agonist effects were reproducible 
(Figure 34) and no significant differences were seen in the IC50 values for the first and 
second dose response curves (Table 15).
Incubation with a single dose of NTI or NTB caused a parallel, rightward shift of the 
agonist dose response curves with no depression of the maximum effect (Figures 35- 
37). Analysis of the curves produced Ke values for NTI versus each of the 8 -agonists 
which did not significantly differ from each other, however, the Ke values obtained for 
NTB showed that this antagonist was significantly less effective at antagonising the 
effects of DPDPE compared with DELT I. The rank order of potency of antagonism 
was opposite for NTI compared to NTB (Table 16).
Determination of the IC50  values in the absence of peptidase inhibitors showed a 
5.3-fold increase in the IC50 value for DSLET showing the peptidase inhibitors were 
affording some protection to this agonist. The IC50  for DPDPE was markedly 
decreased in the absence of the inhibitors, showing a 6.3-fold increase in potency 
making this agonist the most potent in this preparation. The IC50 value for DELT I was 
unchanged by the omission of the cocktail of peptidase inhibitors (Table 17).
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Table 15. IC50 values obtained on repeated determination of concentration response 
curves for DSLET, DPDPE and DELT I in the isolated hamster vas deferens.
Ligand IC50 nM indlCsonM
DSLET 658±181 1037±387
DPDPE 346+94 232+56
DELT I 86+33 142+62
Values are means ± s.e.means of 6  determinations and there are no significant 
differences between first and second IC50 values (ANOVA).
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Figure 34. Repeated cumulative concentration response curves for the
8 -agonists in isolated hamster vas deferens.
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Values are means ± s.e.mean of 2-6 observations and are expressed as percentage 
inhibition of field stimulated contractions versus the final bath concentraion of 
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a 30min incubation with a cocktail of peptidase inhibitors and 20min washout period.
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Figure 35. Effect of NTI (a) and NTB (b) on the concentration
effect curve of DSLET in isolated hamster vas deferens.
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Figure 36. Effect of NTI (a) and NTB (b) on the concentration
effect curve of DPDPE in isolated hamster vas deferens.
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Figure 37. Effect of NTI (a) and NTB (b) on the concentration
effect curve of DELT I in isolated hamster vas deferens.
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Values are means ± s.e.mean of 3-6 observations. (O) represents DELT I alone
and (#) + 20nM NTI or 5nM NTB.
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Table 16. Antagonist potency of NTI and NTB versus 5-agonists in hamster vas 
deferens.
Ke (nM)
Ligand NTI NTB
DSLET 1.7610.46 0.8210.33
DPDPE 0.9010.13 1.2210.31
DELT I 2.0610.56 0.3010.12
Values are means ± s.e.mean of 5-6 determinations. There were no significant 
differences between Ke values for NTI, however the Ke values for NTB versus 
DPDPE and DELT I were significantly different, p<0.05 (ANOVA and post-hoc 
Duncans new multiple range test).
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Table 17. IC50 values obtained in the presence and absence of peptidaes inhibitors in 
hamster vas deferens.
Ligand IC50 with P.I. IC50 no P.I. dr
DSLET 658±181nM 346011170nM 0.19
DPDPE 346±94nM 55119nM 6.30
DELT I 86±33nM 63115nM 1.40
Values are means ± s.e.mean of 4 determinations. P.I. = peptidase inhibitors, lOjiM 
thiorphan, 30jiM bestatin, lOjiM captopril and 2mM Leucyl-leucine. dr = dose ratio 
defined as IC50 in the presence of peptidase inhibitors divided by IC50 in the absence of 
peptidase inhibitors.
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A Imin preincubation of the unstimulated vas deferens with each of the ô-agonists had 
no effect on the response to exogenously applied noradrenaline (Table 18).
Addition of IjiM TTX rapidly and completely inhibited the stimulated contractions of 
the vas deferens (Figure 38). Increasing the pulse width to 40ms produced small 
contractions due to direct muscle stimulation. The muscle also responded to 
exogenously applied noradrenaline (Figure 38).
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Table 18. Effect of DSLET, DPDPE and DELT I on the response to noradrenaline
(mg) in hamster vas deferens.
Ligand + Dose (nM) Without 6 -agonist With 6 -agonist
DSLET 1000 3951109 4481105
DPDPE 1000 350193 353197
DELT I 1000 362177 357182
Values are means ± s.e.mean of 4 observations and represent the tension, in mg, 
generated upon the addition of a submaximal dose (1.6p.M) of noradrenaline to the 
unstimulated tissue.
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4.3. DISCUSSION
The results indicate that the stimulation parameters employed initiate a neurogenic 
contraction of both the mouse and hamster vas deferens. This is shown by the 
inhibition of the stimulated contractions by the sodium channel blocker teterodotoxin at 
a dose which does not block direct muscle contraction nor the effect of exogenously 
applied noradrenaline (Figures 26, 32 and 38). As was stated previously in section 4.1 
stimulation of the mouse (or hamster) vas deferens induces a contraction by the release 
of noradrenaline (Famebo & Malmfors, 1971) and the inhibition of this release is 
thought to be the basis for opioid inhibition of this response (Henderson et a i, 1972). 
Sympathetic transmission in the mouse vas deferens is now known to be due to at least 
two co-transmitter substances, noradrenaline and adenosine 5'-triphosphate (ATP) and 
recently Driessen et a/.(1993) investigated the nature of the opioid modulation the 
purinergic and adrenergic components of this transmission process. Driessen et a i 
(1993) concluded that |i-, 8 - and K-agonists inhibit purinergic and adrenergic 
contractions of the mouse vas deferens in a similar manner. The opioid receptors 
mediating the effects of the agonists used are likely to fit the theory of Henderson et al. 
(1972) and be located presynaptically since preincubation of the tissue with a dose of 
each of the agonists had no effect on the contraction induced by exogenous 
noradrenaline (Tables 10,14 and 18).
DSLET, DPDPE and DELT I all proved to be full and potent agonists in the mouse vas 
deferens (Figures 19, 28 and 34). The IC50 values for DSLET of 1.98nM (Schneider) 
and 1.12nM (TO) are a little above the values cited in the literature, which range 
between 0.3-0.6nM in the absence and presence of peptidase inhibitors (Gacel et al., 
1980; Zajac et al., 1983; Corbett et al., 1984; Takemori et al., 1986). However in the 
absence of peptidase inhibitors the values of 0.68nM and 0.73nM are comparable to 
those previously reported.
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The IC50 values reported for DPDPE range from 1.29-6.05nM in the literature (Corbett 
et aL, 1984; Erspamer et al., 1989; Kreil et ai, 1989; Kramer et ai, 1991; Sagan et al., 
1991) and several studies have shown that the addition of the peptidase inhibitors has 
little or no effect on the response to this agonist (Corbett et al. 1984; Kramer et al., 
1991). The IC50 values obtained in this study, 3.32nM (Schneider) and 4.20nM (TO) 
are comparable to those cited in the literature and the addition of a cocktail of peptidase 
inhibitors had little or no effect on the dose response curve of this ligand.
To date only one paper has reported an IC50 value for DELT I in the presence of 
peptidase inhibitors (Kramer et al., 1991) and these authors quote an IC50 of 0.15nM 
which is lower than the values obtained in this study (0.75 and 0.84nM). Data is 
available for DELT I in the absence of peptidase inhibitors and here the IC50 ranges 
from 0.16-0.36nM (Erspamer et al., 1989; Kramer et al., 1991), and these values 
correspond well to the values found in this study (0.19 and 0.26nM). The explanation 
for the marked increase in potency of this agonist following the omission of the 
peptidase inhibitors is not clear.
In spite of being shown to contain only 5-receptors (McKnight et al., 1985), the 
hamster vas deferens has not been widely used to assay compounds with possible 
selectivity for the 5-receptor. In this study the hamster vas deferens often gave very 
poor contractions even following long equilibration times, and some tissues proved to 
be extremely insensitive to the opioid agonists used. Occasionally, little or no recovery 
was seen following the completion of the first agonist dose response curve. IC50 
values for DPDPE and DSLET were much higher than those quoted in the literature 
which range from 21-25nM for DSLET (McKnight et al., 1985; Sheehan et al., 1986) 
and 41-82nM for DPDPE (McKnight et al., 1985; Sagan et al., 1991) and were all 
determined in the presence of a cocktail of peptidase inhibitors. In the absence of 
peptidase inhibition the effect of DSLET was markedly reduced and the IC50 value 
increased to 491nM (McKnight et al., 1985). Even though in this study the agonist
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action of DSLET was potentiated by inhibition of the peptidase enzymes the value 
obtained in the presence of the peptidase inhibitors was still higher than the value 
quoted for this agonist in the absence of the inhibitors by others (McKnight et al., 
1985). No data is available for the action of DELT I in the hamster vas deferens, but 
consistent with the mouse data this agonist was the most potent, and in this case its 
potency was unaffected by peptidase inhibition. The IC50 value for DPDPE showed a 
greater than 6 -fold decrease in the absence of the peptidase inhibitors, and this value, 
55nM, lies within the range quoted in the literature. The marked increase in the potency 
of DPDPE in the absence of peptidase inhibitors was similar to the results obtained with 
DELT I in the Schneider mouse where a 4-fold increase in potency of DELT I is seen in 
the absence of peptidase inhibitors.
The reason for this large difference with the published results is not clear, however the 
studies quoted above used different stimulus parameters to the ones used for this study. 
Instead of a continuous low frequency stimulus McKnight et al. (1985) employed trains 
of bipolar pulses of supramaximal voltage at 5-7HZ delivered every lOsec. Stimulus 
parameters have previously been shown to vastly affect the action of drugs (including 
the |i-agonist FK 33-824) in isolated mouse vas deferens (Zetler & Kaschube, 1985), 
where a variation in frequency or pulse width led to markedly different EC33 values. 
Variation of the stimulus parameters may affect the action of opioid compounds on the 
prostatic and epididymal halves of the vas differentially (Kitchen, 1981) and thus the 
portion of the vas deferens used in each study may be of importance. In addition the 
current passing across the bath may also play an important part in the agonist effect 
since a large current (800mA) induces a 50% loss in the opioid activity of 
[Metjenkephalin in the presence of a vas deferens (Kitchen & Hart, 1981). However, 
in the presence of a vas deferens the current has no effect on the biological activity of 
[Leujenkephalin (Kitchen & Hart, 1981).
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Both N n  and NTB proved to be extremely potent 6 -antagonists in both the mouse and 
hamster vas deferens and the pA2 value obtained for NTI versus DPDPE is comparable 
to that of Rogers et al. (1991). The slopes of the Schild plots for DPDPE (Schneider 
and TO), DSLET (Schneider) and DELT I (TO) were not significantly different from 
unity indicating a simple interaction with a single site. However, the slopes for DELT I 
(Schneider) and DSLET (TO) were greater than one (Tables 7 and 12) and in addition 
to this there were significant differences in the pA2 values obtained for DSLET and 
DELT I in the Schneider strain. The differences in pA2 in the TO strain may be due to 
the difference in slopes as constrainment of the Schild slope to unity yielded pK^ values 
which did not significantly differ. If NTI was acting at a single site acted upon by all of 
the agonists then the pA2 values for NTI should all be the same and the slope of the 
Schild plot be one. There are two usual explanations for Schild slopes greater than 
one, non-equilibrium conditions and antagonist-induced tissue depression (Kenakin, 
1984). Non-equilibrium conditions are unlikely to be the explanation in this case as the 
slopes of the Schild plots for two out of the three agonists was not significantly 
different from one in each mouse strain. Antagonist-induced tissue depression, where 
the antagonist prevents the tissue response in some way at higher concentrations is also 
unlikely, as the same, if not higher, concentrations of NTI were used for the other 
agonists and no effect was seen.
One other possibility is that DELT I and NTI are acting at multiple sites to produce their 
effects. This would normally be shown by a non-linear Schild plot with the greatest 
deviations being seen at dose-ratios of less than 10 (Kenakin, 1984), however, at the 
higher concentrations the points appear to lie on a straight line with a slope near to, or 
greater than one. Since in this study the doses of antagonist were chosen to give dose- 
ratios of 10-100 it is possible that a non-linear Schild plot may not be seen.
One other study has systematically attempted to demonstrate 6 -subtypes in the mouse 
vas deferens. Wild et al. (1993) showed using ICR mice that the proposed
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Ô2-selective, non-equilibrium antagonist 5'NTII equally antagonised the effects of 
DPDPE and DELT II, while the 5i-antagonist DALCE was ineffective at antagonising 
the effects of these two agonists. In addition to this, the two agonists showed acute 
cross-tolerance to each other. Unfortunately only a single dose of 5'NTII was used so 
no Schild analysis is possible for comparison with the results of this study and the 
nature of the antagonism could not be determined. From these results the author 
suggested that only a single subtype of the 0 -opioid receptor is present in the mouse vas 
deferens, but that the presence of other sites cannot be excluded as they may be only 
few in number and a low efficacy compound may fail to see them. Wild et al. (1993) 
also showed that consistent with in vivo data DALCE produced agonist effects in the 
mouse vas deferens prior to any antagonist effects, however it did not show any 
antagonist effects of its own action nor did it cause tolerance to itself or anything else, 
indicating that this compound is likely to have a low efficacy. Consistent with the 
results obtained in this study, where the pA2 values obtained for NTB versus DPDPE 
and DELT I were similar. Wild et al. (1993) also showed that there was no difference 
in the antagonism of DPDPE and DELT II with NTB. However, the results of this 
study also show that the Schild slope for NTB versus DSLET is significantly different 
from unity which could possibily indicate interactions with multiple sites.
There are examples of differences in the potency of NTI to antagonise the effects of 
selective 0-agonists in the literature. Portoghese et al. (1988) quote Ke values for NTI 
versus DADLE and DPDPE of 0.13 and 0.27nM respectively. In addition, Erspamer 
et al. (1989) showed that NTI appeared to be less potent at inhibiting DELT I than 
DPDPE giving Ke values of 1.2 and 0.64 respectively. These results are in agreement 
with the results obtained in this study for the Schneider and TO mouse vas deferens 
where NTI is 4 and 6 -fold more potent at antagonising DPDPE than DELT I in the two 
mouse strains respectively.
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The current study is the first to report the effects of NTI and NTB in the hamster vas 
deferens and show that the effectiveness of these antagonists in the hamster accords 
well with their affinities in the mouse. Although the only significant differences were 
in the NTB antagonism of DPDPE and DELT I the potency orders of NTI and NTB are 
reversed. That is the order of potency for NTI is DPDPE > DSLET > DELT I whereas 
that for NTB is DELT I > DSLET > DPDPE (Table 16). This reverse order of potency 
is in accordance with the possibility that these compounds are acting at more than one 
site to produce their effects. The results of this study do fit the proposed model for 
5-subtypes in the mouse where DELT II and DPDPE act via different receptors and 
NTB has greater affinity for the DELT II site (Jiang et a l, 1991; Sofuoglu et a l, 
1991a). The results of this study show that NTI and NTB have similar affinity for the 
DPDPE site since the Ke's for NTI and NTB versus DPDPE are similar. But NTB has 
much greater affinity than NTI for the DELT I site shown by the greater difference in 
Ke values for these two antagonists versus this agonist, and the larger differences in Ke 
values for NTB across the agonist group.
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CHAPTER 5
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5.1 INTRODUCTION
Electrophysiological analysis of the effects of opioids on the nervous system has been 
performed at several levels, and by using a variety of preparations, recording 
techniques and methods of drug administration. Two general approaches have been 
used. The first has been the measurement of the change in properties of single 
neurones or groups of neurones during application of opioid agonists and antagonists 
directly to them. This has included studies of passive membrane properties, electrical 
excitability, chemical excitability (see section 1.1.3) and neurosecretory properties (see 
section 1.6). The second approach has been the study of how opioid-induced changes 
in the function of certain neurones affect other areas of the nervous system (see spinal 
antinociception section 1.5.1.). Experiments of the first kind have been performed in 
vivo and in tissue removed from the animal and maintained in vitro. Experiments of the 
second kind must be performed in vivo.
The use of brain slices in vitro has several advantages over the use of in vivo 
techniques, i). The application of drugs can be defined such that drug concentrations 
can be determined directly from bath concentrations, the blood brain barrier is 
circumvented, and drugs that are unstable or are rapidly metabolised can be applied 
directly to the brain, ii). Reproducibility; because of the large number of slices that can 
be prepared from a single animal, it is relatively easy to conduct experiments in which 
comparisons are made in similar slices, whereas in vivo different animals would have 
to be tested, iii). Lack of indirect effects; most in vivo experiments are conducted on 
anaesthetised or immobilised animals, in which case drug interactions may be a 
significant problem, iv). Control of extracellular milieu; changes in the ionic 
composition of the perfusion media can be used to modify pharmacological responses. 
However, the use of in vitro brain slices also has some disadvantages: i). loss of inputs 
from other areas of the brain, ii). drug accessibility problems, the concentration of 
some drugs within the slice may be limited by diffusion or re-uptake, iii). differences
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in ionic environment If a nonphysiological perfusion medium is used, drug responses 
observed in vitro may not reflect those in vivo.
Autoradiographic studies have shown the presence of 0-receptors in the hypothalamus 
of the rat (Desjardins et at., 1990), although very little work has been performed to find 
the function of these sites at a cellular or whole animal level. Administration of the 
|i-agonist, morphine has profound effects on hypothalamic function which include 
changes in body temperature (Baldino et al.y 1980), blood glucose levels (Moore et al., 
1965) and the secretion of pituitary hormones (Haidar & Sawer, 1978). There is also 
some evidence that the enkephalins are able to reduce the firing of hypothalamic 
neurones (Carette, 1981). Intracellular recordings from the ventromedial hypothalamus 
of the guinea-pig showed that administration of the selective 5-agonist DPLPE caused 
an inhibition of the spontaneous firing activity and membrane hyperpolarisation in 
approximately one third of the neurones tested (Charpak et al., 1988).
The aim of this study was to investigate the effects of the three 5-agonists, DSLET, 
DPDPE and DELT I on the neuronal firing induced by 0.5jiM quisqualate in rat 
ventromedial hypothalamus (VMH) in vitro using extracellular recording techniques.
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5.2 MATERIALS AND METHODS
5.2.1 ANIMALS
Male Sprague-Dawley rats (Bantin & Kingman) weighing 70-100g were used in all 
studies. Rats were maintained on a 12hr light-dark cycle under standard conditions 
with water and laboratory chow freely available.
5.2.2. BRAIN SLICE PREPARATION
The rats were killed by decapitation. The skull was then exposed by making a single 
cut, using a pair of sharp scissors, along the midline of the head and folding back the 
scalp. Two incisions, one each side of the spinal column were then made, followed by 
a further cut along the midline of the skull. The skull was then folded back to expose 
the brain and any remaining dura matter was then removed using a pair of fine forceps. 
A small spatula was eased under the brain, and the whole brain gently lifted from the 
cranial cavity and placed ventral surface uppermost on a piece of filter paper soaked in 
artificial cerebrospinal fluid (aCSF), composition NaCl 124mM, KCl 5mM, KH2PO4 
1.25mM, CaCl2 .2 H2 0  2mM, MgS0 4 .7 H2 0  2mM, NaHCOg 25mM and Glucose 
llmM.
A block of tissue containing the VMH was obtained by making the following cuts with 
a single edged razor blade: two transversal, one rostral to the optic chiasm and one 
caudal to the mammilary bodies, two parasagittal, 4mm lateral to the midline and one 
horizontal, dorsal to the third ventricle. The block was then mounted onto the stage of 
a vibrating microtome using cyanoacrylate adhesive. The cutting chamber of the 
microtome (Lancer series 1000) contained oxygenated aCSF solution at 4°C being 
continually gassed with 9 5 %0 2 /5 %C0 2 . Following a trimming cut, 2-3 coronal slices
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350)iM thick were obtained. Each slice was cut in half along the axis of the third 
ventricle. One of these sections was chosen and transferred to the recording chamber.
The slice was placed on a nylon mesh stretched over a plastic ring insert whilst still in 
the bath of the vibrotome. The insert was then transferred to the recording chamber 
where the slice was secured in position using a small platinum weight. The slice was 
then completely submerged in aCSF saturated with 9 5 %0 2 /5 %C0 2  at 33°C, which 
flowed continually through the chamber at a rate of 1. Iml/min.
The recording was placed on an earthed vibration isolation table. The slice was 
illuminated from both above and below using a flexilux 150HL universal lamp and 
viewed using a stereomicroscope under a magnification of x50. This allowed visual 
control of the micromanipulator of the electrode. When placing the slice on the mesh it 
was orientated so that the line of the third ventricle was lying on the right, and the 
fornix on the upper left. The VMH could be found approximately one quarter of the 
way across from the third ventricle and two thirds of the way down from the fornix.
Flow through the chamber was maintained by gravity from a 450ml reservoir. The 
reservoir was sealed from the air, but was connected to a gas bag containing 
9 5 %0 2 /5 %C0 2  such that the head space in the reservoir was replaced with gas as the 
reservoir emptied of the aCSF. The aCSF passed through a heated water jacket before 
entering the recording chamber. Drugs could be applied to the slice in known 
concentrations by changing the perfusion medium to one which differed from the aCSF 
only by its drug content This was achieved by means of a three-way tap. The lag time 
between the turning of the tap and the drug-containing solution entering the chamber 
was 16 sec, since the volume of the recording chamber was 0.4ml, complete exchange 
of the solutions was achieved in 38 sec. The drug solution was removed by changing 
back to the drug-free aCSF solution.
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In order to minimise flow-rate artefacts it was ensured that the bottoms of the reservoirs 
and drug-addition syringes were at the same height. By ensuring that these were at an 
equal height the flow-rate did not change when the taps were turned. Waste was 
removed by means of a capillary action siphon to maintain a constant level in the 
recording chamber.
5.2.3. EXTRACELLULAR RECORDING
Glass micropipettes were prepared from capillary tubes (Radnoti starbore glass O.D.
1.2mm), pulled using a SRI vertical puller, typically set at furnace 6  and pull 7. These
pipettes were pulled to have a DC tip resistance of lOMO and filled with 3M NaCl.
The micropipettes were then carefully placed in a micromanipulator and lowered onto
the surface of the slice; this was done under a microscope with magnification of x50.
Extracellular recordings from single neurones were then obtained. Signals were
amplified using a high-input impedance preamplifier (Neurolog) and passed through a
spike processor before being displayed on an oscilloscope (Tetronix). Active neurones
were found by slowly lowering the micropipette and listening for audio output from the
spike processor and visual output on the oscilloscope. For finding cells the
oscilloscope was set at O.lvolts/division, giving a full scale deflection of O.Svolts.
Sweep speed was set at 5ms/division giving a full picture of 50ms. Once a cell was
found the voltage was often changed to 0.2 or 0.5volts/division so the full spike could
be observed on the oscilloscope. When a cell was found the micropipette was placed as
near to the neurone as possible without interfering with the firing rate. A window was
set using the spike processor such that only signals passing through th^windowjwere
I  measured over 10 sec I  
counted, allowing the noise to be disregarded. Ratemeter records of cell firing were
monitored on a chart recorder (Gould 2400s, chart speed 3mm/min). At the beginning
of each session a lOHz signal was generated to give a reference point.
175
0.5|xM quisqualic acid was routinely added to the bathing solution throughout the 
experiment to increase and stabilise the cell firing rate (Newberry & Priestley, 1988).
5.2.4. DRUGS
DSLET, DPDPE, DAGO and quisqualic acid were obtained from Cambridge Research 
Biochemicals, DELT I from Bachem and NTI from Research Biochemicals 
Incorporated. Buffer salts were obtained from the sources described in section 4.2.5., 
in addition MgS0 4  was obtained from BDH.
All drugs were dissolved in aCSF. DSLET, DPDPE, DELT I and DAGO were 
perfused over the slice for 90s and G ABA was perfused for 60s. For studies of 
antagonism the slices were perfused with NTI for 90min before redetermining agonist 
effects.
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5.3. RESULTS
The addition of the quisqualic acid to the perfusion medium increased the firing of the 
VMH neurones to around 7Hz from a basal firing of less than 2Hz. All of the
5-agonists caused a dose-related inhibition of neuronal firing in VMH neurones 
(Figures 39-42). The responses to DSLET and DPDPE were qualitatively similar 
(Figures 39 & 40), however, the response to DELT I was more prolonged and the 
firing rate often did not fully return to predrug levels (Figure 41). Table 19 shows the 
percentage of slices which responded to any of the opioid drugs used and the 
percentage of cells which responded to each of the individual drugs and the ED75 
values calculated from the concentration response curves shown in Figure 42. The 
percentage of cells responding to the drugs corresponded well with-the percentage of 
responding slices. More cells were responsive to DSLET than DPDPE or DELT I. 
The responses to DAGO were generally poor, in half of the cells tested doses of up to 
lOjiM failed to inhibit the firing by more than 70% and in the cells where a full 
concentration response curve was obtained DAGO appeared to be less potent than the
5-agonists.
Pilot studies showed that the effect of NTI reached a maximum following a 90min 
equilibration time and the effects of all three 5-agonists were antagonised by 50nM NTI 
(n=l). A 90min incubation of the slice with lOnM NTI completely reversed the effects 
of an ED75 of both DSLET (Figure 43) and DPDPE (Figure 44) (n=3). Results also 
show that under the same conditions NTI had no effect on the inhibition induced by a 
submaximal dose of G ABA (n=4) or DAGO (n=2) (Figure 45). The reversibility of the 
NTI antagonism of DSLET was demonstrated in one cell (Figure 46). In this cell 
following the 90min incubation with NTI and the determination of the DSLET response 
the slice was then perfused with NTI-free aCSF and the response to DSLET 
redetermined every 30mins. The response to DSLET was fully recovered 120mins 
after the introduction of NTI-free aCSF.
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Table 19. Responses to DSLET, DPDPE, DELT I, DAGO and GAB A in the rat
VMH in vitro.
Ligand % Responding n ED75 (nM) n
Any Opioid 72 58 N.A.
DSLET 77 47 65 7
DPDPE 61 33 177 6
DELT I 59 27 35 4
DAGO 64 2 2 252±152 5
GABA 96 47 N.D.
% responding represents the number of slices in the case of any opioid but the number 
of cells showing a change in firing upon drug addition in the case of the individual 
drugs. N.A. not applicable, N.D. not determined. ED7 5 S represent the value 
calculated from the mean dose response curves shown in Figure 42 for the 5-agonists 
and the mean±s.e.mean of the individual plots for DAGO since the response to this 
agonist was extremely variable.
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Figure 42. Inhibition of quisqualate-induced neuronal firing by DSLET, 
DPDPE and DELT I in rat VMH in vitro.
100 n
9 0 -
8 0 -
7 0 -
§ 6 0 -
Î 5 0 -
3 0 -
2 0 -
1 0 -
100 500
Dose (nM)
Values are mean ± s.e.mean of 4-6 observations, (■) represents DSLET, 
( • )  DPDPE and (A) DELT I.
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5.4. DISCUSSION
All of the agonists employed showed an inhibition of neuronal firing, the 6 -agonists 
showed a nM affinity for this effect and the order of potency of these agonists is in 
agreement with that found in the isolated tissue studies (Chapter 4), as well as the in 
vivo antinociceptive studies (Chapter 2). The agonist-induced inhibition of neuronal 
firing was reversed by low doses of NTI which had no effect on the inhibition induced 
by the ji-agonist DAGO nor the non-opioid depressant GABA. These results showing 
dose-related, antagonist reversible responses to 6 -opioid in agonists have demonstrated 
the presence of functional 6 -receptors in the rat VMH and the relative insensitivity to 
DAGO suggests that |i-receptors play a minor role in the rat VMH. This is surprising 
as autoradiographic studies have shown that there are twice as many |i-sites in the rat 
VMH as 6 -sites (Desjardins et ai, 1990). Studies using the guinea-pig VMH in vitro 
have shown that in this species ji-receptors appear to be the most important and 
6 -receptors may only have a minor role as only one third of the neurones tested 
responded to DPLPE (Charpak et ai, 1988). These results show a possible species 
difference in the specific opioid receptor involved in the mediation of inhibition of cell 
firing in the VMH.
The results obtained give no indication of which neurones the opioid receptors were 
located on, but it is possible that the |i- and 6 -receptors were colocated on the same 
neurone as some cells responded to both DAGO and the 6 -agonists. However, some
6 -receptors appear to be alone as some neurones appeared to respond only to the
6 -agonists. The VMH contains some glucoreceptive neurones as addition of glucose to 
these cells induces excitation by an inhibition of ATP-sensitive potassium channels 
(Ashford et at., 1990). Since the electrophysiological effects of 6 -receptors have been 
shown to be mediated via potassium channels (North et al., 1987) and it has been 
proposed that one of the 6 -subtypes is coupled to an ATP-sensitive potassium channel
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(Wild et al., 1991), it is possible that the 5-receptors shown in this study are found on 
the same neurones as the glucoreceptors.
The site of action of the 5-agonists used is also unknown, however, in the rat striatum 
the application of 5-selective agonists presynaptically inhibit the excitatory postsynaptic 
potential and decrease the inhibitory synaptic potential by inhibiting the release of 
glutamate and GABA (Jiang & North, 1992).
, However since the effects of quisqualate in this preparation are postsynaptic it is likely that the 
ô-receptors mediating the inhibition of cell firing are also located postsynaptically.
The application of DPDPE to hippocampal neurones in vitro leads to an increase in the 
amplitude of excitatory post-synaptic potentials (Lupica et al., 1992) and to an increase 
in the amplitude of the population spikes (Dunwiddie et al., 1987). Recently Watson & 
Lanthorn (1993) studied the effects of several 5-agonists for their ability to alter 
extracellularly and intracellularly recorded CAl pyramidal cell activity. DPDPE, 
pCl-DPDPE, DSLET and the p-agonist DAGO all increased the primary population 
spike amplitude, while DSLET and DAGO induced secondary population spikes. In 
contrast DELT II was completely inactive. The effects of DPDPE and pCI-DPDPE 
were antagonised by IpM NTI and IpM ICI 174,864 but those of DSLET and DAGO 
were not. From these results it was concluded that the 5i subtype predominates in the 
CAl region of the rat hippocampus.
No evidence for the presence of 5-subtypes in the rat VMH was found in this study but 
this clearly needs further investigation, for example the effect of lOnM NTT on the 
response to DELT I needs to be determined. There appeared to be a greater number of 
cells responding to DSLET compared to the other two agonists, the significance of this 
is unknown and also deserves further investigation.
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In summary this study has shown functional 5-opioid receptors in the rat VMH and that 
these may be relatively more important than p-receptors in this region.
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CHAPTER 6
190
GENERAL DISCUSSION.
This study has shown that the 5-mediated antinociception in 25 day old rats appears to 
be operated via two distinct 0-subtypes. The results show that DSLET and DELT I are 
selective agonists at one of these sites each, whereas DPDPE has affinity for both. The 
highest doses of NTI and NTB used antagonised the effects induced at both sites, but 
lower doses of both antagonists appear to be selective for the DSLET site. These 
results are in agreement with Sofuoglu et aL (1991a) who showed a differential 
antagonism of DSLET and DPDPE by NTI and NTB following i.t. injection in mice. 
However this effect was less pronounced following i.c.v. administration. 
Subsequently Jiang et al. (1991) showed in mice that the antinociceptive effects of 
DSLET and DELT II could be antagonised by 5'NTII but not DALCE whereas the 
effect of DPDPE was not affected by 5'NTII but was reversed by DALCE. These 
receptors were termed 5i for the DPDPE/DALCE sensitive site and Ô2 for the 
DSLET/DELT n/5'NTII site (Mattia et al., 1992). The results presented here indicate 
that DELT I has a different receptor selectivity in the rat compared to DELT II in the 
mouse. It is possible that this reflects a species difference between the rat and the 
mouse as these have previously reported for responses to 5-agonists (Heyman et al., 
1987a). DELT I and DELT II differ by a single amino acid at position 4, aspartate for 
DELT I and glutamate for DELT II. The amino acid at position 4 has been shown to be 
crucial for the 5-receptor binding of DPDPE and its analogues (Toth et al., 1990), and 
it is thus possible that a change of amino acid at this position could alter the subtype 
selectivity of the deltoiphins. However this cannot be resolved until both compounds 
are used in both species and in a variety of assays. In this study the two 5-receptors 
have been termed 5i for the DELT I site and 5 2  for the DSLET site. In the rat DPDPE 
appears to have some selectivity for the 5i site shown by the lack of antagonism by low 
doses of NTB Clearly, the classification of 5-selective ligands will need re-appraisal 
when further data from several species becomes available.
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The results reported here are the first to show that the ôi and Ô2 sites develop 
differentially in the rat. The 62  sites are dependent on weaning to initiate either their 
expression or their coupling to signal transduction systems. From the results described 
in this thesis it is not possible to determine if weaning activates the expression of the 
receptor or activates the coupling of the receptor to its signal transduction system. 
These possibilities could be investigated using radioligand binding studies to 
characterise the 5-binding sites before and after weaning, or autoradiography to study 
the distribution of 5-sites. Studies on neurotransmitter release and/or adenylate cyclase 
and potassium channels could be used to investigate the coupling of these receptors.
It is also possible that the in vivo data obtained in this study is due to differences in the 
pharmacokinetics of the agonists and/or antagonists. Although this explanation would 
appear unlikely as the antinociception induced by the agonists is qualitatively similar 
pharmacokinetic studies would confirm or refute this possibility. An in vivo system 
which allowed a 'steady-state' to be achieved could also be used to give estimations of 
pA2 values for the antagonists.
Similar to the results obtained in the in vivo studies differences in the antagonism of the 
effects of DSLET, DPDPE and DELT I were seen in the mouse and hamster vas 
deferens. In all cases NTI was least effective at antagonising the effects of DELT I and 
in the SCH mice the slope of the Schild plot was significantly greater than one for NTI 
versus this agonist. Since the pA2  values for NTB versus the three 5-agonists were 
similar (SCH mice) it is possible that this antagonist is unable to distinguish the 
5-subtypes in this tissue. However the slope of the Schild plot for NTB versus DSLET 
was significantly different from unity. Assuming that the ligands show similar 
selectivities in the mouse vas deferens as in the in vivo model, DELT I would appear to 
have some selectivity for 5i sites and DSLET 8 2 . Again DPDPE has affinity for both 
sites but shows some selectivity for 52  sites in the TO mouse vas deferens. Only one 
other study has systematically investigated the possibility of 5-subtypes in the mouse
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vas deferens. Wild et al. (1993) found no difference in the antagonism of DPDPE and 
DELT II by NTB, also they reported that the ôi selective antagonist DALCE was 
ineffective in this tissue. From these results Wild et al. (1993) concluded that only a 
single 5-receptor subtype was present in the ICR mouse vas deferens and this receptor 
had a ligand specificity to the proposed 5% subtype (Mattia et al., 1992).
In the hamster vas deferens the results show some differences to the results obtained in 
the mouse vas deferens. NTI and NTB show a reverse order of potency versus the 
5-agonists and if we assume that NTB retains its 52  selectivity then DELT I appears to 
have high affinity for this site and NTI has better affinity for 5% sites. These 
selectivities can only be tentative suggestions as the difference in pA2 and Ke values for 
NTI and NTB only represent one order of magnitude difference. Although the results 
presented in this thesis provide only possible evidence for 5-subtypes in the mouse and 
hamster vas deferens there are definite differences in the antagonism of the three 
5-agonists. The use of other isolated tissue systems sensitive to 5-opioid ligands such 
as the mouse ileum may provide further information about the receptor subtype 
selectivity of 5-selective compounds and the presence of 5-subtypes in peripheral 
tissues.
This study has also shown the presence of functional 5-receptors in the rat VMH 
in vitro . Results also suggest that in this species they are of relatively more 
importance than |i-receptors even though this region contains twice as many |i-sites as 
it does 5 (Desjardins et al., 1990). Although the results obtained from the rat VMH 
provide no evidence for 5-subtypes, further studies are required before their presence in 
this preparation can be performed or denied. More cells appeared to respond to DSLET 
than the other 5-agonists and only increasing the number of cells tested would show if 
this is a true effect. Also the effect of lower doses of NTI on the response to DELT I 
need to be investigated.
193
In conclusion this study has shown that DSLET, DPDPE and DELT I are potent 
5-agonists both in vivo and in vitro and their effects appear to mediated via multiple 
5-sites. NTI and NTB are potent 5-antagonists and they both show some degree of 
selectivity for the 5 2  receptor. However NTI may show a different profile in the 
hamster vas deferens. The existence of multiple 5-receptors awaits confirmation from 
molecular studies but the recent cloning of the 5-gene has shown multiple gene 
transcripts and raises the possibility of alternative splicing as a route to receptor 
subtypes (Evans et aL, 1992).
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Antagonism by the highly selective 5-opioid antagonist naltriben WTB) of the antinociceptive effects of an ED75 
dose of [D-Pen^,D-Pen^] enkephalin (DPDPE), [D-Ser ,^Leu ,^Thr ] enkephalin (DSLET) and D-Ala^ deltorphin I 
(DELT I) has been studied in 25 day old rats. Antinociception was measured by the 50°C tail-immersion test 
following i.p. administration of agonists and/or antagonist. 0.5pg/kg NTB significantly antagonised the antinocicep­
tive effect of DSLET but had no effect on the response to DPDPE or DELT I. 5pg/kg NTB completely abolished 
the response to DSLET whilst responses following administration of DPDPE or DELT I were unchanged. 50pg/kg 
NTB fiilly reversed the antinociceptive effects of all three 5-agonists. NTB (50pg/kg) had no effect on the 
antinociception induced by the p-agonist alfentanil (60pg/kg). The differential antagonism by NTB of the 
antinociceptive effects of tlnee selective 5-agonists suggests 5-receptor heterogeneity in postweanling rats. Further 
the profile of antagonism of the 5-agonists by NTB is dissimilar to the profiles of antagonism by naltrindole 
supporting the concept that these two antagonists have differential affinities for putative 5-receptor subtypes.
KEY WORDS: Antinociception, 5-opioid receptors, naltriben.
IN TRO DU CTIO N
The introduction o f  h ighly selective, non peptide, 6 -opioid receptor antagonists naltrindole 
and naltrindole 5' isothiocyanate (Portoghese e? a /., 1988; 1990) has provided evidence from  
m v/vo studies in m ice for delta receptor subtypes (Jiang e /a / . ,  1991; S o fu o g lu e /a /., 1991). 
R ecently w e  show ed that naltrindole could differentially antagonise antinociceptive re­
sponses to selective 6 -agonists in 25 day old rats suggesting that 6 -subtypes exist in young  
rats (Crook et a l ,  1992). Few er studies have been carried out w ith the benzofuran analogue 
o f  naltrindole, naltriben, (Portoghese et a /., 1991) but in m ice it has been proposed that this 
6 -antagonist has selectivity for a putative 62 site w hilst naltrindole exhibits m ixed  antago­
nism  at 61 and 62  sites (Sofüoglu  et a l , 1992). To address further this question w e  now  report
* Author for correspondence
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the effects o f  naltriben on the antinociceptive responses to three h ighly selective 6 -agonists, 
[D-Pen^,D-Pen^] enkephalin (D PD PE), [D-Ser^,Leu^Thr^] enkephalin (DSLET) and D-Ala' 
deltorphin I (DELT I) in postw eanling rats.
M ETH ODS
25 day old  m ale W istar albino rats (5 0 -9 0 g  U niversity o f  Surrey strain) were used in all 
studies. A nim als w ere housed in groups o f  8 -1 0  under constant temperature (22 ±  1°C) and 
in a 12hr light-dark cycle (lights on 07hr.00m in). Procedures w ere carried out in a quiet, 
w indow less air-conditioned laboratory betw een 14hr.00min and 18hr.00min. Treatment 
groups w ere divided so that testing for both saline and drug treated groups occurred over at 
least 3 days. Drugs (0.9%  %  saline) w ere administered i.p. in volum es betw een 0.05 and 
0.1m l. N ociceptive responses w ere measured using the 50°C  warm water tail im m ersion test 
(Janssen et a l ,  1963) using a protocol previously described (Crook et a l , 1992). Studies o f  
antagonism  by naltriben w ere carried out versus E D 7 5  doses o f  each o f  the 6 -agonists 
(calculated as 75% o f  m axim um  effect from full dose response curves at peak antinocicep­
tion) as previously described (Crook et a l ,  1992). Drugs used w ere DPD PE, DSLET  
(Cambridge Research B iochem icals) DELT I (Bachem ). A lfentanil HCl w as a gift from  
Janssen Pharmaceuticals and naltriben w as a gift from Dr. P. S. Portoghese, U niversity o f  
M innesota. A ntagonism  o f  antinociceptive responses w as analysed using one-w ay A N O V A  
fo llow ed  by post-hoc com parisons at each tim e point w ith Duncans N ew  M ultiple Range 
test using the SU PE R A N O V A  package for the M acintosh.
R ESU LTS
D oses o f  the agonists used w ere those calculated as ED75 concentrations in our previous 
study (Crook et a l,  1992). R esponses to ED75 doses o f  DSLET (0 .65 m g/kg), DPDPE (0 .66  
m g/k g) and DELT I (0 .0 3 2  m g /k g ) w ere  repeated  in  the presen t study to  enab le a 
paired com parison w ith responses in the presence o f  naltriben. R esponses to all three 
agonists w ere quantitatively and qualitatively sim ilar to our previous experim ents (Crook  
e ta l ,  1992).
Figure 1 show s the effect o f  N TB  (0 .5 -5 0 p g /k g ) on the antinociceptive responses to E D 75 
doses o f  D SLET, D PD PE and DELT I. 0.5 |ig /kg  N T B  significantly antagonised the 
antinociceptive response to D SLET but had no effect on responses to D PD PE and DELT I. 
A  higher dose, (5p g/kg), com pletely antagonised the response to DSLET but w as com pletely  
ineffective against D PD PE and DELT I. The highest dose o f  N T B  used (50 pg/kg) 
com pletely antagonised the antinociceptive effect o f  all three 6 -agonists. This dose had no  
effect on the antinociceptive response to a subm axim al dose (60 pg/kg) o f  the highly  
selective p-agonist alfentanil (Figure 2). N T B  had no effect on nociceptive latencies w hen  
administered alone.
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FIGURE 1 Effect of increasing doses o f naltriben (NTB) on the antinociceptive responses to ED75 o f (a) DSLET 
(b) DPDPE and (c) DELT I in 25 day old rats using the tail immersion test. Values are means ± s.e. mean o f at least 
six observations. (O) Saline ( • )  0.65 mg/kg, DSLET 0.66 mg/kg DPDPE 0.032 mg/kg DELT I (Cl)agonists + 0.5 
pg/kg NTB (■) agonists + 5 pg/kg NTB (A) agonists + 50 pg/kg NTB.
Significant differences at 5 min *P < 0.05 vs saline eontrol + P < 0.05 vs agonist alone.
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FIGURE 2 Effect of naltriben (NTB) on the antinociceptive response to alfentanil in 25 day old rats using the tail 
immersion test. Values are means ± s.e. mean of at least six observations. (O) Saline (□) 50 pg/kg NTB ( • )  60 
pg/kg Alfentanil (■) 60 pg/kg Alfentanil + 50 pg/kg NTB.
Alfentanil vs alfentanil + NTB: not significant
D ISC U SSIO N
Our results show  a differential antagonism  o f  the antinociceptive effects o f  three selective
5-agonists b y  the h ighly selective antagonist N T B . N T B  show s a 1,500-fold  selectivity for 
the 5-receptor compared to p-sites in binding studies (Takemori et a l ,  1990). The 5-selee- 
tivity o f  the doses o f  N T B  used in this study w as confirm ed by the lack o f  antagonism o f  a 
subm axim al dose o f  the highly selective p-agonist alfentanil. Thus 5-selective doses o f  N TB  
show  a differential antagonism o f  DSLET, D PD PE and DELT I, w ith D SLET being at least 
10 fold  m ore sensitive to antagonism by N T B  than either D PD PE or DELT I. The 
differentiation betw een D SLET and DELT I confirm  our previous observations w ith  N TI 
(Crook et a l ,  1992) and also lends further support to the proposal o f  5-opioid  receptor 
subtypes, and our suggestion that in young rats D SLET and D ELT I act selectively  at 
different sites. D PD PE w as less sensitive than D SLET to antagonism  by N T B  confirm ing  
the profile o f  sensitivity in m ice (Sofuoglu  e ta l ,  1991). Previous studies, using N TI, in  both 
rats (Crook et a l,  1992) and m ice (Sofuoglu  et a l ,  1991) have show n that this antagonist 
does not so  obviously  differentiate betw een responses to D SLET and D PD PE, and w e have 
suggested that this indicates that D PD PE has affinity for both o f  the proposed 5i and 5% 
subtypes (Crook et a l,  1992) since naltrindole probably has affinity for both. In the present 
study N T B  show s greatest antagonism  o f  D SLET confirm ing the 5% selective profile o f  these
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tw o ligands. The closer correspondence o f  N T B  antagonism  o f  D PD PE and DELT I suggest 
that, in the rat, these agonists have greater affinity for the 5i site.
M ost o f  the evidence for 0-receptor subtypes has com e from studies in m ice and studies 
w ith the antagonists N TI, N T B , 5' naltrindole isothiocyanate (5'NTII) and [D-Ala^-Leu^- 
Cys^] enkephalin (D ALC E) (Sofuoglu  e ta l.,\9 9 \;  Jiang e ta l ,  1991) w hich have led  to the 
proposal that the 0 i sites are sensitive to D PD PE and D ALCE w hilst D SLET, D ELT II and 
5'NTII, have h igh affinity for 6 2  sites (Mattia et a l ,  1992; Jiang et a l ,  1991). Further there 
is lack o f  cross tolerance o f  the antinociceptive effects o f  D PD PE and DELT II (Mattia et 
a l,  1991) supporting the proposal that these agonists differentiate the tw o 5-subtypes. 
A lthough m uch o f  the evidence for 5-opioid  receptor heterogeneity has com e from in vivo 
studies som e supporting evidence from radioligand binding experim ents is now  appearing. 
For exam ple, the order o f  potency o f  5-ligands for com peting w ith [^H] D PD PE and [^H] 
D SLET binding in m ouse brain is dissim ilar (Sofuoglu  et a l,  1992) and N egri et a l,  (1991) 
have show n biphasie inhibition o f  [^H] DELT I binding in rat brain membranes. Further, the 
recently reported cloning o f  a 5-opioid  receptor and identification o f  m ultiple transcripts 
hybridising to the cD N A  (Evans et a l,  1992) has raised the possib ility  that subtypes m ight 
derive from alternative R N A  splicing. The profile o f  selectivity o f  N T B  in the current study 
is consistent w ith the proposal that this antagonist acts at 82 sites in the rat as it does in  the 
m ouse (Sofuoglu  et a l ,  1991; Portoghese et a l ,  1991) and that it is more useful in  
discriminating the subtype responses than N TI (Sofuoglu  et a l,  1991; Crook et a l ,  1992), 
although it should be noted that w hole brain binding studies do not support a 5 i ,  52 
differentiation by N T B  (Sofuoglu  et al., 1992). The clear discrimination o f  5-subtype 
responses by N TB  m ay reflect differences in the sites in regions associated with antinociception.
In conclusion the differential antagonism o f  h ighly selective 5-agonists by 5-seleetive  
doses o f  N T B  is in  agreement w ith the proposal o f  5-opioid receptor subtypes, and w e  
suggest that in young rats D SLET exerts its antinociceptive effects at a different 5 site to 
DELT I. D PD PE has affinity for both o f  these sites but is more potent at the D ELT I site.
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Effects of the <5-opioid receptor antagonist naltrindole on 
antinociceptive responses to selective 6-agonists in 
post-weanling rats
T.J. Crook, ' I. Kitchen & *R.G. Hill
Receptors and Cellular Regulation Research Group, School o f  Biological Sciences, University.of Surrey, Guildford, Surrey 
G U 2 5XH and * Merck Sharp and Dohm e Research Laboratories, Neuroscience Research Centre, Harlow, Essex CM20 2QR
1 Antagonism, by the selective 6 -opioid receptor antagonist naltrindole, o f  the antinociceptive effects o f  
[D-Pen^, D-Pen^] enkephalin (DPDPE), [D-Ser^, L eu \ Thr®] enkephalin (DSLET) and D-Ala^ deltorphin I 
(DELT I) has been studied in 25 day old rats.
2 Antinociception was measured by the 50°C tail immersion test following i.p. administration o f
agonists and/or antagonists.
3 Dose-related antinociception was observed with DPDPE, DSLET and DELT I and ED 75 doses were 
computed (0 .6 6 m g k g “ ‘, 0 .6 5 m g k g “ *, 0.032 mg kg"' respectively) and used for antagonism studies.
4 Naltrindole (0.01 mg kg“ ‘) significantly attenuated the antinociceptive effects o f  DPDPE and DSLET  
with 0.1 mg kg"' producing complete reversal o f the effects o f  the E D 75 dose. In contrast, naltrindole at 
0.01 and 0.1 mg kg'* did not alter antinociceptive responses to DELT I. Naltrindole at 1 mg kg"' 
significantly attenuated DELT I antinociception.
5 Naloxone (1 mg kg"*) produced equivalent degrees o f  antagonism o f  the antinociceptive effects o f  
DPDPE, DSLET and DELT I. ICI 174,864 (1 mg kg"') also antagonized antinociception with a
differential degree o f  attenuation (DSLET >  DPDPE >  DELT I).
6  Naltrindole (1 mg kg"') had no effect on the antinociception induced by the selective ft-agonist 
alfentanil (6 0 ^g kg"'). Naltrindole, naloxone or ICI 174,864 had no effect on nociceptive latencies.
7 The differential antagonism by naltrindole o f the effects o f three selective 6 -agonists suggests
6 -receptor heterogeneity. Further, the lower sensitivity o f  response to DELT I suggests that this agent 
may exert its antinociceptive effects at a different 6  receptor subtype from D PD PE or DSLET.
Keywords: Antinociception; 6 -opioid receptors; ontogeny; naltrindole; 6 -agonists
Introduction
Results from in vitro and in vivo experimental studies strongly 
suggest the existence o f  three primary opioid receptor types 
(H, 6  and k ) (see Paterson et al., 1983). Elucidation o f the 
role o f  the 6 -opioid receptor has in the past been hampered 
because o f  a lack o f  selective, stable, non-peptide agonists 
and antagonists. Several high affinity, 6 -selective peptide 
agonists have now been produced (Grace et a l, 1980; 
Mosberg et al., 1983; Erspamer et al., 1989) and recently a 
selective non-peptide antagonist, naltrindole has become 
available (Portoghese et al., 1988). These pharmacological 
tools have allowed a re-examination o f the possible roles o f  
the 6 -opioid receptor and, in particular, studies in mice with 
naltrindole and its benzofuran analogue have suggested the 
existence o f  6 -receptor subtypes (Sofuoglu et al., 1991). We 
further addressed this possibility by studying the ability o f  
naltrindole to antagonize the antinociceptive responses to 
three highly selective 6 -agonists, [D-Pen^, D-Pen^] enkephalin 
(DPDPE), [D-Ser^, L eu \ Thr®] enkephalin (DSLET) and D- 
Ala^ deltorphin I (DELT I) in postweanling rats.
Methods
Animals and experimental conditions
Male Wistar albino rats (University o f  Surrey strain) 25 days 
old and weighing 6 0 -9 0  g, were used in all studies. All rats 
were housed in groups o f  8 -1 0  and maintained at 2 2 ±  I'C
Author for correspondence.
in a constant 12 h light-dark cycle (lights on at 07 h 00 min). 
Experimental procedures were carried out in a quiet, win­
dowless, air-conditioned laboratory between 14 h 00 min and 
18 h 00 min to minimize diurnal variation. Animals were 
allowed to acclimatize for 2  h before experimentation.
Nociceptive testing
Animals were divided into treatment groups so that nocicep­
tive tests took place for saline- and drug-treated animals on 
at least three separate days. Drugs (in 0.9% w/v saline) were 
administered i.p. in a dose volume no greater than 0 .1  ml. 
Nociceptive responses were measured by the 50°C warm 
water tail immersion test (Janssen et ah, 1963) adapted for 
young rats (Kitchen et al., 1984). Nociceptive responses were 
defined as withdrawal o f  the tail from the surface o f  the 
water and a maximum 10 s cut-off was used. Response laten­
cies were measured 15 min before administration o f  the 6 - 
agonists DPDPE, DSLET, DELT I or the /i-agonist alfen­
tanil and nociceptive responses measured 2, 5, 10 and 15 min 
after treatment.
When studied, antagonists (naloxone, naltrindole or ICI 
174,864) were injected 10 min before agonist administration. 
The ED75 o f  each o f  the 6 -agonists was chosen for 
antagonism studies and calculated as the 75% o f maximum 
effect from full dose-response curves at peak antinociception 
(5 min) with saline control values defined as 0%.
Drugs and statistical procedures
Drugs used were [D-Pen^, D-Pen^], enkephalin (DPDPE), [d- 
Ser ,^ L eu \ Thr«] enkephalin (DSLET), ICI 174,864 (Allyh-
574 T J .  CROO K et al.
Tyr-Aib-Aib-Phe-Leu-OH; Cambridge Research Biochemi­
cals), D-Ala^ deltorphin I (DELT I) (Bachem), alfentanil HCl 
(Janssen Pharmaceuticals), naloxone (Dupont) and naltrin­
dole HCl (NTI) (Research Biochemicals Incorporated).
Antagonism o f  the antinociceptive responses to the ô- 
agonists was analysed by analysis o f  variance followed by 
post-hoc analysis with Dunnett’s test.
Results
Administration o f  increasing doses o f  DPDPE, DSLET and 
DELT I induced a dose-related antinociception with ED75S of  
0.66 mg kg” *, 0.65 mg kg” *, 0.032 mg kg” ‘ respectively. Res­
ponses to alf three agonists were qualitatively similar with 
peak antinociception being observed 5 min after administra­
tion (Figure la,b,c).
Figure 2a,b,c shows the effects o f  NTI (0 .01-1  mg kg” *) 
on the antinociceptive responses to the ED75 dose o f DSLET, 
DPD PE and DELT I respectively. NTI (0.01 mg kg” *) 
significantly attenuated the peak response to DPDPE and 
DSLET, while higher doses (0.1 and 1 mg kg” *) completely 
antagonized the antinociceptive response to DSLET. NTI 
(0.1 mg kg” *) markedly reduced the response to DPDPE and
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Figure 2 Effect o f increasing doses o f naltrindole (NTI) on the 
antinociceptive response to ED75 of (a) DSLET (b) DPDPE and (c) 
DELT I in 25 day old rats using the tail immersion test. Values are 
means ±  s.e.mean of at least six observations. (O) Saline; ( • )  
0.65 mg kg” ' DSLET, 0.66 mg kg"', DPDPE, 0.032 mg kg” *, 
DELT I; (□ )  agonists 4- 1 mg kg"' NTI; (■ )  agonists 4- 0.1 mg kg” ' 
NTI; (A ) agonists 4-0.01 mg kg” ' NTI.
Significant differences vs saline control at 5 min P < 0 .0 1  DSLET 
alone, DSLET-t-0.01 mg kg” ' NTI. Significant differences at 5 min 
< 0.01  vs agonist alone, ^ + P < 0.01  vs saline control. Responses 
to antagonist alone were not significantly different from saline con­
trols (data not shown). For abbreviations see legend to Figure 1.
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Figure 1 Time course o f the antinociceptive effects o f (a) [D-Ser ,^ 
L eu\ Thr ]^ enkephalin (DSLET), (b) [o-Pen^, D-Pen’] enkephalin 
(DPDPE) and o-Ala^ deltorphin (DELT I) in 25 day old rats using 
the tail immersion test. Values are means o f at least six observations. 
Error bars are omitted for clarity o f presentation; s.e.mean varied 
from 3-14%  o f the mean value. (O) Represents saline treated 
controls; ( • )  0.25 (DSLET), 0.25 (DPDPE), 0.02 (DELT I) mg kg” '; 
(□ )  0.5 (DSLET). 0.5 (DPDPE), 0.05 (DELT I) mg kg” '; (■ )  0.75 
(DSLET), 2 (DPDPE), 0.1 (DELT I) mg kg” '; (A ) 1 (DSLET), 4 
(DPDPE), 0.15 (DELT I) mg kg” '.
the response following I mg kg” * NTI was not significantly 
different from saline control values. In contrast, NTI (0.01 
and 0 . 1 mg kg” *) did not alter antinociception induced by 
DELT I, and only the highest dose o f  NTI (I mg kg” *) 
significantly antagonized antinociception induced by this 
agonist.
Naloxone (1 mg kg” *) significantly antagonized response to 
DPDPE, DSLET and DELT I producing a similar degree o f  
attenuation o f  the antinociceptive effects o f  all three agonists 
(Figure 3). ICI 174,864 (1 mg kg” *) also significantly 
antagonized the antinociceptive effects o f  these agonists with 
a differential degree o f  attenuation (D S L E T >  D P D P E >  
DELT I). Further, ICI 174,864 (2 mg kg” *) completely 
blocked antinociceptive responses to all the 5-agonists (data 
not shown) but at this dose in some animals this antagonist 
caused behavioural toxicity, including hindlimb stretching, 
ffaccidity and barrel rolling. NTI and naloxone showed no 
overt behavioural toxicity at the highest doses used.
NTI (1 mg kg” *) and ICI 174,864 (2 mg kg” *) had no 
effect on the antinociceptive response induced by a submax- 
imal dose (60 p g k g ” *) o f  the ^i-agonist alfentanil (Figure 4).
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Figure 3 Effect o f (a) naloxone and (b) ICI 174,864 on the peak 
antinociceptive response (5 min) to an ED75 of DSLET, DPDPE and 
DELT I in 25 day old rats in the tail immersion test. Values are the 
mean ( ±  s.e.mean, vertical bars) o f at least six observations. Sal = -  
saline; Nal =  naloxone I mg kg"'; ICI =  ICI 174,864, 1 mg kg"'; 
DSLET 0.65 mg kg-'; DPDPE 0.66 mg kg"'; DELT I 0.032 mg 
kg-'. For other abbreviations see legend to Figure 1.
**P <0.01; * P < 0 .0 5  vs agonist alone; ^ +P<0.01 vs saline control.
N one o f  the antagonists (NTI, ICI 174,864 and naloxone) 
used had any effects on nociceptive latencies in the tail 
immersion test when administered alone.
Discussion
Determination o f  the importance o f  the 5-opioid receptor in 
mediating antinociception has been difficult because o f the 
lack o f  suitable brain-penetrating selective agonists and 
antagonists. Studies with the selective ligand DPDPE imp­
licate 5-sites in both spinal (Rodriguez et al., 1986) and 
supraspinal (Heyman et al., 1987) antinociception. Most 
studies have employed intrathecal or intracerebroventricular 
routes for administration o f these agonists (Galligan et al., 
1984; Porreca et al., 1987; Suh & Tseng, 1990) and administ­
ration by parental routes in the rat has been generally unsuc­
cessful in inducing antinociception (Tavani et ai, 1989).
Our success in obtaining dose-related antinociceptive res­
ponses to DPD PE, DSLET and DELT I after i.p. injection 
most probably reflects the age o f  the animals used since in 
the rat, the blood brain barrier is not fully mature until 
postnatal day 30 (Keep et al., 1986). We have also previously 
demonstrated 5-receptor operated stress-induced antinocicep­
tion in 25 day old rats (Kitchen & Pinker, 1990).
N TI shows 100 fold selectivity for 5-receptors over other 
opioid receptors in isolated tissue preparations (Portoghese et 
al., 1988) and in radioligand binding studies (Rogers et al., 
1991). The confirmation o f  the 5-receptor selectivity of NTI
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Figure 4 Effect o f (a) naltrindole (NTI) and (b) ICI 174,864 on the 
antinociceptive response to alfentanil in 25 day old rats in the tail 
immersion test. Values are means ( ±  s.e.mean, vertical bars) o f at 
least six observations: (O) 1 mg kg-' NTI (a), 2 mg kg-' ICI 
174,864 (b); ( # )  6 0 p g k g -' alfentanil; (□ )  6 0 p g k g - ' alfentanil 
4-1 mg kg-' NTI (a), 2 mg kg-' ICI 174,864 (b). Alfentanil vs 
alfentanil +  antagonist: not significant.
at doses used in this study was provided by lack o f  
antagonism o f  the highly selective p-agonist, alfentanil, and 
agrees with our previous assessment o f  in vivo selectivity o f  
this antagonist (Kitchen & Pinker, 1990) and that o f  others 
(Calcagnetti & Holtzmann, 1991).
The observation that responses to DPD PE, DSLET and 
DELT I were antagonized to an equivalent degree by nalox­
one confirms opioid receptor mediation. The differential sen­
sitivity to antagonism by NTI points to the possibility that 
these 5-agonists do not all mediate their effects via a common  
site. Others have found differential antagonism o f  DPDPE  
and DSLET by NTI and by its benzofuran analogue after 
intrathecal injection in mice (Sofuoglu et al., 1991) and have 
suggested that these differences might be explained by the 
existence o f  5-receptor subtypes. The differences between our 
work and that o f  Sofuoglu et al. (1991) could reflect the 
species used although route o f  administration may be impor­
tant because Sofuoglu et al. (1991) did not see differential 
antagonism o f  D PD PE and DSLET after intracerebrovent­
ricular injection.
Our results also show there is not equal antagonism o f  the 
5-agonists by ICI 174,864 and although the differences are 
not as marked as for NTI, it supports the possibility o f
5-receptor heterogeneity. Further, the results in rats now  
show that D ELT I provides the best discrimination o f  the 
effects o f  NTI with a 10 fold dose difference in sensitivity to 
either D PD PE or DSLET. The most marked difference is 
seen between DSLET and DELT I since NTI antagonism o f  
D PD PE responses was not quite as marked as the 
antagonism o f  DSLET at O . lmgkg-*  (Figure 2b). This 
might suggest that D PD PE has affinity for both postulated 
sites. Further support for this conclusion is provided by 
differential functional antagonism o f  D PD PE  and D-Ala^ 
deltorphin II responses by tetraethylammonia and gliben- 
clamide, respectively (Wild et al., 1991). Other studies also 
suggest 5-receptor heterogeneity. For example, the two 
irreversible 5-antagonists, naltrindole 5' isothiocyanate (Por­
toghese et al., 1990) and D-Ala^ Leu^ Cys® enkephalin (Jiang
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e t al., 1990) differentially antagonize antinociceptive effects o f  
D-Ala^ deltorphin II, DSLET and DPDPE (Jiang et al., 
1991).
Thus the results from our studies and that o f  others clearly 
demonstrate differential antagonism o f  the antinociceptive 
responses to selective 5-agonists by highly sensitive anta­
gonists suggesting the presence o f  5-opioid receptor subtypes 
in both rats and mice. The possibility that the differential 
antagonist effects o f  NTI might, in part, reflect phar­
macokinetic differences in the distribution or metabolism o f  
the three 5-agonists cannot be excluded. The differences in 
sensitivity to NTI are unlikely to be explained by p-activity 
o f  DELT I since this peptide shows over 3000 fold selectivity 
for 5-sites in, isolated tissue studies (Erspamer e t al., 1989).
Metabolism o f  DELT I to a non-selective p/5 compound is 
also unlikely since its antinociceptive activity is fully reversed 
by ICI 174,864 and NTI at doses that have no effect on 
antinociception mediated by a highly selective p-agonist 
(Figure 4).
In conclusion, the differential antagonism o f the anti­
nociceptive effects o f  three selective 5-agonists by NTI is in 
agreement with the proposal o f  the existence o f 5-opioid 
receptor subtypes and suggests that DELT I exerts its anti­
nociceptive effect at a different receptor subtype from 
DPDPE or DSLET in the rat.
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